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SUMMARY
Diabetes mellitus is known to affect drug and steroid metabolism in the rat 
liver. It was first reported in 1961 by Dixon et.al. that chemically-induced diabetes 
mellitus produces changes in hepatic microsomal drug metabolism. These results were 
later confirmed by other workers ( Kato et.al., 1971; Weiner et.al., 1972; Warren et.al., 
1983 ). Reports from various studies have indicated that streptozotocin-induced diabetes 
mellitus can also influence hepatic steroid metabolism in the rat ( Subbiah and Yunker, 
1984; Skett, 1986 ). The effect of diabetes on hepatic drug and steroid metabolism can be 
reversed by treating the diabetic animals with insulin. Drug and steroid metabolism by the 
rat liver is known to be sex-dependent ( Kato, 1974 ) and the effect of diabetes mellitus 
has been shown also to be sex-dependent with regard to drug and steroid metabolism 
( Skett and Joels, 1985; Skett, 1986 ). It is well recognized that glucagon can influence 
drug metabolism in-vivo ( Weiner et.al., 1972 ). Since hyperglucagonaemia is usually 
present in non-insulin-dependent diabetes mellitus, this hormonal excess has been 
implicated in the overall pathophysiology of the disease ( Unger and Orci, 1981 ). 
However, up to date, no study has been conducted to investigate the effect of insulin and 
glucagon on drug and steroid metabolism in a cell culture system. This is necessary 
bearing in mind the extensive interactions of hormones within the body making it difficult 
to assign the effects seen to any particular hormones in an in-vivo study. The object of 
this thesis is to ascertain the role of insulin and glucagon in the regulation of steroid 
metabolism in the rat liver.
Most of the previous work performed to observe the effect of diabetes on 
steroid and drug metabolism was done on liver microsomes prepared from treated 
animals. As described above, it is difficult to ascribe the effect of diabetes on hepatic 
steroid metabolism to a single action of insulin or glucagon in an in-vivo study. The use 
of isolated hepatocytes is essential to examine the effect of one hormone alone.
In order to achieve our objective, we had to develop a cell culture system which 
is hormone- and serum-free. We have developed and characterized four different types of 
culture medium containing animal serum, synthetic multihormone serum substitute 
( Ultroser G, LKB ) or bovine serum albumin only. When the liver cells were cultured in 
basic Ham's F-10 culture medium supplemented with foetal calf and horse serum or with 
Ultroser G, the steroid enzyme activities were reduced to less than 50 % of control on 
day 3 of culture in normal male rat hepatocytes. We discovered that the steroid enzyme 
activities were best maintained in Ham's F-10 culture medium supplemented with 0.1 % 
bovine serum albumin only. The basal level of enzyme activities was maintained for at 
least 3 days in culture. We, therefore, have a hepatocyte culture method to assess the 
effects of insulin and glucagon on hepatic steroid metabolism in serum- and hormone- 
free, chemically defined medium. Only male rats were used throughout the project 
because previous study had shown that the effect of diabetes on hepatic steroid 
metabolism is only seen in the male rat ( Skett, 1986 ). The substrate chosen for the 
investigation is androst-4-ene-3,17-dione because its metabolites are well defined and 
easily separated and the labelled and unlabelled substrate are easily available. The 
enzymes involved in its metabolism have been shown to be both cytochrome P-450- 
dependent and -independent and sex-specific. Moreover, insulin has been 
demonstrated to affect its metabolism in-vivo ( Skett, 1986).
The effect of insulin on androst-4-ene-3,17-dione metabolism in normal rat 
hepatocytes over the period studied was characterized by the presence of two peaks of 
increased activity at 1/2 and 24 hours. Importantly, these effects of insulin are clearly 
within the physiological range.The dose-response curves at 1/2 and 24 hour insulin 
preincubation suggest that these two peaks are probably generated by different 
mechanisms. Biochemical studies performed indicated that there is no correlation between 
the increase in enzyme activities by insulin at 1/2 hour and changes in cyclic AMP, 
cytochrome P-450 concentrations or phosphoinositide hydrolysis. It seems that insulin's
effect on androst-4-ene-3,17-dione metabolism at 1/2 and 24 hour involves a 
phosphorylation reaction since the protein kinase inhibitor, K-252a, completely inhibited 
the effect of insulin. However, the exact molecular mechanism of action is yet to be 
determined. Our results did not show any selective changes in the male-specific and 
female-specific enzyme activities which is in contrast to the result found in-vivo ( Skett, 
1986 ). This is probably attributed to the continuous exposure of the parenchymal liver 
cells to many different hormones in-vivo, which is absent in our system. The data 
obtained suggest that insulin has a direct effect on hepatic steroid metabolism and the 
hormone, in-vitro, act as a general stimulator of the enzymes in the liver which 
metabolize androst-4-ene-3,17-dione.
Since STZ-induced diabetes has been shown to alter phase 1 drug metabolism 
( Kato, 1974 ) and steroid and drug metabolism share the same metabolizing enzyme 
system ( Skett et.al., 1984 ) it is of interest to investigate whether steroid metabolism is 
similarly affected by STZ-induced diabetes. Hepatocytes from acutely ( 3 days ) STZ- 
treated diabetic rats were resistant, with respect to androst-4-ene-3,l 7-dione metabolism, 
to the effect of insulin addition in-vitro and the responsiveness was partly restored by 
treating the diabetic animals with insulin. Hepatocytes from chronically (21 days ) STZ- 
diabetic rats responded differently; the overall effect of chronic diabetes is much less than 
that seen in the acutely STZ-treated animals. This result is strikingly similar to that 
observed for microsomal drug metabolism ( Skett and Joels, 1985; Dixon et.al., 1963 ). 
Preincubation of hepatocytes from 3 days STZ-diabetic rat with insulin for up to 1 hour 
still resulted in the absence of insulin responsiveness relative to control. However, in the 
21 days diabetic rat, a small but significant increase in enzyme activities was observed 
after 2 hours of insulin preincubation. Thus, the effect of diabetes mellitus on phase 1 
steroid metabolism is time-dependent.
As explained above, glucagon has also been found to affect drug metabolism 
( Weiner et.al., 1972 ). In normal rat hepatocytes, the effect of glucagon on androst-4-
ene-3,17-dione metabolism is time-and concentration-dependent. The effects began to be 
manifested at 1/2 hour of preincubation. Glucagon at 1/2 and 24 hour preincubation
-10 8decreases all the enzyme activities at physiological concentrations (1 0  -10 M ).
Higher concentrations are less effective. Thus, glucagon at 1/2 and 24 hours 
preincubation exhibited V-shaped dose-response curves. Recently, Wakelam et.al. 
( 1986 ), with the aid of TH-glucagon, a glucagon antagonist, unravelled a new 
hypothesis on the mechanism of action of glucagon in the liver. They suggested that the 
effects of glucagon in the liver are mediated by its interaction with two distinct receptors, 
GR-1 ( a receptor coupled to the stimulation of inositol phospholipid breakdown ) and 
GR-2 ( a receptor coupled to the stimulation of adenylate cyclase activity ). The dose- 
dependent effect of TH-glucagon on androst-4-ene-3,l 7-dione, in analogy to the effect of 
TH-glucagon on inositol phosphate turnover, suggests that the effect of glucagon on 
androst-4-ene-3,17-dione metabolism is mediated via the GR-1 receptor linked to 
phosphatidylinositol-4,5 phosphate turnover. The ability of 4P-phorbol-12|3-myristate- 
13a-acetate, a known activator of protein kinase C, but not A 23187, a calcium 
ionophore, to mimic the effect of glucagon and TH-glucagon on the enzyme activity 
suggests that glucagon's effect is to activate protein kinase C via the generation of 
diacylglycerol. Similar to insulin, preincubation with glucagon for 1/2 hour in the 
presence of K-252a resulted in the abolition of the above effect suggesting that 
glucagon's effect on the steroid metabolism is mediated by phosphorylation.
In the diabetic rat hepatocytes, glucagon no longer exhibits the V-shaped dose- 
response curves. The second, inhibitory phase was abolished, probably due to a defect in 
the adenylate cyclase system coupled to the GR-2 glucagon receptor.
The pattern of plasma hormone levels and the interaction of more than one 
hormone may be physiologically important for hormone action. We, therefore, tested the 
effect of insulin and glucagon by adding them together in various combinations. When 
different concentrations of insulin and glucagon are added together, selective changes in
the activity of the male-specific and female-specific enzymes are observed. This is a first 
indication of the possible importance of hormonal interaction in expressing sexual 
differences in steroid metabolism.
Since biguanides and sulphonylureas are the most commonly prescribe 
hypoglycaemic agents for the treatment of diabetes mellitus, we have decided to 
investigate whether any of these group of anti-diabetic agents have any influence in the 
regulation of steroid metabolism. We have chosen phenformin and tolbutamide as 
representatives of biguanides and sulphonylureas respectively.
In normal rat hepatocytes, phenformin was shown to exert a direct effect on 
the liver in elevating androst-4-ene-3,l7-dione metabolism. It is able to mimic the effect 
of insulin in normal and diabetic rats although there was a reduction in responsiveness 
and sensitivity in the latter indicating the existence of receptor and post-receptor defects. 
In normal rat hepatocytes, phenformin caused a dose-dependent increase in androst-4-
ene-3,17-dione metabolism with maximum response observed at 5 x 10 5 M
-9concentration. Physiological insulin concentration (10  M ) potentiated the effect of 
phenformin on almost all of the enzyme activities.
Tolbutamide has the same effect as phenformin in normal rat hepatocytes. It 
elicited a dose-dependent increase in androst-4-ene-3,l7-dione metabolism with
maximum response attained at 10~4 M concentration. In the diabetic rat, tolbutamide was 
still able to increase all the enzyme activities despite a reduction in responsiveness. 
However, unlike phenformin, tolbutamide reduced the responsiveness of the liver cells 
towards insulin.
In conclusion, both insulin and glucagon have been shown to have a direct 
effect on the liver in regulating androst-4-ene-3,l7-dione metabolism in the rat. This 
together with the partial restoration of insulin responsiveness in insulin treated 
streptozotocin-diabetic rats support our hypothesis that both hormones, insulin and 
glucagon, are major factors in the regulation of steroid metabolism in the rat liver.
However, the exact molecular mechanism of how insulin mediates its action here is far 
from being solved. A more thorough investigation of the second messenger system and 
especially of the inositol phosphate-glycan, is needed to unravel the mystery of how 
insulin acts on hepatic steroid metabolism.
xiv
LIST OF TABLES
Ease
1. Metabolism of 4-[-14C] androstene-3,17-dione by isolated hepatocytes derived 65 
from adult male rats cultured in (i) Ham's F-10 culture medium supplemented 
with 2.5 % foetal calf serum and 15 % horse serum and (ii) Ham's F-10 
supplemented with 2 % Ultroser G.
2. Metabolism of 4-[-14C] androstene-3,17-dione by isolated hepatocytes derived 66 
from adult female rats cultured in (i) Ham's F-10 culture medium supplemented 
with 2.5 % foetal calf serum and 15 % horse serum and (ii) Ham's F-10 
supplemented with 2 % Ultroser G.
3. Metabolism of 4-[-14C] androstene-3,17-dione by isolated hepatocytes derived 68 
from adult male rats cultured in (i) Ham's F-10 culture medium supplemented 
with 2 % Ultroser G. 24 hours later the medium was replaced with 
Ham's F-10 plus 0.1 % bovine serum albumin and (ii) Ham's F-10 medium 
supplemented with 0.1 % bovine serum albumin.
4. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 75 
oxidoreductase ( OHSD) and 5a-reductase activities to insulin after 1/2 hour 
preincubation in hepatocytes obtained from normal male rat
5. Dose-response effects of 7a-, 6P-, 16a-hydroxylases (OHases), 17-oxosteroid 78 
oxidoreductase (OHSD) and 5a-reductase activities to insulin after 1 hour 
preincubation in hepatocytes obtained from normal male rat.
6. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 80
oxidoreductase (OHSD) and 5a-reductase activities to insulin after 2 hour 
preincubation in hepatocytes obtained from normal male rat
7. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 82
oxidoreductase (OHSD) and 5a-reductase activities to insulin after 24 hour 
preincubation in hepatocytes obtained from normal male rat.
8. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 85 
oxidoreductase (OHSD) and 5a-reductase activities to insulin after 48 hour 
preincubation in hepatocytes obtained from normal male rat.
XV
Page
9. Dose-response effects of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 87 
oxidoreductase (OHSD) and 5a-reductase activities to insulin after 72 hour 
preincubation in hepatocytes obtained from normal male rat.
10. Time course effect of cumulative insulin addition on 7a-, 6(3- and 16a- 91 
hydroxylases (OHases), 17-OHSD and 5a-reductase activities in hepatocytes 
from normal male rat.
11. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 94 
oxidoreductase ( OHSD ) and 5a-reductase activities to insulin after 1/2 hour 
preincubation in hepatocytes obtained from 3-days STZ-treated diabetic male rat.
12. The effect of streptozotocin and insulin treatment on the metabolism of androst- 96 
4-ene-3,17-dione in isolated hepatocytes from male rat and serum glucose 
concentration and changes in body weight of intact animal.
13. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 97 
oxidoreductase ( OHSD) and 5a-reductase activities to insulin after 1 hour 
preincubation in hepatocytes obtained from 3-days STZ-treated diabetic male rat.
14. Dose-response effects of 7a-, 6P-, 16a-hydroxylases (OHases), 17-oxosteroid 100 
oxidoreductase (OHSD) and 5a-reductase activities to insulin after 1/2 hour 
preincubation in hepatocytes obtained from 21-days STZ-treated diabetic male rat
15. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 102 
oxidoreductase ( OHSD) and 5a-reductase activities to insulin after 1 hour 
preincubation in hepatocytes obtained from 21-days STZ-treated diabetic male rat
16. Dose-response effects of 7a-, 6P-, 16a-hydroxylases (OHases), 17-oxosteroid 104 
oxidoreductase ( OHSD) and 5a-reductase activities to insulin after 2 hour 
preincubation in hepatocytes obtained from 21-days STZ-treated diabetic male rat
17. Dose-response effects,of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 107 
oxidoreductase ( OHSD ) and 5a-reductase activities to insulin after 1/2 hour 
preincubation in hepatocytes obtained from 3-days STZ diabetic male rat treated 
with (A) 2 units (B) 12 units (C) 16 units of insulin.
xvi
Bage
18. Time course assay of cytochrome P-450 content after 1/2, 1,2 and 24 hour pre- 112
-6 -9incubation with insulin (10 M and 10 M ) in hepatocytes obtained from 
normal male rat.
19. Effect of insulin on cyclic AMP content in hepatocytes from normal male rat. 113
20. Dose-response effects of 7a-, 6P-, 16a-hydroxylases (OHases), 17-oxosteroid 119 
oxidoreductase ( OHSD) and 5a-reductase activities to insulin after 1/2 hour 
preincubation in the presence of 20 nM K-252a in hepatocytes obtained from 
normal male rat.
21. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 121 
oxidoreductase ( OHSD ) and 5a-reductase activities to insulin after 24 hour 
preincubation in the presence of 20 nM K-252a in hepatocytes obtained from 
normal male rat.
22. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 124 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 1/2 minute 
preincubation in hepatocytes obtained from normal male ra t
23. Dose-response effects of 7a-, 6P-, 16a-hydroxylases (OHases), 17-oxosteroid 126 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 1 minute 
preincubation in hepatocytes obtained from normal male rat
24. Dose-response effects of 7a-, 6P-, 16a-hydroxylases (OHases), 17-oxosteroid 128 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 2 minutes 
preincubation in hepatocytes obtained from normal male rat
25. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 130 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 5 minutes 
preincubation in hepatocytes obtained from normal male rat.
26. Dose-response effects of 7a-, 6P-, 16a-hydroxylases (OHases), 17-oxosteroid 132 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 10 minutes 
preincubation in hepatocytes obtained from normal male rat
27. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 135 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 1/2 hour 
preincubation in hepatocytes obtained from normal male rat.
xvii
28. Dose-response effects of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 1 hour 
preincubation in hepatocytes obtained from normal male rat
29. Dose-response effects of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 2 hour 
preincubation in hepatocytes obtained from normal male rat
30. Dose-response effects of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 24 hour 
preincubation in hepatocytes obtained from normal male rat
31. Dose-response effects of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 48 hour 
preincubation in hepatocytes obtained from normal male rat
32. Dose-response effects of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 72 hour 
preincubation in hepatocytes obtained from normal male rat
33. Dose-response effects of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 1/2 hour 
preincubation in hepatocytes obtained from 3 days STZ-treated diabetic male rat
34. Dose-response effects of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 1/2 hour 
preincubation in the presence of 20 nM K-252a in hepatocytes obtained from 
normal male rat.
35. Dose-response effects of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 24 hour 
preincubation in the presence of 20 nM K-252a in hepatocytes obtained from 
normal male rat.
36. Dose-response effects of 7a-, 60-, 16a-hydroxylases (OHases), 17-oxosteroid 
oxidoreductase (OHSD) and 5a-reductase activities to insulin or glucagon or to 
various combinations of both hormones after 1/2 hour of preincubation in 
hepatocytes of normal male rat.
Page
137
139
142
144
146
148
151
154
157
xviii
Ease
37. Dose-response effects of 7a-, 6P-, 16a-hydroxylases (OHases), 17-oxosteroid 161 
oxidoreductase (OHSD) and 5a-reductase activities to insulin or glucagon or to 
various combinations of both hormones after 1/2 hour of preincubation in 
hepatocytes obtained from 3-days STZ-treated diabetic male rat
38. Dose-response effects of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 165 
oxidoreductase(OHSD) and 5a-reductase activities to TH-glucagon after 1/2 hour 
preincubation in hepatocytes obtained from normal male rat
39. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 167 
oxidoreductase (OHSD) and 5a-reductase activities to TH-glucagon after 1 hour 
preincubation in hepatocytes obtained from normal male rat
40. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 170 
oxidoreductase(OHSD) and 5a-reductase activities to TH-glucagon after 2 hour 
preincubation in hepatocytes obtained from normal male rat
41. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 172 
oxidoreductase(OHSD) and 5a-reductase activities to TH-glucagon after 24 hour 
preincubation in hepatocytes obtained from normal male rat
42. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 175 
oxidoreductase (OHSD) and 5a-reductase activities to phenformin after 24 hour 
preincubation in hepatocytes obtained from normal male ra t
43. Dose-response effects of 7a-, 6P~, 16a-hydroxylases (OHases), 17-oxosteroid 177 
oxidoreductase (OHSD) and 5a-reductase activities to tolbutamide after 24 hour 
preincubation in hepatocytes obtained from normal male rat
44. Dose-response effects of 7a-, 6P-, 16a-hydroxylases (OHases), 17-oxosteroid 180 
oxidoreductase ( OHSD) and 5a-reductase activities to insulin 1/2 hour 
preincubation after 24 hour exposure to 1 mM phenformin in hepatocytes 
obtained from normal male rat.
45. Dose-response effects of 7a-, 6P~, 16a-hydroxylases (OHases), 17-oxosteroid 183 
oxidoreductase ( OHSD) and 5a-reductase activities to insulin 1/2 hour 
preincubation after 24 hour exposure to 1 mM tolbutamide in hepatocytes 
obtained from normal male rat.
xix
Page
46. Dose-response effects of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 187 
oxidoreductase ( OHSD) and 5a-reductase activities to phenformin after
24 hour preincubation followed by another 1/2 hour exposure to 1 nM insulin 
in hepatocytes obtained from normal male rat.
47. Dose-response effects of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 190 
oxidoreductase ( OHSD) and 5a-reductase activities to tolbutamide after
24 hour preincubation followed by another 1/2 hour exposure to 1 nM insulin 
in hepatocytes obtained from normal male rat.
48. Dose-response effects of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 193 
oxidoreductase (OHSD) and 5a-reductase activities to phenformin after 24 hour 
preincubation in hepatocytes obtained from 3-days STZ-treated diabetic male rat
49. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 196 
oxidoreductase (OHSD) and 5a-reductase activities to tolbutamide after 24 hour 
preincubation in hepatocytes obtained from 3-days STZ-treated diabetic male rat.
50. Dose-response effects of 7a-, 6P~, 16a-hydroxylases (OHases), 17-oxosteroid 198 
oxidoreductase ( OHSD) and 5a-reductase activities to insulin 1/2 hour 
preincubation after 24 hour exposure to 1 mM phenformin in hepatocytes 
obtained from 3-days STZ-treated diabetic male rat
51. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 202 
oxidoreductase ( OHSD) and 5a-reductase activities to insulin 1/2 hour 
preincubation after 24 hour exposure to 1 mM tolbutamide in hepatocytes 
obtained from 3-days STZ-treated diabetic male rat.
52. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 205 
oxidoreductase ( OHSD) and 5a-reductase activities to phenformin after
24 hour preincubation followed by another 1/2 hour exposure to 1 nM insulin 
in hepatocytes obtained from 3-days STZ-treated diabetic male rat.
53. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 208 
oxidoreductase ( OHSD) and 5a-reductase activities to tolbutamide after
24 hour preincubation followed by another 1/2 hour exposure to 1 nM insulin 
in hepatocytes obtained from 3-days STZ-treated diabetic male rat.
54. Comparison of liver preparations in assessing drug metabolism. 216
X X
Eage
55. Composition of the synthetic multi-hormone culture medium, Ultroser G (LKB) 220 
[ content/vial ]
xxi
LIST OF FIGURES
Page
1. A hypothesis for the mechanism of action of insulin. 25
2. The phase 1 metabolism of androst-4-ene-3,l7-dione in the liver. 53
3. Schematic representation of androst-4-ene-3,l 7-dione metabolites separation 54 
by one-dimensional thin layer chromatography.
4. Schematic representation of phospholipid separation by two-dimensional 60 
thin layer chromatography.
5. Androst-4-ene-3,17-dione metabolism by isolated liver cells from normal 70 
male rat as a function of increasing number of cells per incubation.
6. Androst-4-ene-3,17-dione metabolism by isolated liver cells from normal 72 
male rat as a function of time of incubation.
7. Dose-response curves of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 76 
oxidoreductase ( OHSD) and 5a-reductase activities to insulin after 1/2 hour
of preincubation in hepatocytes obtained from normal male rat.
8. Dose-response curves of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 79 
oxidoreductase (OHSD) and 5a-reductase activities to insulin after 1 hour
of preincubation in hepatocytes obtained from normal male rat
9. Dose-response curves of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 81 
oxidoreductase (OHSD) and 5a-reductase activities to insulin after 2 hour
of preincubation in hepatocytes obtained from normal male rat.
10. Dose-response curves of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 83 
oxidoreductase (OHSD) and 5a-reductase activities to insulin after 24 hour
of preincubation in hepatocytes obtained from normal male rat.
11. Dose-response curves of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 86 
oxidoreductase (OHSD) and 5a-reductase activities to insulin after 48 hour
of preincubation in hepatocytes obtained from normal male rat.
xxii
Eagg
12. Dose-response curves of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 88 
oxidoreductase (OHSD) and 5a-reductase activities to insulin after 72 hour
of preincubation in hepatocytes obtained from normal male rat
13. Time course of the effect of insulin ( 10"9 M ) on 7a-, 6(3- and 16a- 89 
hydroxylases (OHases), 17-OHSD and 5a-reductase activities in hepatocytes 
obtained from normal male rat.
14. Time course effect of cumulative insulin (10"9 M) addition on 7a-, 6(3- and 16a- 93 
hydroxylases (OHases), 17-OHSD and 5a-reductase activities in hepatocytes 
obtained from normal male rat.
15. Dose-response curves of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 95 
oxidoreductase ( OHSD ) and 5a-reductase activities to insulin after 1/2 hour 
preincubation in hepatocytes obtained from 3-days STZ-treated diabetic male rat.
16. Dose-response curves of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 98 
oxidoreductase ( OHSD) and 5a-reductase activities to insulin after 1 hour 
preincubation in hepatocytes obtained from 3-days STZ-treated diabetic male rat.
17. Dose-response curves of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 101 
oxidoreductase (OHSD) and 5a-reductase activities to insulin after 1/2 hour 
preincubation in hepatocytes obtained from 21-days STZ-treated diabetic male rat
18. Dose-response curves of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 103 
oxidoreductase ( OHSD) and 5a-reductase activities to insulin after 1 hour 
preincubation in hepatocytes obtained from 21-days STZ-treated diabetic male rat.
19. Dose-response curves of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 105 
oxidoreductase ( OHSD) and 5a-reductase activities to insulin after 2 hour 
preincubation in hepatocytes obtained from 21-days STZ-treated diabetic male rat.
20. Dose-response curves of 7a~, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 109 
oxidoreductase ( OHSD ) and 5a-reductase activities to insulin after 1/2 hour 
preincubation in hepatocytes obtained from 3-days STZ-induced diabetic 
male rat treated with 2 units, 12 units and 16 units of Neulente insulin.
xxiii
Page
21. Effect of insulin on cyclic AMP content in hepatocytes obtained from 114 
normal male rat.
22. Concentration-response curves for insulin-induced (A) [32-P] phosphatidic acid 116 
and (B) [32-P] phosphatidylinositol formation in hepatocytes obtained from 
normal male rat.
23. Concentration-response curves for insulin-induced (A) [32-P] phosphatidic acid 117 
and (B) [32-P] phosphatidylinositol formation in hepatocytes obtained from 
3-days STZ-treated diabetic male rat
24. Dose-response curves of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 120 
oxidoreductase ( OHSD) and 5a-reductase activities to insulin after 1/2 hour 
preincubation in the presence of 20 nM K-252a in hepatocytes obtained from 
normal male rat.
25. Dose-response curves of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 122 
oxidoreductase ( OHSD) and 5a-reductase activities to insulin after 24 hour 
preincubation in the presence of 20 nM K-252a in hepatocytes obtained from 
normal male rat.
26. Dose-response curves of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 125 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 1/2 minute 
preincubation in hepatocytes obtained from normal male rat
27. Dose-response curves of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 127 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 1 minute 
preincubation in hepatocytes obtained from normal male rat
28. Dose-response curves of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 129 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 2 minutes 
preincubation in hepatocytes obtained from normal male rat
29. Dose-response curves of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 131 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 5 minutes 
preincubation in hepatocytes obtained from normal male rat
30. Dose-response curves of 7a-, 6P-, 16a-hydroxylases (OHases), 17-oxosteroid 133
( contd. )
xxiv
Page
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 10 minutes 
preincubation in hepatocytes obtained from normal male rat
31. Dose-response curves of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 136 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 1/2 hour 
preincubation in hepatocytes obtained from normal male rat.
32. Dose-response curves of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 138 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 1 hour 
preincubation in hepatocytes obtained from normal male rat
33. Dose-response curves of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 140 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 2 hour 
preincubation in hepatocytes obtained from normal male rat
34. Dose-response curves of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 143 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 24 hour 
preincubation in hepatocytes obtained from normal male rat
35. Dose-response curves of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 145 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 48 hour 
preincubation in hepatocytes obtained from normal male rat
36. Dose-response curves of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 147 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 72 hour 
preincubation in hepatocytes obtained from normal male rat
37. Dose-response curves of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 149 
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 1/2 hour 
preincubation in hepatocytes obtained from 3 days STZ-treated diabetic male rat
38. Dose-response curves of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 152 
oxidoreductase (OHSD) and 5 a-reductase activities to glucagon after 1/2 hour 
preincubation in the presence of 20 nM K-252a in hepatocytes obtained from 
normal male rat.
39. Dose-response curves of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 155
( contd.)
XXV
Eage
oxidoreductase (OHSD) and 5a-reductase activities to glucagon after 24 hour 
preincubation in the presence of 20 nM K-252a in hepatocytes obtained from 
normal male rat.
40. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 158 
oxidoreductase (OHSD) and 5a-reductase activities to insulin or glucagon or to 
various combinations of both hormones after 1/2 hour of preincubation in 
hepatocytes of normal male rat
41. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 162 
oxidoreductase (OHSD) and 5a-reductase activities to insulin or glucagon or to 
various combinations of both hormones after 1/2 hour of preincubation in 
hepatocytes obtained from 3-days STZ-treated diabetic male rat.
42. Dose-response curves of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 166 
oxidoreductase(OHSD) and 5a-reductase activities to TH-glucagon after 1/2 hour 
preincubation in hepatocytes obtained from normal male rat.
43. Dose-response curves of 7a-, 6P-, 16a-hydroxylases (OHases), 17-oxosteroid 168 
oxidoreductase (OHSD) and 5a-reductase activities to TH-glucagon after 1 hour 
preincubation in hepatocytes obtained from normal male rat.
44. Dose-response curves of 7a-, 6P-, 16a-hydroxylases (OHases), 17-oxosteroid 171 
oxidoreductase(OHSD) and 5a-reductase activities to TH-glucagon after 2 hour 
preincubation in hepatocytes obtained from normal male rat.
45. Dose-response curves of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 173 
oxidoreductase(OHSD) and 5a-reductase activities to TH-glucagon after 24 hour 
preincubation in hepatocytes obtained from normal male rat.
46. Dose-response curves of 7a-, 6P-, 16a-hydroxylases (OHases), 17-oxosteroid 176 
oxidoreductase (OHSD) and 5a-reductase activities to phenformin after 24 hour 
preincubation in hepatocytes obtained from normal male rat.
47. Dose-response curves of 7a~, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 178 
oxidoreductase (OHSD) and 5a-reductase activities to tolbutamide after 24 hour 
preincubation in hepatocytes obtained from normal male rat.
xxvi
Page
48. Dose-response effects of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 181 
oxidoreductase ( OHSD) and 5a-reductase activities to insulin 1/2 hour 
preincubation after 24 hour exposure to 1 mM phenformin in hepatocytes 
obtained from normal male rat.
49. Dose-response effects of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 184 
oxidoreductase ( OHSD) and 5a-reductase activities to insulin 1/2 hour 
preincubation after 24 hour exposure to 1 mM tolbutamide in hepatocytes 
obtained from normal male rat.
50. Dose-response effects of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 188 
oxidoreductase ( OHSD) and 5a-reductase activities to phenformin after
24 hour preincubation followed by another 1/2 hour exposure to 1 nM insulin 
in hepatocytes obtained from normal male rat.
51. Dose-response effects of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 191 
oxidoreductase ( OHSD) and 5a-reductase activities to tolbutamide after
24 hour preincubation followed by another 1/2 hour exposure to 1 nM insulin 
in hepatocytes obtained from normal male rat
52. Dose-response curves of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 194 
oxidoreductase (OHSD) and 5a-reductase activities to phenformin after 24 hour 
preincubation in hepatocytes obtained from 3-days STZ-treated diabetic male rat
53. Dose-response curves of 7a-, 6(3-, 16a-hydroxylases (OHases), 17-oxosteroid 197 
oxidoreductase (OHSD) and 5a-reductase activities to tolbutamide after 24 hour 
preincubation in hepatocytes obtained from 3-days STZ-treated diabetic male rat
54. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 199 
oxidoreductase ( OHSD) and 5a-reductase activities to insulin 1/2 hour 
preincubation after 24 hour exposure to 1 mM phenformin in hepatocytes 
obtained from 3-days STZ-treated diabetic male rat.
55. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 203 
oxidoreductase ( OHSD) and 5a-reductase activities to insulin 1/2 hour 
preincubation after 24 hour exposure to 1 mM tolbutamide in hepatocytes 
obtained from 3-days STZ-treated diabetic male rat.
( contd. )
xxvi i
Page
56. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 206 
oxidoreductase ( OHSD) and 5a-reductase activities to phenformin after
24 hour preincubation followed by another 1/2 hour exposure to 1 nM insulin 
in hepatocytes obtained from 3-days STZ-treated diabetic male rat.
57. Dose-response effects of 7a-, 6p-, 16a-hydroxylases (OHases), 17-oxosteroid 209 
oxidoreductase ( OHSD) and 5a-reductase activities to tolbutamide after
24 hour preincubation followed by another 1/2 hour exposure to 1 nM insulin 
in hepatocytes obtained from 3-days STZ-treated diabetic male rat.
INTRODUCTION
1.0 HISTORICAL BACKGROUND : CYTOCHROME P-450
The first reported study on cytochrome P-450 was done by Williams in 1955 at 
the Johnson Foundation for Medical Physics, University of Pennsylvania. Using the 
double-beam recording spectrophotometer he noticed the appearance of a broad but 
intense absorption band at 450 nm upon bubbling carbon monoxide into a dithionite- 
reduced rat liver microsomal suspension. Although this novel observation was not 
published, it was reported by Klingenberg ( 1958 ) who was working in the same 
laboratory as Williams. However, it was only after four years that Omura and Sato 
( 1962 ) published a preliminary account of their studies on this pigment which was a 
new b-type cytochrome, in which they presented conclusive spectral evidence for its 
hemeprotein nature and proposed the name ' P-450 ’. The discovery of its physiological 
function as a principal enzyme responsible for the hydroxylation or oxidative 
dealkylation of various drugs by liver microsomes ( Cooper et.al., 1965 ) provided a 
great impetus into the research of this newly discovered hemeprotein.
The liver is the major site of the biotransformation of foreign compounds into 
more polar derivatives and the enzymes effecting many of these transformations were 
suggested to be located in the endoplasmic reticulum ( Brodie et.al., 1955 ) of the 
parenchymal cells. Although first discovered in the rat liver, it was later demonstrated to 
exist in the mitochondria of the adrenal gland ( Harding et.al., 1964 ) and in the kidney, 
lung and intestine ( Paine, 1981 ). Recently, it was demonstrated that the non- 
parenchymal cells of the liver also have the capacity, though lower than the parenchymal 
cells, to metabolize a wide range of drugs and chemicals ( Steinberg et.al., 1987 ). In the 
later half of the 1960's, successive reports on the discoveiy of this hemeprotein 
( molecular weight 45,000-60,000 ) in various forms of life, demonstrated that the 
distribution of cytochrome P-450 among living creatures was much wider than initially
thought. The presence of cytochrome P-450 in the yeast, Saccharomyces cerevisiae, was 
described by Lindenmayer and Smith ( 1964 ). Subsequently, the discoveries of 
cytochrome P-450 in several species of bacteria ( Dus et.al., 1970 ), plants ( Murphy 
and West, 1970) and insects ( Morello et.al., 1971) have been reported.
Interest in the research on this hemeprotein was shared by pharmacologists, 
endocrinologists, toxicologists and biochemists because its discovered functions included 
some of the most important metabolic reactions in their respective research fields. 
Cytochromes P-450 are needed for the synthesis of prostaglandins and steroid hormones 
( Kupfer, 1980 ) and are responsible for the oxidative conversion of many foreign 
compounds such as drugs, pesticides, carcinogens and environmental pollutants. These 
foreign compounds are generally converted into a form that can be more readily excreted 
from the body. However, some compounds, which are themselves inert, are metabolized 
to form potential carcinogenic by-products and sometimes result in the formation of 
pharmacologically active end-products.
The capacity to metabolize such a broad spectrum of substrates is in part due to 
the existence of many forms of cytochrome P-450, which exhibit unique but overlapping 
substrate specificities ( Lu and West, 1980 ). The use of different inducers such as 
phenobarbital, 3-methylcholanthrene and pregnenolone 16a-carbonitrile, to manipulate 
the biochemical and biophysical properties of the microsomal hydroxylation system has 
played a major role in establishing the existence of multiple forms of cytochrome P-450. 
The finding of the successful stabilization of cytochrome P-450 by glycerol ( Ichikawa 
and Yamano, 1967 ) permitted solubilization and purification experiments on cytochrome 
P-450. Recent techniques have helped in the isolation and purification of a number of 
cytochrome P-450 isoenzymes such as cyt. P-450 15|3-hydroxylase ( MacGeoch et.al., 
1984 ), cyt. P-450 16a-hydroxylase ( Morgan et.al., 1985a ) and cholesterol 7a- 
hydroxylase ( Ogishima et.al., 1987 ).
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Many factors have been shown to affect the metabolism of xenobiotics and these 
have been reviewed in detail by others ( Paine, 1981; Gibson and Skett, 1986 ) and 
amongst these factors are hormones. The many alteration in drug and steroid metabolism 
have been attributed to the imbalance of the hormones of the endocrine system as a result 
of endocrinological disorders. One of the most widely researched endocrine organ, 
whose secretions affect xenobiotic metabolism, is the pancreas. At least 4 peptides with 
hormonal activity are secreted by the islets of Langerhans in the pancreas, two of these 
hormones are insulin and glucagon. Absolute or relative deficiency of insulin results in a 
disease called diabetes mellitus. Numerous studies have demonstrated the influence of 
diabetes mellitus on xenobiotic metabolism in experimental animals and this aspect of 
metabolism will be discussed in detail in the next section.
1.1 THE EFFECT OF DIABETES MELLITUS ON XENOBIOTIC AND
STEROID METABOLISM
The first reported effect of diabetes mellitus on xenobiotic metabolism was made 
in 1961 when Dixon and co-workers demonstrated an alteration in drug metabolism in the 
rat after acute treatment with the P-cell toxin, alloxan. Livers from diabetic animals were 
able to metabolize hexobarbital, codeine and chlorpromazine at only a fraction of the 
normal rate. The metabolism of the drugs returned to normal 24 hours after treatment of 
the animals with insulin. As the effect on drug metabolism was usually accompanied by a 
decreased in hepatic glycogen content, the authors suggested a relationship between the 
decrease in the drug metabolism and hepatic glycogen content since the latter is stored in 
parts of the smooth-surfaced endoplasmic reticulum ( SER ). Changes in the hepatic 
glycogen levels is accompanied by structural alterations of the SER ( Porter and Bruni, 
1959 ) and this may result in structural alteration and orientation of the cytochrome 
P-450. This is substantiated by a similar decrease in the metabolism of a variety of 
drugs in starved male rats ( Kato and Gillette, 1965a ). The observation of the reduction 
of drug metabolism in diabetic animals were also confirmed by other workers ( Kato and 
Gillette, 1965b; Weiner et.al., 1972 ). However the effect of diabetes is not always to 
decrease drug metabolism as documented by Dixon et.al. ( 1963 ). Aniline hydroxylation 
was reported to be stimulated in the diabetic condition. Furthermore their work revealed 
that the effect on the metabolism of codeine was time-dependent. The metabolism of 
codeine was decreased in the acutely diabetic rats but was found unaltered in the 
chronically diabetic rats.
The paradoxical effect of diabetes on aniline metabolism was later resolved by 
Kato and Gillette ( 1965b ) where they demonstrated the existence of sex-differences in 
the effect of diabetes on drug metabolism in the rat. They confirmed the works of Dixon
et.al. ( 1961 ) by observing a decrease in hexobarbital metabolism and an increase in 
aniline metabolism in the diabetic male rats . They also observed a decrease in 
aminopyrine metabolism. However, all these three parameters were found to increase in 
the diabetic fem ale  rats. They have shown previously that there is a marked sex 
difference in the metabolism of aminopyrine but little, if any, sex difference in the 
hydroxylation of aniline ( Kato and Gillette, 1965a ). They postulated that alloxan 
diabetes impairs mainly the markedly sex-dependent enzymes. It is interesting to note that 
a similar decrease in the hexobarbital hydroxylation was also observed in castrated male 
rats and the administration of methyl testosterone to such rats restored the activity to the 
level of the intact males. Alloxan diabetes did not produce a further decrease in the 
hexobarbital hydroxylation in the castrated rats but produced a marked decrease in the 
hexobarbital hydroxylation both in the methyltestosterone treated castrated rats and the 
intact males suggesting that the effect of alloxan diabetes could probably be mediated 
through the impairment of an androgen-dependent stimulating mechanism ( Kato and 
Onoda, 1970 ). A later study by Kato et.al. ( 1971 ) demonstrated that the magnitude of 
the difference spectrum of cytochrome P-450 induced by hexobarbital and aminopyrine 
was markedly decreased in the male, but not in the female, alloxan-treated rats. This 
suggests that the binding capacities of cytochrome P-450 for hexobarbital and 
aminopyrine, which are normally stimulated by androgen ( Schenkman et.al., 1967 ), are 
decreased in the microsomes of the diabetic male rats.They also reported that treatment 
with alloxan decreases the Vmax value for hexobarbital hydroxylation by liver 
microsomes of male rats, whereas it increased the Km and Ks ( spectral dissociation 
constant ) values. Previous work by Kato and Onoda ( 1970 ) indicated that the 
administration of androgen increases both the Km and Ks values for hexobarbital and 
aminopyrine. These results indicate that the actions of androgen to increase the binding 
capacity and affinity of cytochrome P-450 with the drug substrates are impaired by
diabetes, resulting in the decrease in the oxidation of hexobarbital and aminopyrine.
In 1972, Weiner et.al. demonstrated that the inhibitory effect of alloxan diabetes 
and starvation on hepatic drug metabolism could be mimicked by glucagon. This 
inhibitory effect of glucagon could be partially reversed by insulin, an effect similarly 
seen with diabetic rats ( Dixon et.al., 1961; Dixon et.al., 1963 ). Insulin antagonism of 
the effects caused by diabetes and glucagon provided an insight into the role of cyclic 
nucleotides and the possible mechanism of action, at the membrane level, of diabetes 
mellitus on hepatic drug metabolism since both glucagon and diabetes have been shown 
to increase liver cyclic AMP concentration ( Weiner et.al., 1972; Jefferson et.al., 1968 ).
All of these studies described above, relating to the effect of diabetes mellitus on 
drug metabolism in experimental animals, employed alloxan as a diabetogenic agent. 
Alloxan has been criticized for its overt toxicity since it not only affects the p-cells of the 
pancreas but has also been reported to have a toxic effect on the kidney, making it 
uncertain whether the effects seen were related to its diabetogenic action. It thus may not 
serve as a good model of diabetes. A relatively new diabetogen, streptozotocin ( STZ), 
which has a more P-cell-selective action with less general toxic effects, has become more 
popular as a diabetogenic agent ( Hoftiezer and Carpenter, 1973 ). Thus, STZ-treated 
animals have been used as a model for type 1 diabetes in this study.
Although the microsomal metabolism of the androgenic hormones, testosterone 
and androst-4-ene-3,17-dione, has been studied in several laboratories ( Conney et.al., 
1973; Einarsson et.al.,1974 ), Reinke et.al. ( 1978 ) were the first to report an alteration 
in hepatic steroid metabolism in STZ-diabetic male rats. The diabetic state resulted in an 
overall decrease in the rate of microsomal metabolism of androst-4-ene-3,17-dione, 
compared to controls. Differential effects on metabolism were observed with individual 
metabolites. The hepatic microsomes from the diabetic rats exhibited an increased and 
decreased activities of the female-specific 7a-hydroxylase ( Stenberg,1976 ) and male-
specific 16a-hydroxylase respectively, indicating a sex-differentiation in the effect of the 
diabetic state. All of these alterations were restored to normal levels when the diabetic rats 
were treated with insulin. This result is in good agreement with previous reported work 
relating to drug metabolism where the diabetic state produces the sex-dependent effects by 
interfering with androgen-dependent microsomal pathways in the rat ( Kato and Gillette, 
1965b; Kato et.al., 1971 ). Skett ( 1986 ) also reported the sex-dependent effect of 
diabetes mellitus on steroid metabolism in rat where alterations were only seen in the male 
and the effect is always to abolish the sex differences in steroid metabolism found in the 
intact animals.
In the late 1970s and early 1980s work was concentrated on the relationship 
between the changes in the cytochrome P-450 content and the changes seen in drug 
metabolism in diabetic animals. Inconsistent reports on the effect of diabetes mellitus on 
hepatic microsomal cytochrome P-450 content were presented. Ackerman and Liebman 
( 1977 ), Kato et.al. ( 1971 ) and Faas and Carter ( 1980 ) reported no alteration in 
cytochrome P-450 content in diabetic male rats but increased levels in the diabetic female 
rats whereas Reinke et.al. ( 1978 ) reported an increase in cytochrome P-450 content in 
both the male and female diabetic rats. The reason for this lack of agreement was pointed 
out by Skett ( 1987 ) as being due to the difference in the time the animals were killed 
after STZ treatment. In 1980, by using sodium dodecyl sulphate (SDS)-polyacrylamide 
gel electrophoresis, Past and Cook managed to separate different forms of cytochrome 
P-450. In this study they discovered that diabetes mellitus induced, in both the male and 
female rat hepatic microsomes, specific increases and decreases in the cytochrome P-450 
isoenzymes. The notion of specific alteration of cytochrome P-450 isoenzymes by 
diabetes mellitus was substantiated by the discovery by the same workers in 1982 of a 
diabetes-dependent form of cytochrome P-450 which they were able to isolate. This 
cytochrome P-450, with a molecular weight of 52,000 , was also induced in the diabetic 
female rat ( Past and Cook, 1983 ) but was not detected in hepatic microsomes from
normal, 3-methylcholanthrene- or phenobarbital-treated rats. This cytochrome P-450 
was, however, not detected in the insulin-treated diabetic rats. When compared to normal 
P-450 in a reconstituted system, this unique 52,000 molecular weight cytochrome P-450 
was shown to increase the hydroxylation of aniline and decrease the N-demethylation of 
morphine. In another laboratory, Warren et.al. ( 1983 ) found that the diabetic females, in 
comparison to the controls, showed an increase in the 52,000 molecular weight band 
without a decrease in the 46,000 and 61,000 molecular weight regions. On the other 
hand, in the diabetic males, there was a similar rise in the 52,000 molecular weight band, 
but there was a marked reduction in the 46,000, 56,000 and 61,000 regions. Insulin 
treatment reversed these changes in both male and female diabetic animals. Further 
evidence of alterations in specific constitutive cytochrome P-450 isoenzymes in the 
diabetic state was provided by Favreau and Schenkman ( 1987 ) when they measured 
cytochrome P-450- dependent hydroxylation of testosterone in hepatic microsomes of 
control, diabetic and insulin-treated diabetic rats. Cytochrome P-450 RLM5 has been 
shown to be the major form of cytochrome P-450 responsible for 16a-hydroxylase 
activity ( Waxman, 1984 ). Favreau and Schenkman ( 1987 ) showed that testosterone 
16a-hydroxylase activity was decreased in diabetes and this was accompanied by a 
dramatic decrease in immunodetectable cytochrome P-450 RLM5. Insulin treatment 
resulted in partial restoration of the 16a-hydroxylase activity and the cytochrome P-450 
RLM5 levels. In that same year, Favreau et.al. ( 1987 ) also reported the isolation of two 
specific forms of cytochrome P-450, both of which were found to be elevated in the 
streptozotocin-induced diabetic male rats. One enzyme, cytochrome P-450 RLM6, 
metabolizes aniline and acetol, but not testosterone, and insulin treatment of diabetic rats 
for 1 week lowered the immunologically detectable levels of cytochrome P-450 RLM6 to 
levels found in the control rat. The second form, cytochrome P-450 RLM5b does not 
metabolize aniline and only poorly metabolizes acetol and testosterone. However, 1 week
of treatment of the diabetic animals with insulin only partially restored the microsomal 
content to that of the normal rat. Recently, Favreau and Schenkman (1988) reported three 
different types of responses by constituents of the cytochrome P-450 population to 
diabetes. The immunodetectable levels of cytochrome P-450 RLM3 and RLM5 were 
decreased when the animals were made diabetic by STZ . In contrast, the levels of 
cytochrome P-450 RLM5b and RLM6 were elevated in diabetes and the level of the fifth 
enzyme, cytochrome P-450 RLM5a, was not markedly altered by diabetes. Two forms of 
sex-dependent cytochrome P-450 have been described in the rat, P-450 male and P-450 
female. They are developmentally controlled by androgenic and estrogenic hormones 
( Kamataki et.al., 1983 ), as well as by growth hormone ( Morgan et.al., 1985b ). 
Since the diabetic state is usually associated with alteration of testosterone ( Warren 
et.al., 1983 ) and growth hormone ( Press et.al., 1986 ) levels, this could explain the 
changes in the levels of the constitutive cytochrome P-450 isoenzymes.
Alteration of drug metabolism has also been demonstrated in the liver of STZ- 
diabetic mice ( Rouer and Leroux, 1980 ) and these modifications were completely 
corrected by insulin treatment of the diabetic mice. Interestingly, they have also 
demonstrated that normal male mice treated with glucagon by injection or continuous 
infusion, exhibited alteration of drug metabolism. These hyperglucagonemic animals 
showed a decrease in cytochrome P-450 content but also an increased synthesis of a 
specific cytochrome P-450 isoenzyme which differs from those induced by the two 
classical chemical inducers, phenobarbital and 3-methylcholanthrene (Rouer etal., 1985). 
The increases in aniline hydroxylation and benzphetamine N-demethylation seen in the 
STZ-diabetic mice were also seen in the glucagon-treated animals suggesting that the 
alteration of the glucagon level in the diabetic state could play a part in the altered 
xenobiotic metabolism.
Since diabetes affects only the androgen-responsive enzymes in the male rat and
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has little effect in the female, it has been postulated that diabetes in some way interferes 
with the androgenic stimulation of drug metabolism in the male and, thus, exerts its 
sex-dependent effect ( Kato, 1974 ). This is supported by observations that diabetes 
alters the serum androgen levels by interfering with the release or production of 
testosterone from the testes ( Murray et.al., 1981 ). However, the newly discovered 
system, the hypothalamo-pituitary-liver axis regulating the sex differences in steroid and 
xenobiotic metabolism in the liver, as suggested by Gustafsson and co-workers ( 1983 ), 
has led to a restyling of this idea. Skett et.al. ( 1984 ), in their study to link serum 
testosterone and the effect of diabetes on drug metabolism, discovered that there was a 
complete dissociation of change in serum testosterone and effect on hepatic drug 
metabolism. The level of androgen does not change in the acute diabetic phase when a 
marked alteration of drug metabolism is seen but serum androgen levels are markedly 
reduced in the chronic phase with little effect on hepatic drug metabolism. Skett and 
Gustafsson ( 1979 ) found that androgens do not exert a direct effect on the liver but 
probably have an indirect effect via the hypothalamo-pituitary axis. It has been suggested 
that androgens and insulin affect drug metabolism by acting through a common 
mediator - and this mediator has been proposed to be growth hormone ( Skett, 1987 ). 
Diabetes mellitus is associated with reproductive disorders and lesions of the testes and 
accessory sex organs in man ( Schoffling et.al., 1963 ) and in male animal models 
( Foglia et.al., 1963 ). A later study has shown that STZ-diabetes induces different 
neuroendocrine and morphological alterations in the hypothalamo-pituitary axis of male 
and female rats ( Bestetti et.al., 1985 ). From the anatomical data, this study also 
indicated that the brain and pituitary are less severely affected by diabetes in female than 
in male rats. According to the hypothalamo-pituitary-liver axis concept, these differential 
effects, resulting from insulin deficiency, and the effect of diabetes on androgen turnover 
would somehow influence the drug metabolism in both sexes of the ra t
In 1985, Skett and Joels reported that diabetes mellitus has a transient effect on 
drug metabolism. Acute diabetes had a marked effect on drug metabolism while the 
chronic effect was much less than that seen in the acute phase. In another study, 
MacFarlane and Skett ( 1986 ) reported that there is no correlation between STZ-induced 
changes in drug metabolism and the serum parameters i.e. serum glucose and triglyceride 
levels.
The diabetic effect on drug and steroid metabolism can be partially or completely 
restored to normal by treating the animals with insulin. Glucagon infused animals also 
showed alteration in drug metabolism that resembles the effect of diabetes on the 
metabolism of some substrates. All this is indicative of the role of both hormones in the 
regulation of xenobiotic and steroid metabolism in the rat liver. In the next two sections 
we will focus our discussion on the receptor structure of both of the hormones and then- 
possible mechanism of action at the molecular level.
1.2 INSULIN
1.2.1 THE STRUCTURE OF THE INSULIN RECEPTOR
There is general consensus that the mature insulin receptor is an integral membrane 
glycoprotein that spans the plasma membrane bilayer of most animal cells. A large body 
of evidence generated by a variety of approaches is consistent with the concept that the 
major form of the native insulin receptor complex is a symmetrical heterotetrameric 
glycoprotein composed of two a  and two p subunits covalently linked to one 
another by cc-p and a - a  disulphide bonds [ Kahn, 1985; Czech, 1985 ]. The 
isolated receptor consists of two types of subunits : a 135,000 M.W. a  subunit and 
a 95,000 M.W. p subunit [ Jacobs et.al., 1979 ]. A smaller subunit of 45-50 
kilodaltons ( kDa ), identified on electrophoretic gels after affinity-purification and 
labelling, was found to be derived from the insulin receptor complex [ Massague 
et.al., 1980 ] and appears to be a proteolytic ( elastase ) fragment of the p-subunit 
and has been denoted pj [ Massague et.al., 1981]. This general model for the insulin 
receptor subunit configuration was originally proposed independently by Jacobs and co­
workers [ Jacobs et.al., 1979 ] using photolabelling and affinity purification 
techniques and by Massague and colleagues [ Massague et.al., 1980; Czech 
et.al., 1981 ] using affinity cross-linking techniques. Several observations strongly 
suggest the oc2p2  stoichiometry [ Kasuga et.al., 1982a ] and the disulphide-linked 
configuration [ Pilch and Czech, 1980 ]. An alternative structure of the insulin-receptor 
complex has been put forward by Yip and Moule [1983] whereby evidence supporting a 
different type of insulin-receptor structure in rat adipocytes was obtained using two 
photoreactive derivatives of insulin. The authors suggested that the receptor exists in three 
interconvertible redox forms of 380, 300 and 230 kilodaltons and the interconversion of 
these three receptor species is the result of oxidation and reduction of the intersubunit
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sulphydryl groups. The substantial differences in receptor structure from that obtained in 
fat cells [ Massague et.al., 1981 ] and liver membranes [ Jacob et.al., 1979 ] signify 
that further studies are required for its full elucidation.
Recent evidence suggests that the a  and (3 subunits are synthesised in cells as a 
single polypeptide precursor that is ultimately processed to the mature cell-surface 
receptor subunits by proteolytic cleavages [ Ronnett et.al., 1984 ]. Data from many 
studies indicate that the insulin receptor subunits are synthesised as a high Mr polypeptide 
precursor that is rapidly glycosylated and identified as an endoglycosidase H-sensitive 
190 kDa species. This is followed by further glycosylation yielding a 210 kDa precursor. 
It is known that glycosylation is a prerequisite for the formation of a functional insulin 
receptor [ Reed et.al., 1981; Ronnett et.al., 1984 ]. The endoglycosidase H-sensitive 
210 kDa species is a substrate for one or more proteolytic processing cleavages, which 
result in the formation of 125 kDa and 83 kDa subunit precursors.These two precursors 
contain oligosaccharide chains that are ultimately capped with sialic acid residues near the 
time of their appearance at the cell surface. The insulin receptor has been shown to be 
a glycoprotein [ Reed et.al., 1981; Ronnett et.al., 1984 ] in which the oligosaccharide 
side chains are N-linked complex structures. These complex carbohydrate side chains are 
linked to asparagine in the polypeptide backbone of the receptor and contain N- 
acetylglucosamine, mannose, galactose, fucose and sialic acid.
The identification of the a  subunit as one of the component of the insulin- 
receptor complex was first suggested by visualisation of protein-stained electrophoretic 
gels containing a preparation of insulin receptor that had been affinity purified by 
adsorption and elution from insulin-agarose [ Jacobs et.al., 1977 ]. A band of similar 
apparent mass was subsequently identified by photoaffinity labelling [ Yip and Moule, 
1983 ] and affinity cross-linking techniques [ Pilch and Czech 1980 ]. The a  subunit 
can now be readily identified by photoaffinity labelling [ Yip and Moule 1983 ], 
affinity purification [ Jacobs et.al., 1979 ], specific immunoprecipitation of insulin
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receptors [ Kasuga et.al., 1981b ], affinity cross-linking [ Czech et.al., 1981 ], and 
immunoaffinity purification [ Harrison and Itin, 1980; Heinrich et.al., 1980 ]. 
The amino acid sequencing studies indicate that the a  subunit contains no 
transmembrane sequence [ Ullrich et.al., 1985; Ebina et.al., 1985 ] suggesting that it is 
located entirely external to the plasma membrane, presumably being firmly attached to the 
external membrane surface through covalent disulphide cross-links to the (3 subunit. First 
evidence to indicate that the a  subunit is a glycoprotein was demonstrated by an altered 
electrophoretic mobility after treatment with neuraminidase [ Jacobs et.al., 1980 ]. It was 
further confirmed by receptor immunoprecipitation techniques using a variety of anti­
insulin receptor antibody preparations whereby labelled saccharides were shown to 
incorporate into the a  subunit [ Roth et.al., 1982 ]. Affinity labelling of the receptor 
using either photosensitive insulin analogues [Jacobs et.al., 1979], or cross-linking 
insulin with bifunctional reagents [ Pilch and Czech, 1979 ] have shown that the a  subunit 
is the predominant labelled species when compared to the (3-subunit, the labelling of 
which is much weaker [ Massague et.al., 1981 ], or even absent [ Yip et.al., 1978 ]. This 
suggests that the a  subunit of the receptor oligomer houses the insulin-binding site which 
is located on the outer face of the plasma membrane where it is accessible to extracellular 
insulin. An insulin receptor a  subunit of similar features to that found in human and 
rodent has been identified in tissues of the hagfish, denoting a substantial conservation of 
its properties over the last 500 million years of evolution [ Czech and Massague, 1982 ].
The identification of the (3 subunit has been more elusive than the a  on the grounds 
that it is poorly labelled by most [ Czech et.al., 1981 ], although not all, affinity 
labelling procedures [ Yip and Moule, 1983 ] , is poorly stained by Coomassie blue or 
silver compared to the a  subunit [ Fujita-Yamaguchi, 1984 ], and also is relatively 
more sensitive to fragmentation by proteases [ Massague et.al., 1981]. It was first 
detected in affinity purification studies as a receptor band [ Jacobs et.al., 1979 ] and was
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deduced to be part of the native insulin receptor structure by affinity cross-linking 
[ Czech et.al., 1981 ] and affinity purification [ Jacobs and Cuatrecasas, 1981] techniques 
and two dimensional gel electrophoresis in the presence and absence of reductant. In 
intact cells, insulin was found to stimulate the phosphorylation of the insulin receptor 
purified on wheat-germ-agglutinin-agarose. This was first demonstrated in rat hepatoma 
cells and human IM-9 lymphoblasts [ Kasuga et.al., 1982b ], and later in freshly isolated 
rat hepatocytes [ Van Obberghen and Kowalski, 1982 ]. The cells were preincubated with
32P-orthophosphate to label cellular ATP, then solubilised in detergent and affinity 
purified on wheat-germ-agglutinin-agarose. Immunoprecipitation of phosphorylated 
proteins by antibodies to insulin receptor followed by sodium dodecyl sulphate (SDS) 
polyacrylamide gel electrophoresis under reducing conditions and autoradiography 
revealed a labelled band ( Mr ~ 95,000 ). Its identity with the insulin receptor P subunit 
was established for the following reasons. First, non-immune serum did not precipitate a 
band with a similar electrophoretic mobility. Second, the molecular size was identical 
with that determined previously, using biosynthetic and affinity labelling methods 
[ Pilch and Czech, 1979; Massague et.al., 1981 ]. Subsequently, the phosphorylation of 
the P subunit of the insulin receptor was demonstrated in cell-free systems using [y- 
32P]-ATP in solubilised and partially purified receptor preparations from rat liver and 
human placenta [ Kasuga et.al., 1982b; Petruzzelli et.al., 1982 ]. Phosphoaminoacid 
analysis of the phosphorylated p-subunit of partially purified receptors showed 
phosphoserine, phosphothreonine and phosphotyrosine under basal conditions. Insulin
32induced a several-fold increase in P-incorporation into tyrosine, and had in addition a 
smaller, but consistent stimulating effect on the labelling of serine [ Kasuga et.al., 
1982b]. An interesting feature is that insulin stimulates the autophosphorylation of the 
P subunit of its own receptor in both intact cells [ Kasuga et.al., 1982b ]
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and in a cell-free system [ Petruzzelli et.al., 1982 ]. The 90,000-dalton subunit 
contains oligosaccharide as evidenced by its biosynthetic labelling with labelled 
monosaccharides [ Hedo et.al., 1981 ]. It is possible that receptor phosphorylation could 
participate in altering the affinity for insulin, play a role in receptor internalisation, or 
initiate some of insulin's biological responses. The latter possibility is supported by the 
demonstration that vanadate ions, which mimic the biological effects of insulin [ Shechter 
and Karlish, 1980; Dubyak and Kleinzeller, 1980 ], are also potent inhibitors of 
tyrosine-specific phosphoprotein phosphatase [ Swarp et.al., 1982 ]. Amino acid 
sequence studies indicate that the p-subunit possesses a single hydrophobic 
transmembrane domain consisting of 23 amino acid residues which separate the external 
one-third of its polypeptide chain from the intracellular two-thirds. Hence, the kinase 
catalytic site is disposed on the inner face of the plasma membrane where it has access to 
intracellular ATP and target protein substrates.
Peptide-mapping experiments indicated distinct overall peptide maps of the a  and 
P subunits and are consistent with the apparent different functional roles of the subunits, 
whereby the a  subunit binds hormone while the p subunit carries tyrosine kinase activity 
and is the predominant subunit autophosphorylated. The postulated insulin receptor 
structure suggests a scenario for transmembrane signalling induced by insulin. The 
binding of insulin at the 'extracellular' ligand-binding site of the receptor presumably 
induces a conformational change in the a  subunit that is transmitted through the 
membrane bilayer to the tyrosine protein kinase domain of the p subunit where catalysis 
is activated. This in turn would allow the receptor to phosphorylate an intracellular target 
protein(s), thereby initiating the cascade of events eliciting a remarkable array of 
biological responses.
1.2.2 THE TNSIJLTN RECEPTOR KINASE
The earliest known event that follows the binding of insulin to its receptor is 
activation of the receptor protein tyrosine kinase. Kasuga and colleagues [ Kasuga et.al.,
321982b ] first demonstrated that incubation of P-labelled cultured human lymphocytes 
and rat hepatoma cells with insulin (at physiological concentrations) leads to the increased
32incorporation of P into the insulin receptor (3 subunit and it was shown to reflect 
32incorporation of [ P] phosphate into both serine and tyrosine residues of the P subunit. 
These results are strikingly similar to the ability of epidermal growth factor to stimulate 
the phosphorylation of its own receptor observed by Cohen et.al., [1980] who pioneered 
the discovery of growth factor receptors as enzymes that catalyse tyrosine 
phosphorylation. However, early studies were not conclusive as to whether the insulin 
receptor is a protein kinase or only a substrate for an intrinsic protein kinase. Two series 
of observations have led to the idea that the insulin receptor itself is likely to be a protein 
kinase. Firstly, insulin receptors isolated by specific immunoprecipitation can be 
phosphorylated and insulin increased several-fold their phosphorylation [ Van Obberghen 
et.al., 1983 ]. This indicates that anti-receptor antibodies immunoprecipitate an insulin- 
responsive kinase, which is closely associated with the receptor, or contained in the
32receptor. Secondly, using covalent affinity labelling with oxidised (a- P) ATP, a 
specific ATP binding site on a polypeptide with Mr 95,000 was identified indicating that it 
contains a catalytic site for the insulin receptor-associated tyrosine kinase [ Va n  
Obberghen et.al., 1983 ]. At the same time it was demonstrated that highly purified 
insulin receptor from human placenta [ Fujita-Yamaguchi etal., 1983 ] retained protein 
kinase activity [ Kasuga et.al., 1983 ]. Further support to show the localisation of the 
tyrosine kinase on distinct subunits of the insulin receptor comes from the observation
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that selective degradation of the p subunit of the receptor by collagenase was 
accompanied by concomitant loss of kinase activity, whilst exerting no effect on the a  
subunit and insulin binding [Roth et.al., 1983b].
1.2.2.1 REGULATION OF THE INSIJLTN RECEPTOR KINASE
1.2.2.1.1 In-vivo studies
In intact cells, insulin stimulates not only the phosphorylation of its own receptor 
on tyrosine but also the subsequent phosphorylation of the receptor on serine and 
threonine residues. A rapid rise in the level of phosphotyrosine is followed by a slower 
increase in the content of phosphoserine [ Denton, 1986]. The insulin receptor from 
insulin-treated cells can be isolated in its phosphorylated, active form [ Stadmauer and 
Rosen, 1986 ] indicating that the phosphorylation-induced activation of the receptor 
kinase occurs in-vivo. Czech [1984] found at least seven phosphorylation sites on the
32insulin receptor upon addition of high concentrations of [y- P]ATP. Also in their study, 
serine and tyrosine, as well as a much smaller number of threonine residues, were found 
to be phosphorylated by ATP during tyrosine kinase activation. When the phosphorylated 
insulin receptor, that exhibited elevated tyrosine kinase activity, was dephosphorylated by 
incubation with alkaline phosphatase, deactivation of the receptor-associated tyrosine 
kinase activity could be achieved. Under these conditions of tyrosine kinase deactivation, 
about 90 % of the phosphate removed from the receptor could be accounted for by 
tyrosine phosphate in the insulin receptor, indicating that tyrosine phosphorylation of the 
insulin receptor is directly regulating the receptor - associated tyrosine kinase activity 
in-vitro. Although the location of all of the sites phosphorylated in intact cells are not 
known, the tyrosine-containing peptide whose phosphorylation correlates with in-vitro 
activation of the kinase is also phosphorylated in response to insulin in intact cells
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[ Herrera et.al., 1985 ]. When the insulin receptor is phosphorylated in intact cells in the 
absence of insulin, phosphoserine and phosphothreonine are found in the receptor p 
subunit. While direct data are now implicating tyrosine phosphorylation in the regulation 
of the insulin receptor kinase, indirect data obtained suggest that serine phosphorylation 
leads to decreased receptor kinase activity in the presence of insulin [ Takayama et.al., 
1988 ]. Van Obberghen and Gammeltoft [ 1986 ] hypothesised that the insulin receptor- 
kinase complex contains two separate protein kinases, a tyrosine- and a serine-specific 
kinase, the latter of which is non-covalently associated with the receptor in the cell 
membrane but would not be an integral part of the receptor. Serine phosphorylation of the 
receptor has been demonstrated to inhibit its kinase activity [ Stadtmauer and Rosen, 
1986].
1.2.2.1.2 In-vitro studies
In cell-free systems, the differences with which phosphopeptide residues of the 
P subunit are phosphorylated, is dependent on the nature of the receptor preparation used 
as a protein kinase source. The p subunit of the insulin receptor has been demonstrated to
32be phosphorylated by insulin in a cell-free system using [y- P] ATP and solubilised and 
partially purified receptor preparations from human placenta and rat liver. Predominant 
labelling of the tyrosine residues, and to a smaller extent the serine residues, was 
observed as shown by phosphoaminoacid analysis [ Petruzzelli et.al., 1982; Van 
Obberghen et.al., 1983; Roth and Cassell, 1983 ]. In highly purified insulin receptors, 
phosphorylation occurred exclusively on tyrosine residues under basal conditions and the 
insulin stimulatory action was accounted for by a several-fold increase in 
phosphotyrosine [ Kasuga et.al., 1983 ], indicating tyrosine kinase as a constituent of the 
insulin receptor. The tyrosine kinase activity is an intrinsic property of the insulin receptor
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as demonstrated by the ability of the insulin receptor of high purification to
32incorporate P in response to added insulin. Further studies supporting this
hypothesis include affinity labelling with ATP analogues [ Roth and Cassell, 1983],
sequence homology with other known tyrosine kinases [ Ullrich et.al., 1985; Ebina
et.al., 1985 ] and by its copurification to homogeneity with insulin binding activity
[ Petruzzelli et.al., 1984 ]. Insulin receptor kinase exhibits a preference for tyrosine
residues that are close to acidic amino acid residues in exogenous substrates which is
srcsimilar, but not identical, to EGF receptor kinase or pp60 [Bishop, 1985; Hunter and 
Cooper, 1985]. Immunoprecipitated insulin receptors obtained from patients with severe 
insulin resistance and Acanthosis nigricans [ Van Obberghen et.al., 1983 ], or 
monoclonal immunoglobulin G directed against insulin receptors [ Roth et.al., 1982; 
Roth et.al., 1983a ] have been shown to exhibit insulin stimulated protein kinase activity 
which catalysed phosphorylation of both the p subunit and exogenous substrates like 
histones, synthetic tyrosine-containing peptides and casein [ Kasuga et.al., 1982b; 
Kasuga et.al., 1983; Petruzzelli et.al., 1984 ]. Rosen et.al. [1983] showed directly that 
incubation of insulin receptor with unlabelled ATP, prior to a second incubation with 
32[y- P]ATP plus substrate, resulted in markedly enhanced substrate phosphorylation by 
the insulin receptor. They also demonstrated that the phosphorylated, activated insulin 
receptor kinase no longer exhibits sensitivity to modulation by insulin itself. Thus, the 
insulin receptor appears to be converted, upon tyrosine phosphorylation of its P subunit, 
to a form that is hormone-independent with respect to its kinase activity. The 
phosphorylation of the receptor does not affect insulin binding. Dephosphorylation of the 
receptor restores its insulin dependency with concomitant loss of the activated state 
indicating that the hormone-induced activation is reversible [ Rosen et.al., 1983; Yu and 
Czech, 1984 ]. Site-specific antibodies generated to different domains of the P subunit of 
the receptor have been used to elucidate the structural basis for the kinase activity of the
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receptor. Herrera and Rosen [1986] were able to inhibit the kinase activity of the insulin 
receptor by using an antipeptide antibody directed to a domain surrounding tyrosine 960 
which lies between the transmembrane region of the molecule and the nucleotide 
binding site [ Ullrich et.al., 1985; Ebina et.al., 1985 ]. This antibody is able to bind to the 
phosphorylated receptor but is unable to inhibit the kinase activity of this form of the 
receptor suggesting conformational changes may result from receptor phosphorylation. 
An antipeptide antibody directed to a domain surrounding Tyr 1150 recognises only the 
phosphorylated form of the receptor under nondenaturing conditions. The major in-vitro 
autophosphorylation sites on the p subunit of the insulin receptor are located at the 
carboxyl terminal and in the domain that includes Tyr 1150 and phosphorylation of the 
latter is correlated with the activation of the kinase [ Pang et.al., 1985 ] implying that the 
Tyr 1150 domain plays a critical role in the mechanism of signal transduction.
At present, it seems plausible that the receptor kinase activity is involved in a 
cascade of events that leads to phosphorylation and /  or dephosphorylation of other 
cellular proteins that control the metabolic pathways regulated by insulin. Collected 
evidence from recent years has reinforced the role of the kinase activity of the insulin 
receptor in insulin action :
i) The insulin receptor-kinase activity appears to be widespread and has been 
characterized in insulin receptor preparations solubilised from a variety of tissues such 
as liver plasma membranes [ Kasuga et.al., 1982a; Van Obberghen and Kowalski, 1982 ] 
and microsomes [ Blackshear et.al., 1983 ], adipocytes [ Haring et.al., 1982 ], 3T3- 
L1 adipocytes [ Petruzzelli et.al., 1982; Rosen et.al., 1983 ], muscle [ Haring et.al., 
1984a ], placenta [ Roth and Cassell, 1983 ; Petruzzelli et.al., 1984 ], erythrocytes 
[ Grigorescu et.al., 1986 ], lymphocytes [ Grunberger et.al., 1984a ], brain cortex 
[ Rees-Jones et.al., 1984 ], monocytes [ Grunberger et.al., 1984b ] and several cultured 
cell lines [ Kasuga et.al., 1982a; White etal., 1985 ]. Besides that, the kinase activity of
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the insulin receptor has also been detected in non-mammalian species such as birds 
[ Aiyer, 1983 ] and insects [ Petruzzelli et.al., 1986 ].
ii) The insulin-induced activation of the receptor kinase is a rapidly reversible
process [ Rosen et.al., 1983; Yu and Czech, 1984 ].'There is a correlation between the 
concentrations of insulin required for kinase activation and the specificity of the ligand 
stimulation with the binding of insulin to the receptor and generation of biological activity 
[ Haring et.al., 1982; Petruzzelli et.al., 1984; Kahn, 1985 ].
iii) The impairment of the receptor kinase activity in cells from various insulin 
resistant states including cultured melanoma cells [ Haring et.al., 1984b ], gold- 
thioglucose-treated mice [ LeMarchand-Brustel et.al., 1985 ], human patients with 
insulin resistance associated with acanthosis nigricans type A [ Grunberger et.al., 
1984a ] and streptozotocin diabetic rats [ Kadowaki et.al., 1984 ].
iv) Microinjection of an inhibitory monoclonal antibody into Xenopus oocytes was 
found to inhibit insulin's ability to stimulate oocyte maturation [ Morgan et.al., 1986 ] 
possibly by binding to an antigenic region containing an important phosphorylation 
site of the insulin receptor ( tyrosines 1162 and 1163 ) [ Ellis et.al., 1986 ].
v) Monoclonal insulin receptor antibody did not stimulate the phosphorylation of
the insulin receptor either in intact IM-9 cells or in purified receptor preparations. In 
contrast, three agents which mimic insulin action in intact cells ( concanavalin A, wheat 
germ agglutinin, and polyclonal insulin receptor antibody), mimicked insulin's ability to 
stimulate the kinase activity of purified insulin receptors [ Roth et.al., 1983a ].
vi) When antibodies to the insulin receptor tyrosine kinase are incorporated into 
various cells by osmotic lysis of pinocytotic vesicles, there is a decreased ability of 
insulin to stimulate the uptake of 2-deoxyglucose in Chinese hamster ovary (CHO) cells 
and freshly isolated rat adipocytes; of ribosomal protein S6 phosphorylation in CHO cell; 
and glycogen synthesis in the human hepatoma cell line HepG2 [ Morgan and Roth,
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vii) Mutant human insulin receptors deficient in kinase activity fail to stimulate
glucose transport [ Ellis et.al., 1986 ] ; expression of normal human receptors enhances 
the insulin responsiveness in these cells.
However, efforts to establish a role for the receptor kinase in insulin action 
have not been entirely successful. It has been suggested that the receptor kinase may not 
be important in mediating certain rapid effects of insulin. Certain polyclonal antisera have 
been shown to stimulate glucose uptake in rat adipocytes without stimulating receptor 
phosphorylation or receptor kinase activity [ Simpson and Hedo, 1984; Zick et.al., 
1984].
1.2.3 MECHANISMS OF ACTION OF INSULIN
Insulin was discovered more than 60 years ago. Much is known about the 
physiological and biochemical consequences of insulin action ; however, the molecular 
mechanism by which the interaction of insulin with its receptor is transduced into an 
insulin response has yet to be elucidated. Insulin has both long and short term effects on 
the metabolism of its target cells. The long term effects involve changes in both general 
and specific protein synthesis and breakdown, while short term effects are those brought 
about solely through changes in the activity of pre-existing enzymes and membrane 
transporters. There are many theories to explain how insulin works and below are 
descriptions of the prevailing hypotheses of the mechanism of insulin action.
1.2.3.1 Changes in cyclic nucleotides
Many of the metabolic effects of insulin on liver, skeletal muscle, and adipose
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tissue oppose the actions of cyclic AMP. Early reports indicated that insulin could reduce 
hormonally- elevated levels of cyclic AMP in adipose tissue ( Butcher et.al., 1966; 
Soderling et.al., 1973 ) which is consistent with the situation in-vivo. However, insulin 
alone has little or no effect on cyclic AMP levels in fat or liver cells although many 
effects of insulin are manifested under these conditions ( Denton et.al., 1981 ). In rat 
diaphragm, insulin had no effect on total cyclic AMP content but the physiological effect 
of insulin was demonstrable ( Lamer, 1975 ). Thus, it must be concluded that although 
insulin may exert some of its effects by decreasing cyclic AMP levels in adipose and 
hepatic tissue, the simple lowering of previously elevated concentrations of cyclic AMP 
cannot explain many well-established physiological actions of insulin.
The ability of insulin to depress cellular cyclic AMP may be a result of inhibition 
of adenylate cyclase ( Illiano and Cuatrecasas, 1972 ) and/or the stimulation of a specific 
membrane-bound cyclic nucleotide phosphodiesterase ( Zinman and Hollenberg, 
1974 ) - see Figure 1. In a recent report, Gawler et.al. ( 1987 ) demonstrated the ability of 
insulin to inhibit adenylate cyclase in strep to zotocin- or alloxan-induced diabetic rats 
despite the loss of Gv the guanine nucleotide-binding regulatory ( G ) protein that 
mediates the inhibitory effects on adenylate cyclase activity. It appears, therefore, that 
insulin inhibits adenylate cyclase via a G protein different from Gp Indeed, there is 
evidence that the insulin receptor does interact with, and activate, a specific G protein 
called Gjns which has tentatively been identified as having a 25 kDa subunit ( Houslay, 
1986). However, there are conflicting results as to the activity of adenylate cyclase in 
response to insulin. Pilkis and Park ( 1974) failed to see any inhibitory effect of insulin 
on the adenylate cyclase.
Treatment of hepatocytes with insulin has been reported to activate two distinct 
cyclic AMP phosphodiesterases, one termed the peripheral plasma membrane 
phosphodiesterase and the second, ' dense-vesicle 'phosphodiesterase, since it is 
associated with an intracellular vesicle fraction ( Heyworth and Houslay, 1983 ). Insulin
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FIGURE 1.A  HYPOTHESIS FOR THE MECHANISM OF ACTION OF INSULIN
Abbreviations: cAMP = cyclic AMP, cAMP PDE = cyclic AMP-dependent phosphodiesterase, 
DAG = diacylglycerol, Gins = guanine nucleotide regulatory protein specific for insulin,
IPG = inositol phosphate-glycan, P = phosphate, PI-PLC = phosphatidylinositol-specific 
phospholipase C, Tyr-P = insulin receptor tyrosine kinase
( Adapted from Espinal, 1987)
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activation of the peripheral plasma membrane phosphodiesterase is dose-dependent, and 
requires the presence of GTP, ATP and intriguingly, also requires cyclic AMP which is 
consistent with the observation that insulin can lower elevated but not basal levels of 
intracellular cyclic AMP. It has been suggested that insulin might exert its action on 
adenylate cyclase and on the peripheral cyclic AMP phosphodiesterase through a distinct 
guanine nucleotide regulatory protein called Gjns ( Hey worth and Houslay, 1983 ).
Insulin might also antagonise the effects of cyclic AMP without changing the 
concentration of cyclic AMP in target cells. One mechanism by which this could occur is 
the inhibition of cyclic AMP dependent protein kinase by insulin. However, the exact 
mechanism of this response still remains obscure. It has been suggested that insulin 
decreases the affinity of the protein kinase for cyclic AMP in isolated hepatocytes ( Mor 
et.al., 1981 ). Another study has also reported a similar effect, but also added that insulin 
raises the Ka without influencing the Vmax of the enzymes, resulting in a decrease in the 
capacity of protein kinase to be dissociated (Gabbay and Lardy, 1987). In addition, they 
also suggested that insulin may act to decrease the affinity of the protein kinase for cyclic 
AMP through a possible regulation of intrachain site 2 binding on the enzyme. The site 2 
intrachain cyclic AMP binding domain has been shown to be involved in protein kinase 
activation ( Ogreid et.al., 1983 ). Another mechanism which has been proposed by 
Walkenbach et.al. (1978) involves the generation of a second messenger which may be 
directly associated with the holoenzyme protein kinase. This association results in the 
formation of a second messenger-protein kinase complex which has a reduced ability to 
bind cyclic AMP.
1.2.3.2 Generation of inositol-glvcans
The concept of the ' insulin mediators a term coined by Lamer ( 1972 ), was
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modelled on the cyclic AMP -second messenger system. In 1974, Lamer and co-workers 
reported that an acid- and heat-stable inhibitor of cyclic AMP-dependent protein kinase 
was generated in rat muscles within a few minutes of insulin administration. Since then 
numerous papers have reported the isolation and purification of these chemical mediators 
( Jarett and Seals, 1979; Seals and Czech, 1980 ). However, the exact nature of the 
mediators was not elucidated until recently. They were initially thought to be peptides, but 
recent studies by Saltiel and Cuatrecasas ( 1986 ) indicate that insulin stimulates the 
generation of a glycan containing inositol phosphate which has an apparent molecular 
weight between 1500 and 2500. The generation of this glycan, termed IPG by Saltiel, is 
associated with a concomitant release of diacylglycerol, containing myristate. The 
molecular events that bring about the release of IPG and diacylglycerol, are unclear. It is 
thought that insulin receptor activation leads to stimulation of the membrane 
phospholipase C probably via a G protein, resulting in the formation of IPG and 
diacylglycerol - see Figure 1. IPG can mimic the effects of insulin on several insulin- 
sensitive enzymes in liver and hepatoma broken cell preparations. They have been shown 
to inhibit adenylate cyclase and the catalytic subunit of cyclic AMP-dependent protein 
kinase ( M alchoff et.al., 1987 ) while stimulating cyclic AMP-dependent 
phosphodiesterase and pyruvate dehydrogenase ( Saltiel, 1987 ). The IPG has also been 
shown to mimic insulin-induced changes in phosphorylation of phospholipid 
methyltransferase ( Kelly et.al., 1987b), ATP-citrate lyase, hormone-sensitive lipase and 
glycogen phosphorylase ( Alemany et.al., 1987 ) thus supporting the role for IPG in 
some of insulin actions. The ability of this long list of insulin-sensitive enzymes to be 
modulated by IPG substantiates the claim that the latter functions as a second messenger 
of insulin action.
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1.2.3.3 Effect of insulin on inositol phospholipid metabolism
As described above insulin-mediated activation of a specific phospholipase C 
results in the formation of diacylglycerol which is known to act as a second messenger. 
Diacylglycerol which remains in the membrane, together with the cofactor 
phosphatidylserine, activates protein kinase C. It has been shown that phorbol esters, 
which are known activators of protein kinase C, are able to imitate several of insulin's 
effects on metabolism ( Farese et.al., 1985a; Sato et.al., 1988 ). In fact, insulin has also 
been shown to stimulate protein kinase C activity in myocytes ( Cooper et.al., 1987 ).
In-vivo ( Takayama et.al., 1988 ) and in-vitro ( Bollag et.al., 1986 ) studies 
have revealed that phorbol ester activation of protein kinase C stimulates the 
phosphorylation of serine in the insulin receptor resulting in inhibition by 50-65 % of the 
insulin receptor's intrinsic tyrosine-specific protein kinase activity without having any 
effect on the insulin-binding activity ( Bollag et.al., 1986 ). The data suggest that protein 
kinase C may regulate the function of the insulin receptor. In contrast, protein kinase C- 
deficient cells have been shown to maintain some of insulin's effect ( Blackshear et.al., 
1987 ) indicating that some of insulin actions such as activation of ribosomal S6 protein 
kinase and increases in ornithine decarboxylase activity, are not mediated by protein 
kinase C. However, studies from many laboratories have indicated that the effect of 
insulin on the turnover of diacylglycerol is tissue specific; e.g. it is reported to occur in 
myocytes and adipose tissue ( Cooper et.al., 1987 ) but not in liver cells ( Sakai and 
Wells, 1986).
1.2.3.4 Insulin-stimulated serine kinases
Many of the effects of insulin ultimately involve altered phosphorylation of target
proteins, usually on serine residues. In intact cells phosphorylation of the insulin receptor 
on serine residues is increased by insulin ( Takayama et.al., 1984 ) and Denton et.al. 
( 1981 ) have proposed that insulin actually causes the dissociation of a serine kinase 
from the plasma membrane. Yu et.al. ( 1987 ) have reported the identification of a novel 
2+Mn -dependent cytosolic serine kinase in rat adipocytes which is stimulated by insulin 
in a dose-dependent manner. Recently, Sakanoue et.al. ( 1988 ) also reported the 
presence of an insulin-stimulated serine kinase in Xenopus oocyte plasma membrane. 
The insulin-stimulated serine kinase significantly phosphorylated HI histone and 
phosphoaminoacid analysis revealed that phosphate was incorporated into serine 
residues. Despite this evidence, serine kinases activated in cells by insulin are poorly 
characterized and need further investigation before they can be accepted as playing a role 
in mediating insulin's effects.
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1.3 GLUCAGON
1.3.1 THE STRUCTURE OF THE GLUCAGON RECEPTOR
Glucagon regulates carbohydrate metabolism in the liver by binding to cell surface 
receptors on the external surface of hepatocytes ( Rodbell et.al., 1971 ). The glucagon- 
bound receptor activates adenylate cyclase via a guanine nucleotide-regulated mechanism 
( Rodbell, 1980 ) resulting in enhanced cyclic AMP synthesis rates. While the glucagon- 
sensitive adenylate cyclase has been purified and extensively characterized ( Stemweis 
et.al., 1981 ), relatively little is known about the glucagon receptor. Understanding the 
basic features of glucagon action is important, particularly since in certain diseases like 
diabetes, glucagon has been implicated in contributing to the overall pathophysiology 
( Unger and Orci, 1981 ).
The glucagon receptor was first identified by Rodbell and his co-workers in 1971 
who simultaneously discovered that guanine nucleotides were essential for glucagon 
activation of adenylate cyclase. Specific binding sites and/or a glucagon-sensitive 
adenylate cyclase have been described in a variety of mammalian and avian tissues 
( Desbuquois, 1985 ). Studies with adipocytes ( Desbuquois and Laudat, 1974 ) and 
hepatocytes ( Rouer et.al., 1980 ) indicated that both the glucagon receptor and adenylate 
cyclase are localized in the plasma membrane of these cells although glucagon-sensitive 
adenylate cyclase has been detected in endoplasmic reticulum and Golgi membranes 
( Yunghans and Morre, 1978 ).
The delay in the identification of the glucagon receptor is due to the lack of a 
purification technique that is able to monitor the receptor after it is extracted from the 
membrane with detergents. An added complication is that the amphipathic nature of the 
glucagon receptor makes it difficult to distinguish true receptor binding from interactions 
with lipids and detergents. Covalent labelling of receptors using cross-linking agents,
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125I-labelled hormones, and ligands has become a very useful tool for the study of the
structure of receptors. By cross-linking [1 2 5 I-Tyr10]monoiodoglucagon ( [1 2 5 I] MIG ) to 
liver membrane receptors with hydroxysuccimidyl-p-azidobenzoate, Iyengar and 
Herberg ( 1984 ) were able to identify a Mr = 63,000 peptide on the SDS-PAGE gels as 
the glucagon receptor since unlabelled glucagon added prior to cross-linking of labelled 
hormone abolished appearance of the labelled protein. In another study ( Herberg et.al.,
1984 ) demonstrated that if the liver membranes were preincubated at 32 °C for 20
125minutes before the addition of [ I] MIG, then a labelled band with an apparent 
M r = 113,000-115,000 was observed. Labelling of the Mr = 113,000 band was 
decreased by the inclusion of GTP, abolished by the inclusion of glucagon, and 
unaffected by insulin, indicating that the Mr = 113,000 protein also recognized glucagon 
specifically in a GTP-dependent manner. They concluded that the hepatic glucagon 
receptor is a dimer of the Mr = 63,000 hormone-binding subunit. Furthermore, the size of 
the glucagon receptor determined by hydrodynamic measurements is similar to the 
molecular weight obtained for the functional receptor by target size analysis ( Schlegel 
et.al., 1979 ). However, definitive proof to support the authors contention must await 
purification of the glucagon receptor. Treatment of the covalently labelled Mr = 63,000 
peptide with endo-p-iV-acetylglucosaminidase F (Endo F) results in the appearance of 
four discrete bands suggesting that the peptide is a glycoprotein and contains four N- 
linked glycans ( Iyengar and Herberg, 1984 ) having A-acetylglucosamine and/or sialic 
acid residues ( Herberg et.al., 1984 ).
Structural analysis of the hepatic glucagon receptor revealed that elastase treatment
195of the unlabelled Mr = 63,000 peptide yields a Mr = 24,000 peptide that binds [ I] MIG 
specifically and is sensitive to GTP but not ATP, indicating that the fragment retains the 
capacity to interact with the stimulatory guanine nucleotide regulatory protein, Gs. It is 
not sensitive to Endo F treatment suggesting that this peptide does not contain N-linked
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glycans. The presence of detergent is needed for its solubilization implying that at least 
this part of the glucagon receptor monomer is embedded in the bilayer. The Mr = 24,000 
peptide is said to be contained within a Mr = 33,000 peptide, the latter is formed upon 
treatment of the hormone-occupied Mr = 63,000 peptide with proteases ( Iyengar and 
Herberg, 1984 ).
In order to understand the structure of the glucagon receptor, many chemical 
derivatives of glucagon have been prepared by treating native hormone with conventional 
protein-modifying reagents. Simultaneous modification of both free amino groups of the 
hormone causes a great decrease of binding affinity and ability to activate adenylate 
cyclase. An example is Na -trinitrophenyl, 12-homoarginine glucagon (TH-glucagon) 
which is a competitive antagonist of glucagon at the glucagon receptor ( Bregman et.al., 
1980 ). It is generally accepted that the actions of glucagon on the liver cell metabolism 
are primarily mediated through changes in intracellular cyclic AMP levels. In man and 
experimental animals, the enhanced hepatic production of cyclic AMP observed after 
glucagon injection accounts for almost all of the increase in plasma concentration and 
urinary and biliary excretion of the nucleotide ( Desbuquois, 1985 ). TH-glucagon has 
essentially no ability to activate adenylate cyclase from rat liver nor to increase the levels 
of cyclic AMP in isolated hepatocytes nor to stimulate cyclic AMP-dependent protein 
kinase activity ( Cote and Epand, 1979 ). The ability of TH-glucagon to mimic the effect 
of glucagon on glycogenolysis, gluconeogenesis and urea production have cast some 
doubts on the involvement of cyclic AMP as the sole factor mediating the actions of 
glucagon ( Corvera et.al., 1984 ) while others have suggested the existence of two 
glucagon receptor populations ( Musso et.al., 1984 ). A recent discovery by Wakelam 
et.al. ( 1986 ) has altered fundamentally the idea on the postreceptor effects of glucagon. 
They demonstrated that both TH-glucagon and glucagon caused a rapid dose-dependent 
hydrolysis of phosphatidylinositol and that glucagon-stimulated production of inositol
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1,4,5-trisphosphate is biphasic. Inhibition occurs at higher glucagon concentrations when 
adenylate cyclase activity is maximally stimulated where excess cyclic AMP production 
inhibits the polyphosphoinositide phosphodiesterase. They have suggested that 
hepatocytes possess two distinct receptors for glucagon, a GR-1 receptor coupled to the 
stimulation of inositol phospholipid breakdown and a GR-2 receptor coupled to the 
stimulation of adenylate cyclase activity. At physiological glucagon concentrations it is 
probable that a significant proportion of glucagon activity on cellular metabolic processes 
will be mediated via the GR-1 receptors. At higher glucagon concentrations, the 
functioning of the GR-2 receptors coupled to adenylate cyclase activation predominates. 
Thus, glucagon is able to exert its action on liver via two signal-transduction systems.
1.3.2 MECHANISMS OF GLIJCAGON ACTION
Most, if not all, of the effects of glucagon are mediated by cyclic AMP, the 
synthesis of which is catalysed by the membrane-associated enzyme adenylate cyclase. 
This nucleotide activates cyclic AMP-dependent protein kinase , which in turn affects, by 
phosphorylation reactions, the activity of specific enzymes within the cell. Treatment of 
isolated liver cells with glucagon has been demonstrated to increase the phosphorylation 
of at least 1 2  cytoplasmic proteins, many of which are important regulatory enzymes in 
intermediary metabolism ( Garrison and Wagner, 1982 ). Another mechanism through 
which glucagon could influence the intracellular cyclic AMP concentration is by 
modulating the activity of the enzyme, cyclic AMP phosphodiesterase. Recent 
developments have also shown an effect of glucagon on plasma membrane phospholipid 
metabolism as a second means of signal transduction of the hormone. The mechanism 
through which glucagon acts in both signal transduction systems will be discuss in detail 
below.
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1.3.2.1 Changes in cyclic nucleotides
The glucagon-sensitive adenylate cyclase system in rat liver plasma membranes is 
composed of three functionally and structurally distinct entities : the receptor, which 
specifically binds glucagon, the guanine nucleotide-regulatory protein which mediates the 
activation of the catalytic unit of the adenylate cyclase by the glucagon-receptor complex 
and GTP and the catalytic unit of the cyclase, which converts ATP, the substrate, to 
cyclic AMP. Treatment of intact hepatocytes with glucagon causes a rapid and transient 
rise in intracellular cyclic AMP concentrations, which reach a peak within 5 minutes 
before returning to basal values within 30 minutes ( Heyworth et.al., 1983a ). This 
accumulation of cyclic AMP is largely due to the activation of adenylate cyclase by 
glucagon since the addition of 3-isobutyl-1-methylxanthine ( IBMX ), a 
phosphodiesterase inhibitor, greatly enhanced intracellular cyclic AMP accumulation but 
did not change the time for it to reach the maximal. In membranes, stimulation of 
adenylate cyclase activity by the hormone exhibits a lag time of several minutes ( Rodbell 
et.al., 1974 ). The ability of glucagon to increase cyclic AMP concentration in intact cells 
and to stimulate adenylate cyclase activity in broken cell preparations is saturable with 
respect to hormone concentration. In the isolated perfused rat liver ( Exton et.al., 1971) 
and in isolated rat hepatocytes ( Christofferson and Berg, 1974 ), glucagon increases 
cyclic AMP concentration at least 50-fold with a half-maximal effect at about 10 and 1 nM 
respectively. In human liver membranes, glucagon stimulated the production of cyclic 
AMP with half-maximal activation elicited by 6  nM glucagon ( Livingston et.al., 1985 ). 
Both glucagon-stimulated cyclic AMP accumulation in intact hepatocytes ( Sonne et.al., 
1978 ) and hormone-stimulated adenylate cyclase activity in liver membranes ( Rodbell 
et.al., 1974 ) are nonlinearly related to receptor occupancy. Half-maximal stimulation 
occurs with less than 1 0  % receptor occupancy.
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Glucagon stimulation of the liver adenylate cyclase activity was dependent on GTP 
as demonstrated in various animal species ( Padrell et.al., 1987 ) and in 
human liver ( Livingston et.al., 1985 ). In the absence of glucagon, GTP stimulates 
adenylate cyclase activity about threefold. Rodbell et.al., ( 1974 ) found that in the 
absence of added GTP, 100 % occupancy of glucagon receptors was required to achieve 
maximal activation of adenylate cyclase. At optimal GTP concentrations, the maximal 
adenylate cyclase activity found in the presence of glucagon was much greater, but only 
10 % receptor occupancy was required. On the other hand, glucagon , at maximal 
concentrations, causes a marked increase in the ability of guanine nucleotides to stimulate 
adenylate cyclase activity.
Treatment of intact hepatocytes with glucagon led to a rapid time- and dose- 
dependent loss of the glucagon-stimulated response of the adenylate cyclase activity seen 
in membrane fractions isolated from these cells. This particular type of desensitization, by 
glucagon, does not occur in isolated membranes which exhibit linear rates of cyclic AMP 
production for at least 20 minutes ( Houslay et.al, 1987 ). Any further addition of 
glucagon after 5 or 10 minutes failed to increase cyclic AMP production, showing that 
degradation of glucagon was not responsible for this event. Also, the rate of onset and the 
extent of desensitization were unaffected by the addition of IBMX. Since it has been 
found that challenge of hepatocytes with glucagon does not lead to any rapid 
internalization of glucagon receptors, it has been suggested that the desensitization 
process may involve a lesion occurring at the coupling interface of either the stimulatory 
guanine nucleotide regulatory protein, Gs, or the glucagon receptor. TH-glucagon, which 
has no effect on the intracellular cyclic AMP concentration, was also able to elicit 
desensitization of adenylate cyclase and this was mimicked by phorbol ester, 4p-phorbol- 
12P-myristate-13a-acetate (PMA) ( Murphy et.al., 1987 ). Thus the authors suggested 
that the glucagon GR2 receptor-stimulated adenylate cyclase undergoes desensitization
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through a cyclic AMP-independent process, which involves the stimulation of inositol 
phospholipid metabolism by glucagon acting through GR1 receptors. They proposed that 
the molecular mechanism for the desensitization of glucagon-stimulated adenylate cyclase 
may involved the phosphorylation of the glucagon receptor or Gs or both by protein 
kinase C. This is hardly surprising since it is known that activation of protein kinase C 
can either inhibit or enhance the accumulation of cyclic AMP promoted by activators of 
adenylate cyclase in different cell types ( Kelleher et.al., 1984; Bell and Brunton, 1987 ).
Another means by which glucagon could affect cell metabolism is by acting on 
the cyclic AMP-dependent protein kinase. In hepatocytes, glucagon has been 
demonstrated to dissociate a holoenzyme of cyclic AMP-dependent protein kinase in 
a dose-dependent manner ( Ciudad et.al., 1987 ) and by using two cyclic AMP 
analogues, Connelly et.al. ( 1987 ) provided direct pharmacological evidence for the 
activation of the cyclic AMP-dependent protein kinase in response to glucagon in the 
intact cells. The increase in free catalytic subunits explains the activation of this enzyme 
by glucagon in the liver.
Intriguingly, conditions which result in high levels of cyclic AMP in liver and fat 
tissue also lead to activation of phosphodiesterase ( Loten et.al., 1978 ; Solomon, 1975 ). 
Allan and Sneyd ( 1975 ) reported that activation of the low Km phosphodiesterase by 
glucagon was concentration dependent and occurred at the same concentration required to 
observe an increase in cyclic AMP levels in the cell. The maximal increase in activity 
occurred within 5 minutes of incubation with glucagon, similar to activation of adenylate 
cyclase, but the activity of the former was sustained for at least 35 minutes. It seems a 
reasonable hypothesis that the action of glucagon on hepatic phosphodiesterase is 
mediated by cyclic AMP via cyclic AMP-dependent protein kinase ( Cherrington et.al., 
1976 ). It has been shown that glucagon can stimulate the activity o f ' dense-vesicle ' 
phosphodiesterase which is associated with a unique intracellular vesicle fraction resolved
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on Percoll gradients ( Wilson et.al., 1983 ). The mechanism whereby glucagon activates 
the 'dense-vesicle' enzyme is mediated by cyclic AMP.
1.3.2.2 Glucagon and phosphoinositide metabolism
Wakelam et.al. ( 1986 ) have reported that concentrations of glucagon below 
10 nM can increase myo-inositol 1,4,5-trisphosphate ( IP3  ) by. a cyclic AMP-independent 
mechanism and this phosphoinositide breakdown results in the mobilization of calcium 
from an intracellular pool. Inositol trisphosphate may act as a messenger to cause a
9 _ i_
release of Ca from non-mitochondrial intracellular stores, thereby contributing to the
2+  2+  increase in intracellular Ca concentration [Ca ]j(  Berridge and Irvine, 1984 ). The
glucagon action on cellular calcium has been well documented both in isolated
hepatocytes and in perfused rat liver. Charest et.al. ( 1983 ) reported that glucagon could
2+increase [Ca ]j in isolated hepatocytes without causing an increase in the concentration 
of inositol trisphosphate ( Charest et.al., 1985 ). The results so far accumulated indicated 
that glucagon action on calcium mobilization is mediated by both cyclic AMP- 
dependent and -independent mechanisms. The glucagon-stimulated increases in the level
9 .
of Ca can be mimicked by the stimulatory diastereomer of adenosine cyclic 3',5-
phosphorothioate ((Sp)-cAMPS), and inhibited by pretreatment with the inhibitory
diastereomer of adenosine cyclic 3',5-phosphorothioate ((Rp)-cAMPS), a cyclic AMP
antagonist ( Connelly et.al., 1987 ). Both of these two compounds ( (Sp)-cAMPS and
(Rp)-cAMPS) bind to the regulatory subunit of the purified cyclic AMP-dependent protein
kinase ( O'Brian et.al., 1982 ), but only the (Sp) diastereomer releases the active catalytic
2+subunit ( DeWit et.al., 1982 ). Their results indicate that glucagon can elevate [Ca ] j via 
cyclic AMP and the cyclic AMP-dependent protein kinase. Blackmore and Ex ton ( 1986) 
have shown that glucagon, forskolin and 8 -/?-chlorophenylthio cyclic AMP produce
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2+small increases in IP3  in hepatocytes which are sufficient to mobilize intracellular Ca 
( Lynch et.al., 1985 ).On the other hand, Mine et.al. ( 1988 ) reported that glucagon-
2+induced elevation of [Ca ]j was mimicked by forskolin and exogenous cyclic AMP but
2+
these two agents induced a more prolonged elevation of [Ca ]p Glucagon-induced
2+elevation of [Ca ][ was accompanied by a small increase in cyclic AMP. 3-isobutyl-1- 
methylxanthine addition potentiated the cyclic AMP production by glucagon but did not
2+affect the glucagon-induced increase in [Ca ]j suggesting that part of glucagon's action 
on calcium mobilization is independent of cyclic AMP. Staddon and Hansford ( 1986 )
2+found that 4p-phorbol 12-myristate 13-acetate attenuates the increase in [Ca ]j, caused by 
glucagon and suggested that it is probably mediated by a mechanism independent of 
changes in cyclic AMP concentration. However, the effects of glucagon on
2+glycogenolysis and gluconeogenesis are not impaired in Ca -depleted hepatocytes
2+( Assimacopoulos-Jeannet et.al., 1977 ) indicating that Ca plays no role in these actions 
of glucagon.
2+Another suggested mechanism for the way in which glucagon elevates [Ca ]j is 
2 + 2 +by inhibition of the ( Ca -Mg )-ATPase activity. However, high concentrations
of glucagon (>  10 M ) are required to produce this effect ( Lotersztajn et.al., 1984 ). 
This effect was neither mimicked by cyclic AMP nor by dibutyryl cyclic AMP nor by
TH-glucagon suggesting the absence of correlation between (Ca2 +-Mg2+)-ATPase 
inhibition and adenylate cyclase activation and inositol phosphate production. However,
2+m the presence of bacitracin, an inhibitor of glucagon degradation, the Ca pump is no 
longer sensitive to glucagon ( Mallat et.al., 1987 ). They discovered that a proteolytic ally
2 +  24-generated fragment of glucagon is responsible for the inhibition of the (Ca -Mg )- 
ATPase. The physiological significance of the glucagon fragment in the regulation of liver
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cell Ca2+ and other processes awaits further developments.
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1.4 ORAL HYPOGLYCAEMIC AGENTS
The most commonly used drugs in treating diabetes mellitus come from two groups 
of compounds, the sulphonylureas and the biguanides. The first sulphonylurea 
approved by the Food and Drug Administration for use in the management of non-insulin 
dependent diabetes mellitus ( NIDDM ) or Type II diabetes mellitus was tolbutamide 
(in 1957) while a biguanide, phenformin, was approved by the FDA two years later 
( Kennedy et.al., 1988 ). Although tolbutamide was the most frequently used oral 
hypoglycaemic agent in the 1960's, the reported findings of the University Group 
Diabetes Project ( UGDP ) in 1970 suggested that the use of tolbutamide was related to an 
increase in cardiovascular mortality ( UGDP, 1970 ) and later, the same group reported a 
similar finding for phenformin ( UGDP, 1971 ). About nine years later, a reevaluation 
study of the first group found that the report unknowingly included cardiovascular high- 
risk patients in the tolbutamide group ( Williamson and Kilo, 1980 ) thus opening to 
question the validity of analysis and conclusions of the first group report. The association 
of phenformin with fatal lactic acidosis ultimately resulted in the product's removal from 
the market in the United States ( Anon, 1977 ). A recent survey has indicated that 
chlorpropamide is currently the most frequently used oral hypoglycaemic agent in the 
United States ( Kennedy et.al., 1988 ) and that the second-generation sulphonylureas 
such a glyburide and glipizide have been readily accepted.
1.4.1 Molecular mechanisms of action of the oral hypoglycaemic agents
Although the ability of these agents to lower blood glucose is unquestioned, the 
underlying molecular mechanisms of action are still not fully resolved. Reports from 
many laboratories have indicated that sulphonylureas increase the number of insulin
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receptors ( Feinglos and Lebovitz, 1978; Zuber et.al., 1985 ). However, the effect of 
sulphonylureas on insulin binding has been variable. Salhanick et.al. ( 1983 ) found that 
tolazamide significantly increased insulin binding in hepatocytes from normal rats 
cultured in the absence of insulin. Others have reported that sulphonylureas had no 
significant influence on insulin binding ( Vigneri et.al., 1982; Dolais-Kitabgi et.al., 
1983 ). Maloff and Lockwood ( 1981 ) reported that tolazamide-potentiated, insulin- 
stimulated hexose transport is not associated with alteration in insulin binding, suggesting 
a direct effect of sulphonylureas on the postbinding pathways of insulin action. There is 
increasing evidence that sulphonylurea drugs exert long term hypoglycaemic actions that 
are partly extrapancreatic and related to potentiation of the effects of insulin ( Lockwood 
et.al., 1983 ). Specific binding of sulphonylureas to receptors on the P-cell 
membrane has been shown (Lebovitz, 1984 ) and recent developments have indicated
that the sulphonylurea receptor may be part of an ATP-sensitive K+ channel ( Sturgess. 
et.al., 1985 ).
The effect of biguanides on insulin receptor binding has also been inconsistent. It 
has been reported that metformin increased insulin receptor binding in erythrocytes 
of normal subjects ( Holle et.al., 1981 ) and in various cell lines ( Vigneri et.al., 1982 ). 
However, metformin can increase the hypoglycaemic response to insulin without a 
measurable effect on insulin receptor binding ( Lord et.al., 1983; Lord et.al., 1985 ). 
The latter results suggest that metformin can influence postreceptor sites of insulin action 
independent of insulin receptor binding.
The effect of sulphonylureas on adenylate cyclase activity may be variable, 
depending on the tissue studied and the experimental system used. Lasseter et.al. ( 1972) 
reported a stimulation of myocardial adenylate cyclase activity by sulphonylureas whereas 
an inhibition of renal adenylate cyclase activity was noted by Leichter and Chase ( 1978 ). 
Luly et.al. ( 1977 ) have reported that chlorpropamide decreased the intracellular cyclic
AMP concentration of isolated hepatocytes without being effective on plasma membrane- 
bound adenylate cyclase. This effect is also seen with phenformin.
The effect of sulphonylureas on cyclic AMP-dependent phosphodiesterase has 
also been inconsistent. Goldfine et.al. ( 1971 ) observed that tolbutamide inhibits cyclic 
AMP-dependent phosphodiesterase activity in preparations of rat brain, liver, lung, and 
kidney. Brooker and Fichman (1971) demonstrated that chlorpropamide and tolbutamide 
inhibited cyclic AMP-dependent phosphodiesterase in rat kidney. However, Luly et.al. 
( 1977 ) demonstrated that chlorpropamide, as well as phenformin, stimulated low Km 
cyclic AMP-dependent phosphodiesterase activity in the rat liver plasma membrane and 
this is associated with a marked decrease in intracellular cyclic AMP level. A second 
generation sulphonylurea, glyburide, was found to restore low Km cyclic AMP- 
dependent phosphodiesterase activity in the liver and fatty tissue of streptozotocin-treated 
diabetic rat ( Solomon et.al., 1986a ).
Tolbutamide has been shown to increase soluble and particulate guanylate cyclase 
activity in rat liver, lung, colon, pancreas, kidney cortex, heart and spleen ( Vesely, 
1986 ). Further development is needed to elucidate the role of cyclic GMP in 
sulphonylurea action.
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1.5 ATMS OF THE PROJECT
These may be summarized as follow :-
i) to develop a hormone- and serum-free cell culture system for cultivation of 
hepatocytes from adult rats under maximally controlled conditions to make it possible to 
study , in-vitro, the effect of the individual hormones, insulin and glucagon, on steroid 
metabolism. Under controlled conditions, this will enable us to ascribe any change in 
androst-4-ene-3,17-dione metabolism to the added hormone.
ii) to investigate the acute and chronic effect of insulin on steroid metabolism in 
hepatocytes from normal, 3- and 21-days STZ-diabetic rats and insulin-treated STZ- 
diabetic rats.
iii) to investigate the possible molecular mechanisms of action of insulin that brought 
about the changes in androst-4-ene-3,17-dione metabolism on acute exposure to the 
hormone in normal rat hepatocytes.
iv) to investigate the acute and chronic effect of glucagon on androst-4-ene-3,17- 
dione metabolism in hepatocytes from normal and 3 days STZ-treated diabetic rats.
v) to investigate the acute and chronic effect of TH-glucagon, a glucagon antagonist, 
on androst-4-ene-3,17-dione metabolism in hepatocytes from normal rats.
vi) to investigate the effect of insulin in the presence of glucagon on androst-4-ene- 
3,17-dione metabolism in normal rat hepatocytes.
vii) to investigate the effect of phenformin or tolbutamide on androst-4-ene-3,17-dione 
metabolism in hepatocytes from normal and 3 days STZ-treated diabetic rats.
viii) to investigate the effect of phenformin or tolbutamide in the presence of
O
physiological insulin concentration (10 ' M ) on androst-4-ene-3,17-dione metabolism in 
hepatocytes from normal and 3 days STZ-treated diabetic rats.
ix) to investigate the effect of insulin in the presence of phenformin or
tolbutamide on androst-4-ene-3,17-dione metabolism in hepatocytes from normal and 3  
days STZ-treated diabetic rats.
METHODS AND MATERIALS
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2.0 EXPERIMENTAL ANIMALS
Mature male or female rats of the Wistar strain, bred in the department were used 
throughout the study. The animals were allowed free access to water and food ( CRM 
Nuts, Labsure, Croydon) and housed in light- and temperature-controlled conditions 
( light 0800-2000; 19 ± 1° C ) and were used when they were, 10-12 weeks old at the 
beginning of the experiment When comparing groups age-matched animals were used, 
and each group consisted of at least four animals. The weights of individual rats ranged 
from 250 to 300 g and variation within each group was ± 25 g.
In experiments where blood was required for detection of serum glucose levels, 
the animals were asphyxiated by carbon dioxide in a sealed box. Immediately after 
cervical dislocation, the throat was cut and blood was collected by using a 1 0  ml 
syringe. The blood was allowed to clot at + 4° C and serum prepared by centrifugation 
at 2000g for 10 minutes at 4° C ( in a DAMON/BEC Model DPR-6000 refrigerated 
centrifuge ). The upper serum layer was removed using a Pasteur pipette and then stored 
at -20° C. The assay was usually done within 3 days of serum collection.
In experiments where diabetes mellitus was induced by streptozotocin ( STZ ), 
the rats were weighed before treatment and then 3 days or 21 days post-treatment prior to 
sacrifice.
2.1 INDUCTION OF DIABETES BY STREPTOZOTOCIN
Diabetes mellitus could be induced in experimental animals by administering to 
the animals the p-cell toxins, alloxan or streptozotocin. The diabetogenic action is 
mediated by selective destruction of pancreatic P-cells. Alloxan, however, does not
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produce a good model of diabetes because of its overt toxicity ( Hoftiezer and Carpenter, 
1973 ). Streptozotocin may provide a better model for type 1 ( insulin-dependent) 
diabetes than alloxan because of its more selective p-cell toxicity ( Arison and 
Feudale, 1967).
Since STZ is unstable in solution, it was dissolved in distilled water immediately 
before use and then injected intravenously ( 1 0 0  mg/kg ) into the tail vein of the rat under 
halothane/nitrous oxide anaesthesia. The tail was rubbed with cotton wool dampened 
with xylene to dilate and expose the vein before injecting the drug. Control animals were 
treated identically except that they were injected with vehicle only. The animals were left 
for 3 and 21 days after injection before sacrifice.
2.2 TNSIJLIN TREATMENT OF STZ-DIABETIC RATS
Insulin-treated STZ diabetic rats received 2, 12 or 16 units of insulin
subcutaneously ( Neulente Insulin Zinc Suspension ), given one hour after STZ and at 24
hour intervals for two days, after which they were sacrificed. The international unit of 
insulin is the activity contained in 0.04167 mg of the Fourth International Standard 
Preparation ( 1958 ).
23  ISOLATION OF RAT HEPATOCYTES
Isolated hepatocytes from control, 3 - days and 21 - days STZ - treated 
and insulin - treated STZ - diabetic male and female ( where appropriate ) rats were 
prepared using collagenase digestion, a modification of the method described by 
Seglen ( 1973 ). While the rat is under anaesthesia (3.5 % halothane : 400 ml/min 
oxygen : 800 ml/min nitrous oxide - Mini Boyle anaesthetic machine), the abdomen was 
cut open and the portal vein was freed of any fat. A cannula was inserted into the vein at 
a position just before it branches into the liver. Perfusion ( using a Watson Marlow 
501 U perfusion pum p) was commenced with calcium-free Hank's balanced salt solution
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( calcium-free HBSS ) at a rate of 90 ml/min until the liver reached twice its normal size 
after which the vena cava was cut and the perfusion rate reduced to 50 ml/min. The 
perfusion with calcium-free HBSS was allowed to continue for another 7 minutes. 
The perfusion was then switched over to warm (37° C ) collagenase buffer 
( calcium-free HBSS supplemented with 4 mM calcium chloride and 0.5 mg/ml 
collagenase ). The collagenase buffer was recycled for about ,12.5 minutes before the 
liver was removed from the animal into a petri dish containing calcium-free Hank’s 
balanced salt solution. The liver capsule was gently removed and the cells dispersed 
using a steel comb. The suspension of cells was filtered through gauze and centrifuged at 
200g for 2 minutes to clear the parenchymal cells of debris. The isolated cells were 
resuspended in incubation medium ( calcium-free HBSS supplemented with 1 g/L 
glucose, 100 mg/LM gS04, 1 0 0  mg/LMgCl2  and 185mg/L CaCl2  ) and their number
counted in a haemocytometer with average yield of 1 x 10 cells/g liver. Viability was 
estimated by their exclusion of a vital dye, trypan blue, and cell preparations which 
showed an initial viability greater than 90 % were used in the experiments.The buffers 
were bubbled for 20 minutes with oxygen : carbon dioxide ( 95 % : 5 % ) before 
use and continuously during perfusion and care was taken not to introduce any air bubble 
into the portal vein. Viability of the cells was also checked after preincubation and the 
number of cells at this stage was used in the final calculation.
2.4 DEVELOPMENT AND CHARACTERIZATION OF HORMONE-FREE 
■CLOLTUEE MEDIUM
Suitable medium for maintaining androst-4-ene-3,17-dione metabolism in primary 
cultures of adult rat hepatocytes was investigated. Ham's F-10 nutrient media 
supplemented with amino acid or serum were chosen and tested. Hepatocytes from
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normal male and female rats were cultured in Ham's F-10 medium supplemented 
with either 2.5 % foetal calf serum and 15 % horse serum or a multihormone serum 
substitute, 2% Ultroser G ( LKB Products, Sweden ) for 3 and 6  days. Medium 
was changed after 3 days. In a second set of experiments, male rat hepatocytes were 
cultured with Ham's F-10 medium supplemented with 2 % Ultroser G for 24 hours. 
The medium was removed and then replaced with Ham's F-10 supplemented with 0.1 % 
bovine serum albumin and left for a further 24, 48 and 72 hours. In another similar time- 
scale experiment, male rat hepatocytes were cultured in Ham's F-10 medium 
supplemented with 0 . 1  % bovine serum albumin only.
Androst-4-ene-3,17-dione metabolism by normal male rat hepatocytes using 
five different amounts of hepatocytes ( 1, 2, 3, 5 and 10 million cells/incubation ) and 
five time periods of incubation (5 , 10, 20, 30 and 60 minutes ) was also studied.
2.5 ADDITION OF HORMONES AND DRUGS
2.5.1 Preincubation with insulin or glucagon or TH-glucagon for 1/2. 1 and 2 hours
The serum-free nutrient medium used was Ham's F-10 medium containing the 
following additions/liter : 100 U of penicillin and 100 1ig of streptomycin. The cells were 
plated out on sterile petri dishes ( NUNCLON, Denmark, 9 cm diameter ) at a 
density of 3 x 105  cells/cm2  in Ham's F-10 nutrient medium supplemented with 0.1 % 
bovine serum albumin (10 ml final volume ). The plates were swirled carefully to ensure 
even distribution of cells over the surface of the plates. The additions of hormones and 
drugs were made directly to the cell culture and in all cases the compounds were added in 
the smallest volume possible and controls were treated with a similar amount of vehicle. 
Insulin, glucagon and TH-glucagon were dissolved in 0.1 M hydrochloric acid and their 
additions did not alter the pH of the medium. The hormones and drugs were added at 
concentrations ranging from 10_1° to 10' 6  M. The plated cells were subsequently
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incubated at 37° C under 95 % air and 5 % C 0 2  in a humidified incubator ( Forma 
Scientific Model 3028 ) for the various time period, i.e. 1/2, 1  and 2 hours.
2.5.2 Preincubation with insulin or glucagon or TH-glucagon for 24. 48 and 72 hours
The method was essentially similar to the short period incubation as 
described above ( 2.5.1) except that cells were initially plated in Ham's F-10 nutrient 
medium supplemented with 2 % Ultroser G (LKB), which is a multihormone serum 
substitute, to promote monolayer cell formation. After a period of 24 hours, the medium 
was removed and replaced with Ham's F-10 supplemented with 0.1 % bovine 
serum albumin. The hormones or drug ( concentrations ranging 10" 1 0  to 10" 6  M ) 
were then added and the cells preincubated for a further 24,48 or 72 hours. In one 
set of experiments, insulin ( 10' 9  M ) was added at 24-hour intervals from 0 to 72 
hour.
2.5.3 Preincubation with glucagon for 1/2. 1. 2. 5 and 10 minutes
The method was essentially similar to that described in ( 2.5.1) except that due 
to the very short preincubation time intervals involved, experiments were conducted in 
glass tubes. Isolated hepatocytes ( ~ 2 x 107  cells/m l) were suspended in Ham's F-10 
nutrient medium containing 0 . 1  % bovine serum albumin ( final volume of 1 0  ml ). 
Glucagon was added ( at various concentrations between 10" 1 0  and 10- 6  M ) and the 
tubes inverted a few times to ensure uniform distribution of the hormone. The tubes were 
then incubated at 37° C in a rotatory shaking water bath ( Citenco, U.K. ) for the 
indicated time period.
2.5.4 Preincubation with insulin and glucagon for 1/2 hour
Hepatocytes from normal or 3-days STZ-treated rats were plated out in petri
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dishes in Ham's F-10 nutrient medium supplemented with 0.1 % bovine serum albumin. 
Various combinations of insulin and glucagon concentrations were added directly to the 
petri dish and then left in the incubator for 1 / 2  hour.
2.5.5 Preincubation with insulin or glucagon in the presence of K-252a for 1/2 and 24 
hours
Primary cultures of hepatocytes were established by plating cells in the 
petri dishes in Ham's F-10 nutrient medium supplemented with 0.1%  bovine 
serum albumin. K-252a ( 20 nM ) was added to the plated cells and then left in the 
incubator for 15 minutes. The hormones were then added ( 10* 1 0  to lO 6  M ) and the cells 
reincubated at 37° C for a further 1/2 or 24 hours. K-252a was dissolved in 
dimethylsulphoxide and controls were treated with a similar amount of vehicle.
2.5.6 Preincubation with oral hypoglvcaemic agents in the absence or presence of insulin
Phenformin and tolbutamide were dissolved in 0.1 M NaOH. Phenformin 
or tolbutamide ( concentration ranging from 10' 6  to 10' 3  M ) was added to primary 
cultures of hepatocytes obtained from normal or STZ-treated rats, and the culture was left 
in the incubator for 24 hours. In another set of experiments, the cells were further 
challenged with insulin for 1/2 hour after preincubating with the drugs for 24 hours.
2.6 ASSAY OF STEROTD METABOLISM
After treatment with the hormones or drugs for the various time periods, the cells 
were harvested by scraping the plates with a rubber policeman. The suspensions 
were centrifuged ( 200g; 2 min; 4° C ) and the supernatant layer discarded. The cells 
were washed once with incubation medium and finally resuspended in the same medium.
The cells were counted, assessed for viability and diluted with incubation medium to a 
concentration of 3 x 106  cells/ml and incubated with the substrate, androst-4-ene-3,17- 
dione, by a modification of the method of Berg and Gustafsson ( 1973 ) as described 
below. Triplicate samples at each hormone or drug concentration were taken in all cases. 
The calculated final substrate concentration in the incubation was 0.58 mM and this 
represents a saturating concentration of substrate for some, but not all, of the enzymes 
studied ( Skett et.al., 1978 ). This concentration of substrate was employed as this is the 
limit of solubility of androst-4-ene-3,17-dione under the conditions used in the assay.
2.6.1 Incubation and assay procedure
Each incubation tube contained the following reagents in a total volume of 3 m l:
1 . 0  ml of the diluted cell suspension
50jil of androst-4-ene-3,17-dione (500 jig, dissolved in acetone )
10 jil of [4-14C]-androst-4-ene-3,17-dione ( 105  c.p.m, dissolved in acetone) 
1.94 ml of incubation medium
The tubes were incubated in a rotatory shaking waterbath at 37° C 
for 30 minutes. The incubations were terminated by the addition of 10 ml of 
Folch's solution ( chloroform : methanol; 2:1; v/v ) and 1 ml of 0.9 % sodium chloride. 
The tubes were shaken gently and left to stand overnight for phase 
separation. The tubes were centrifuged ( 500g; 5 minutes ) for complete separation 
between the aqueous and organic phases. The lower organic layer was transferred to 
another tube and dried at 40° C under oxygen-free nitrogen using a Techne Dri- 
Block. The extract was redissolved in 5 drops of chloroform ( in ultrasonic 
waterbath for at least 30 seconds ) and then spotted on silica gel thin layer
chromatography plates ( 20 cm x 10 cm; Merck, Darmstadt, F.R.G. ). A mobile phase 
consisting of chloroform : ethyl acetate ( 4 : 1 ;  v/v ) was used for chromatographic 
separation of substrate and metabolites. The tanks were equilibrated with the solvent 
mixtures for one hour before commencing the separation. The samples were spotted ( 3 
samples on a plate ) at the lower side of the t.l.c. plate ( ~1.5 cm in ), using a 10 pi 
disposable micropipette. After the solvent front had run to about 1 cm from the edge of 
the plates they were dried in warm air. Individual substrate and metabolites were 
visualised by autoradiography ( Kodak, France ) and have previously been identified 
( see Figure 2 ) by gas chromatography - mass spectrometry using authentic 
standards ( Berg and Gustafsson,1973 ). The radio-labelled bands ( see Figure 3 ) were 
scraped into polythene scintillation vials and suspended in Ecoscint liquid scintillant. 
Radioactivity in each sample was measured in a Packard Tri-Carb ( Model 2000 CA ) 
scintillation counter and enzyme activity calculated using a custom-made computer 
program.
2.7 DETERMINATION OF CYTOCHROME P-450 CONTENT
Cytochrome P-450 concentrations were determined from the carbon monoxide 
difference spectra of the reduced protein by the method described by Omura and Sato 
( 1964 ), with an extinction coefficient of 91 mM_ 1  cm - 1  for the wavelength couple 
450-490 nm. All solutions and utensils were pre-cooled on ice before the start of 
the experiment. Cells suspended in incubation medium ( 5  x 106  cells/ml ) were 
homogenised using a Potter-Elvehjem homogeniser with a tight-fitting Teflon pestle for 
10 complete strokes. Trypan blue inclusion was used as a method to indicate the cells 
were broken.
A base line was then determined between 400 nm and 500 nm. The sample
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Figure 3. Schematic representation of androst-4-ene-3.17-dione metabolites 
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suspension was put into two cuvettes; 1 ml aliquots in each. Similar amount of the 
reducing agent, sodium dithionite, was added to both sample and reference cuvettes with 
gentle stirring and the sample cuvette only was gently bubbled with carbon monoxide for 
approximately 60 seconds. Cytochrome P-450 content of the homogenised cell 
preparation was then determined using a dual beam Shimadzu UV-240 recording 
spectrophotometer. The cytochrome P-450 content being expressed as nanomoles 
P-450/ million cells.
2.8 HEPATOCYTE CYCLIC AMP CONTENT
Following incubation with insulin as described in Section 2.5, cell samples were 
pooled and counted and then centrifuged ( 200g ; 2 min ; room temperature ). The 
supernatant was removed and the cells were resuspended in sodium acetate buffer to give
an approximate concentration of 1 x 1 0  cells per ml ( an expected concentration of 
20 nM cyclic AMP ). 0.5 ml of 10 % perchloric acid was added to each sample and 
vortex-mixed. 1 M potassium hydroxide in 0.9 % sodium chloride ( to precipitate 
excess perchloric acid as potassium perchlorate ) was added to adjust the pH to 7 and the 
final volume was adjusted to 2 ml by adding 0.9 % sodium chloride. The mixture was 
centrifuged ( 500g ; 5 min ; room temperature ) and a third of the supernatant was 
collected and resuspended in sodium acetate buffer ( final volume of 1 m l ; pH 5 ) The 
samples were then stored at -20° C prior to assay for cyclic AMP.
The cyclic AMP concentration was estimated by radioimmunoassay 
essentially as described by Brooker etal. ( 1979). Authentic cyclic AMP standard 
concentrations ( 0 .0 1 - 1 0 0  pmoles / 1 0 0  | i l ; triplicate samples ) were prepared in sodium 
acetate buffer. To maximise assay sensitivity, samples (100 p.1) were acetylated by the 
addition of 5pl of a freshly made mixture of acetic anhydride and triethylamine, 1: 2 by
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volume ( Frandsen & Krishna, 1976 ) and the samples were rapidly vortex-mixed. To 
each tube was added 150 }il of a 1/10,000 dilution ( 0.1 % bovine serum albumin ) of 
anti-cyclic AMP serum ( raised in goats against human serum albumin conjugated to 
succinyl cyclic AMP ) and 25 p.1 of a 1/175 dilution of [1 2 5 I] - iodotyrosine methyl 
ester succinyl cyclic AMP ( approximately 3000 cpm/sample). Samples were mixed and 
incubated for 16 hours at 4° C.
After this incubation period, 0.5 ml of a suspension of washed charcoal ( 1 % , 
w/v ) in potassium phosphate buffer containing 0.25 % bovine serum albumin ( at 4° C ) 
was added. The samples were mixed and the charcoal sedimented by 
centrifugation ( 4000g ; 4 min ; 4° C ). Aliquots (0.5 ml) of the supernatant were 
taken to assess antibody -bound [1 2 5 I] - cyclic AMP which was counted (2 min) in a 
gamma counter (LKB 1275 Gamma Counter). Standard calibration curves in each 
experiment were plotted as radioactivity bound (cpm) against concentration of cyclic 
AMP or as B/B0  against concentration of cyclic AMP where B and B0  represent the 
amount of [1 2 5 I] - cyclic AMP bound in the presence or absence, respectively, of 
unlabelled cyclic AMP. In the absence of unlabelled cyclic AMP, approximately 30 % of 
the total added [1 2 5 I] - cyclic AMP was bound. Amounts of cyclic AMP in unknown 
samples were determined by reference to the calibration curve. The specificity of the 
antiserum was tested by measuring the ability of a range of adenine and guanine 
nucleotides to compete with [ 1 2 5 I]-cyclic AMP for binding to the antiserum. The 
antiserum was relatively specific for cyclic AMP with 103  fold ( cyclic G M P), 104  fold 
( AMP, ADP, ATP ) and 103  fold ( adenosine ) higher concentrations of the other 
nucleotides required to produce 50 % displacement of the [ 1 2 5 I]-cyclic AMP ( Berry and 
S kett, 1988 ).
-5 7 -
2.9 PHOSPHOLIPID STUDIES
2.9.1 Lipid Extraction
Hepatocytes (5  x 107  cells/ml) suspended in a phosphate free buffer were 
incubated ( 37° C; 90 minutes ) with carrier-free [32P]-orthophosphate ( 30 pC i/m l) and 
0.025 % bovine serum albumin. At the end of the incubation time the suspension 
was centrifuged at 200g for 2 minutes and the supernatant layer removed. The pellet 
was washed once with phosphate free buffer to remove excess carrier-free [32P] - 
orthophosphate and the cells ( 4 x 107  cells/m l) resuspended in 10 ml of the same 
buffer and 1 . 0  ml aliquots were dispensed into glass tubes containing nutrient medium 
Ham's F-10 supplemented with 0.1 % bovine serum albumin ( final volume 10 m l) 
at 37° C. The cells were allowed to equilibrate for 10 minutes before being challenged 
with insulin. After the appropriate time, the reaction was terminated and the lipids 
extracted essentially by the method of Schacht, (1981 ) as described below.
Briefly, the treated-cell suspension was centrifuged at 200g for 2 minutes and 
the supernatant layer removed. The reaction was terminated by adding ice-cold 10 % 
trichloroacetic acid ( w/v ) to the lipid soluble pellet fraction. After thorough mixing of 
their contents, the tubes were centrifuged ( lOOOg; 10 min ) and the supernatant 
layer discarded. A solvent mixture ( consisting of 1.5 ml of chloroform-methanol 
1: 2; 0.5 ml of chloroform; 1 ml of 1 M hydrochloric acid) was added to each 
sample, vortex - mixed, centrifuged ( 500g; 5 min ) and the lower phase was transferred 
into new tubes. The interface and upper phase were extracted twice with 1 ml of 
chloroform. The combined lower phases were washed with 2 ml of methanol-1M HC1, 
1:1 ( v/v), and the upper phase was discarded after centrifugation ( 500g; 5 min ). The 
lower organic phase was then dried at 40° C under oxygen-free nitrogen, and stored at 
-20° C until used.
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2 .9 .2  Separation bv thin-laver chromatography of phosphatidic acid and 
phosphatidvlinositol
Lipids were dissolved in 0.1 ml of chloroform-methanol, 9:1 (v/v) and spotted 
on silica-gel t.l.c. plates ( 10 cm x 10 cm, Silica Gel, Merck, Darmstadt ) for two- 
dimensional separation of phospholipids ( Yavin and Zutra, 1977 ). This t.l.c. 
system employs 3 basic solvents ; in the first dimension - chloroform: methanol: 
40 % aqueous methylamine ( 13:6:1.5, v/v/v ); diethylether : glacial acetic acid (19:1, 
v/v ) for the intermediary run ( through the second dimension ) and chloroform : 
acetone : methanol: glacial acetic acid : distilled water ( 10:4:2:3:1, v/v/v/v/v ) for the 
second direction. The chromatographic chamber was lined at both ends with Whatman I 
filter paper, and the tanks were equilibrated with the solvent mixtures for 1  hour before 
commencing the separation. All three organic mixtures were freshly prepared .
Phospholipid samples were applied to the lower left hand comer ( 2 cm in ) of 
the t.l.c. plates, using a 10 pi disposable micropipette. A total of 8  plates could be run in 
one batch. The solvent front was allowed to run within 1 cm from the edge of the plate, 
they were then removed and dried in a stream of warm air for 15 minutes whilst placed 
on a tray. Each plate was then exposed to the fumes of a concentrated solution of HC1 
( 36 % w/w ) for approximately 5 minutes. The plates were then dried in warm air for 
approximately 5 minutes, then cool air for an additional 5 minutes. The plates were then 
placed in the second solvent running in the second dimension ( origin at lower right 
com er) for a period of 15 -20 minutes. Following this, the plates were removed, dried in 
a stream of cool air for 5  minutes before placing in the third solvent in the same 
dimension as the second solvent. After the solvent front had run to 1 cm from the edge 
of the plates they were dried thoroughly in a stream of cool air. After drying, the 
phospholipids were visualized by placing the plates in an iodine vapour tank for
-59 -
approximately 3 minutes. The spots corresponding to phosphatidic acid and 
phosphatidylinositol ( see figure 4 ) were scraped into polythene scintillation vials and 
counted for radioactivity in a liquid-scintillation counter.
2.10 ASSAY OF SERUM GLUCOSE
Serum glucose was measured colourimetrically using an assay kit obtained from 
Sigma, U.K. Serum glucose was assayed by the method of Carroll et.al. ( 1970) and is 
based on the hexokinase catalysed conversion of glucose to glucose-6 -phosphate coupled 
with the subsequent reduction of nicotinamide adenine dinucleotide phosphate [NADP] to 
[NADPH] by action of glucose-6 -phosphate dehydrogenase. The final formation of a 
reduced quaternary salt was measured colourimetrically at 520 nm in a 
spectrophotometer. The colourimetric response is proportional to the glucose 
concentration and serum glucose concentration was calculated from the following 
formula :
A test
Glucose [mmol/L] = ------------------- X 5.56
A standard
A = absorbance at 520 nm
2.11 CALCULATION AND STATISTICS
Results were expressed as % of the relevant control. Means and standard 
deviations were calculated using a custom-made computer program and statistical analysis 
was performed by means of Student's f-test. Statistical significance was set at P < 0.05 
in all cases.
Figure 4. Schematic representation of phospholipid separation bv two- 
dimensional thin laver chromatography
Phospholipids identified by iodine staining are indicated, 
o - origin E. Sphyngomyelin
A. Neutral lipid _____________
B. Phosphatidylethanolamine F. Phosphatidylinositol
C. Plasmalogen lyso-phosphatidyl G. Phosphatidylserine
ethanolamine H. Phosphatidic acid
D. Phosphatidylcholine
-6 1 -
2.12 SOURCES OF CHEMICALS AND HORMONES USED
Androst-4-ene-3,17-dione
[4- 1 4  C] androst-4-ene-3,17-dione
Bovine serum albumin ( Fraction V )
Collagenase
Cyclic AMP
Adenosine 3',5Lcyclic phosphoric acid 2’-0- 
succinyl 3-[1 2 5 I] iodotyrosine methyl ester.
( 1 2 5 I-cyclic AM P)
Glucagon 
Glucose assay kit 
Ham's F-10 culture medium 
Insulin ( porcine)
K-252a
Neulente Insulin Zinc Suspension BP
p  P] orthophosphate carrier free
Penicillin / Streptomycin
Phenformin
Phosphatidic Acid
Streptozotocin
TH-Glucagon
Tolbutamide
Ultroser G
X-ray films ( X-Omat S )
Sigma Chemical Co., Poole, Dorset. 
Amersham International pic. (Bucks.). 
Sigma Chemical Co., St. Louis, U.S.A. 
Boehringer Mannheim Co. (F.R.G). 
Sigma Chemical Co., St. Louis,U.S.A. 
Amersham International pic. (Bucks.).
Sigma Chemical Co., Poole, Dorset. 
Sigma Chemical Co., Poole, Dorset. 
GIBCO BRL Limited, Paisley, Scotland. 
NOVO Research Institute, Denmark. 
Kyowa Hakko Kogyo Co., Japan.
( a gift from Dr. H. Kase).
Wellcome, Welwyn Garden City, U.K. 
Western Infirmary, Glasgow University. 
GIBCO BRL Limited, Paisley, Scotland. 
Sterling Winthrop, Surrey, U.K.
Sigma Chemical Co., St. Louis, U.S.A. 
Sigma Chemical Co., St. Louis , U.S.A. 
A gift from Dr. V J . Hruby ( U.S.A ) 
Sigma Chemical Co., St. Louis, U.S.A. 
LKB Products, Sweden.
Kodak, France.
All other chemicals used were of analytical grade.
2.13 BUFFERS AND OTHER SOLUTIONS TJSF.D
1) Calcium-free Hank's balanced salt solution ( 1 0%  stock solution i 
KC1 - 2.0 g/L
KH 2 PO 4  ( anhydrous ) . 0 . 3  g/L
NaCl - 40.0 g/L
NaHC0 3  ( anhydrous ) - 10.5 g/L
Na2 HP0 4  ( anhydrous) - 0.238 g/L
The above were dissolved in distilled water and the pH adjusted to 7.4 
(1M).
2) Incubation medium
Glucose - 1.0 g/L
MgCl2 .6 H 20 - 0.1 g/L
MgSO4 .7H20 - 0.1 g/L
CaCl2 . 6H20 - 0.185 g/L
HBSS - 100 ml of 10 % stock solution
The above were dissolved in 1 L of distilled water.
3) Potassium phosphate buffer (100 m M )
K2 H P0 4  . 3H20 ( 200 m M ) - 66.25 ml
KH2 P 0 4  ( anhydrous )(2 0 0  mM ) - 183.75 ml
Distilled water - 250 ml
The above were mixed and the pH was adjusted to 6.4 using HC1 (10  M ).
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4) Phosphate free buffer for phospholipid studies
NaCl - 8.18 g/L
NaHC0 3  ( anhydrous) - 0.24 g/L
KC1 - 0.37 g/L
MgCl2 . 6H20 - 0.20 g/L
M gS04 . 7H20 - 0.015 g/L
Glucose - 1.01 g/L
HEPES - 3.60 g/L
CaCl2 . 6H20 1.60 mM
Bovine serum albumin - 0.025 %
The above were dissolved in distilled water and the pH was adjusted to 7.2 using HC1 
(1M).
RESULTS
-64-
3.0 DEVELOPMENT AND CHARACTERIZATION OF HORMONE-FREE
CULTURE MEDIUM
The assay for metabolism of androst-4-ene-3,l7-dione allowed for the 
measurement of the 6 p-, 7a- and 16a-hydroxylases, 17-oxosteroid oxidoreductase 
( 17-OHSD ) and 5a-reductase activities. Hepatocytes from adult rats were isolated and 
cultivated as primary monolayers in four different types of culture media.
Male rat hepatocytes cultured in Ham's F-10 medium supplemented with 2.5 % 
foetal calf serum and 15 % horse serum show a fall in activity of between 15 to 50 % of 
control depending on the enzyme studied after 3 days in culture ( Table 1, top panel). 
After 6  days in culture, the enzyme activities were partially restored and this varied with 
the enzymes measured. The activity of the female-specific enzymes, 7a-hydroxylase and 
5a-reductase recovered to about 90 % and 80 % of control respectively and the male- 
specific enzymes, 6 p- and 16a-hydroxylases and 17-OHSD to 59 %, 23 % and 97 % 
of control respectively. With the female rat hepatocytes, sexual differences in androst-4- 
ene-3,17-dione metabolism could be detected after 3 days of culture in the same culture 
medium. Selective significant decreases in both the female-specific enzymes activities, 
7a-hydroxylase and 5a-reductase ( 1 9 %  and 21 % respectively) could be observed 
( Table 2, top panel). Significant increases in the male-specific enzyme activities, 6 P- 
hydroxylase and 17-OHSD, could be seen while 16a-hydroxylase activity was unaltered 
when compared to freshly prepared cells. After 6  days in culture, with the exception of 
the 5 a-reductase activity ( still significantly below control level ), all the enzyme 
activities increased and exceeded the control values.
Similar decreases in enzyme activity were seen when male rat hepatocytes were 
cultured for 3 days in Ham's F-10 supplemented with a well-defined synthetic serum 
substitute, Ultroser G 2%.  No sexual differences in steroid metabolism were observed
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( Table 1, bottom panel). The enzyme activities declined to about 10 to 20 % of control. 
Only slight improvements in activity were seen after 6  days in culture. After 3 days, a 
significant fall in all the enzyme activities was observed when hepatocytes derived from 
female rats were cultured in Ham's F-10 medium plus 2 % Ultroser G. Activity declined 
to 63 % and 59 % of control for the 7a-hydroxylase and 5a-reductase respectively while 
6 p- and 16a-hydroxylases and 17-OHSD activities fell to 81 % , 78 % and 95 % of 
control respectively ( Table 2, bottom panel). After 6  days, the 6  p-hydroxylase and 5a- 
reductase activity were restored to control level and the 7a- and 16a-hydroxylases and 
17-OHSD activity rose significantly above the control.
In a shorter time scale experiment, only male rat hepatocytes were cultured in 
Ham's F-10 culture medium supplemented with 2 % Ultroser G. After 24 hours the 
medium was removed and washed once with Ham's F-10 medium supplemented with 
0.1 % bovine serum albumin. The cultures were incubated in the latter medium for a 
further 24, 48 and 72 hours. After 1 day in culture, the enzyme activities decreased to 
between 25 and 80 % of control ( Table 3, top panel ). After 2 days in culture, the 
cytochrome P-450 dependent enzyme activities ( 7 a - , 6 P- and 16a-hydroxylases ) were 
partially restored. Both the non-cytochrome P-450 dependent enzyme activities ( 17- 
OHSD and 5a-reductase ) rose above the control level though the changes were not 
statistically significant. After 3 days, all the enzyme activities had exceeded the basal 
control level.
In another similar time scale experiment, male rat hepatocytes were directly 
cultured in Ham's F-10 medium supplemented with 0.1 % bovine serum albumin 
( Table 3, bottom panel). After 1 day, a similar fall in all of the enzyme activities was 
seen ( to between 30 and 60 % of control). This was followed by restoration of all the 
enzyme activities to control level ( except 7 a-hydroxylase ) after 2 days in culture. After 
3  days in culture, all the enzyme activities rose significantly above the control level.
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The metabolism of androst-4-ene-3,17-dione was also studied using different 
numbers of liver cells per incubation. In this study it was observed that the androst-4- 
ene-3,17-dione metabolism as a function of cell number showed a linear relationship 
( Figure 5 ). The amount of all the metabolites produced increased with increasing 
number of liver cells used implying that all the five enzyme activities also increased with 
increasing cell numbers.
A similar linear relationship was found with increasing period of incubation. The 
conversion to all the five metabolites increases with time of incubation ( Figure 6  ). No 
lag phase in the metabolism of androst-4-ene-3,17-dione was observed at any time.
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Figure 5 . Androst-4-ene-3,17-dione metabolism by isolated liver cells from normal 
male rat as a function of increasing of number of cells per incubation. The 
liver cells were incubated and the reaction was terminated at the indicated 
time period as described in the Methods section and the amount of 
metabolites ( pmole/min) was calculated. The conversion of androst-4- 
ene-3,17-dione to the 5 different metabolites are produced by 5 different 
respective enzymes namely, (A) 7 - hydroxylase (B)5« -reductase
(C) 6  p -hydroxylase (D) 16 « -hydroxylase and (E) 17-oxosteroid 
oxidoreductase. Results are expressed as mean + S.D(N = 3).
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Figure 6
A)
Androst-4-ene-3,17-dione metabolism by isolated liver cells from normal 
male rat as a function of time of incubation. The liver cells were incubated 
and the reaction was terminated at the indicated time periods as described 
in the Methods section and the amount of metabolites produced ( pmole/ 
million cells ) was calculated. The conversion of androst-4-ene-3,17-dione
to the 5 different metabolites are produced by 5 different respective enzymes 
namely, (A) 7 « - hydroxylase (B) 5 « -reductase (C) 6  p -hydroxylase
(D) 16 * -hydroxylase and (E) 17-oxosteroid oxidoreductase.
Results are expressed as mean + S.D ( N = 3 ).
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4.0 INSULIN.
4.1 ACTION OF INSULIN ON THE METABOLISM OF ANPROST- 
4-ENE- 3.17-DIONE
For convenience and space purposes, most of the graphic presentation for the five 
enzymes are divided into two graphs, the 7a-hydroxylase ( OHase ) and 5a- 
reductase activities ( both are female-specific enzymes ) are presented in one graph 
and the other three, male-specific enzymes [ 17-oxosteroid oxidoreductase ( OHSD ), 
6 p- and 16a-hydroxylases ] in a second graph. Error bars and stars to indicate the 
level of significance are omitted from the graphs ( except in figures 5, 6 , 40 and 41 ) 
for reason of clarity but the respective tables give the complete results ( mean ± S.D ). 
Tables are expressed in absolute terms whereas the graphs are expressed as percentage of 
control values.
4.1.1 HEPATOCYTES FROM NORMAL RAT
4.1.1.1 Preincubation with insulin for 1/2. 1 and 2 hours
After 1/2 hour preincubation with insulin, all the enzymes showed a dose-related 
increase in activity, significant ( P < 0.05 ) at concentrations as low as 10* 1 0  M 
insulin, which had not reached a maximum at 10* 6  M ( Table 4 ). When compared to 
control, insulin at 10' 6  M, increased the activity of 7a-hydroxylase and 5a-reductase 
to 305 % and 214 % respectively ( Figure 7 A ) and 6 P- and 16a-hydroxylases, and 17- 
OHSD to 211%, 279% and 210 % respectively ( Figure 7B). Evidently, there is no sex- 
difference in the effect of insulin on the various enzyme activities as the female-specific
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Figure 7. Dose-response curves of (A) 7 « -hydroxylase [ ■ ] and 5 a -reductase [ ♦ ] and 
(B) 17-OHSD [ ■ ], 6  p - [ * ] and 16 a -hydroxylases [ o ] to insulin after 1/2 
hour of preincubation in hepatocytes obtained from normal male rat.
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3). Absolute data is given in Table 4 .
C = control
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enzyme activities ( 7a-OHase and 5a-reductase ) are affected to the same extent as the 
male-specific activities (6(3- and 16a-OHases and 17-OHSD ).
This stimulation of activity virtually disappears after 1 hour of insulin 
preincubation ( Table 5 ). The effect of insulin ( 10- 1 0  M to 10- 6  M ) on all the five 
enzymes measured was found to display a bell-shape dose-response curve with 
significant increase in enzymes activity seen at physiological insulin concentration ( 1 0 ' 9  
and 10' 8  M ) [ although 5a-reductase exhibited a reduction in activity at higher insulin 
concentrations ( 10' 7  and 10- 6  M ) which were statistically significant ( Figure 8  )].
Exposure of the primary culture of hepatocytes to insulin for 2 hours resulted in 
the return of all the enzyme activities to almost basal level ( Table 6  ). Although insulin 
at 10* 1 0  M concentration increased the activity of 7a-hydroxylase, 5a-reductase 
and 16a-hydroxylase (145 %, 138 % and 116 % of control respectively ), they 
are not statistically significant ( P > 0.05 )( Figure 9 ). However, at high ( 10' 6  M ) 
concentration, insulin significantly increased all the enzyme activities.
4.1.1.2 Preincubation with insulin for 24. 48 and 72 hours
An increase in all of the enzyme activities is seen at 24 hour insulin 
preincubation ( Table 7 ). Maximum response could be observed at 10‘ 9  or 10- 8  M 
concentration ( to about 140- 150 % of control). Unlike the dose-related effect of 
insulin seen at 1/2 hour ( see Figure 7 ), the percentage maximal response against 
control seemed to fall as the concentration of insulin is increased above the physiological 
level ( Figure 10 ) with activity declining significantly below the control at 10’ 6  M 
insulin concentration.
At 48 hours, insulin ( 10’ 9  M ) elicited a significant increase in activity of
-78-
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Figure 8 . Dose-response curves of (A) 7 a -hydroxylase [ » ] and 5 a -reductase [ • ] and 
(B) 17-OHSD [ ■ ], 6  P - [ A ] and 16 a -hydroxylases [ p  ] to insulin after 1 
hour of preincubation in hepatocytes obtained from normal male rat.
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3). Absolute data is given in Table 5 •
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Figure 9. Dose-response curves of (A) 7 a -hydroxylase [ «* ] and 5 « -reductase [ ♦ ] and 
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(N  = 3). Absolute data is given in Table 6  .
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Figure 10* Dose-response curves of (A) 7 « -hydroxylase r ® ] and 5 « -reductase [ • ] and 
(B) 17-OHSD [ ■ ], 6  f> - [ * ] and 16 « -hydroxylases [ □ ] to insulin after 24 
hour of preincubation in hepatocytes obtained from normal male rat.
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3 ). Absolute data is given in Table 7 .
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all of the enzymes with the exception of the 6 p-hydroxylase ( Table 8  ). The activity 
began to decline sharply and significantly below control to about 50 % of control for both 
7a-hydroxylase and 5a-reductase (Figure 11A) and about 4 0 - 7 0 %  of control for 
6 p- and 16oc-hydroxylases and 17-OHSD ( Figure 11B ) at higher concentrations of
insulin. Maximal decrease in activity was seen at 10' 8  M insulin concentration after 
which it began to plateau.
After 72 hours of insulin preincubation, all of the enzymes exhibited a U-shaped 
dose-response curve with significant reductions in enzyme activity at concentration as 
low as 10' 9  M, reaching maximal reduction at 10' 8  M insulin concentration ( Table 9 
and Figure 12 ). The enzyme activities increased again at 10' 7  and 10* 6  M although they 
were still significantly below control levels. It is interesting to note that the basal level of 
the five enzymes measured increased with time as illustrated in Table 7, 8  and 9.
From the data from Tables 4 to 9, we are able to construct a graph illustrating 
the time-course of events following the addition of insulin at physiological 
concentration ( 10' 9  M ) over the time period studied ( 1/2 hour to 72 hours 
preincubation ) for all the five enzyme activities in the normal rat hepatocytes.
Figure 13 shows the response of the cultured hepatocytes to various periods of 
preincubation with insulin (a t 10' 9  M ) on all the enzyme activities studied. Evidently, 
the effect of insulin on 7a-hydroxylase and 5a-reductase ( female specific ) and 17- 
OHSD, 6 P- and 16a-hydroxylases ( male specific ) was non-selective with respect to 
sex differences in steroid metabolism. Maximal increase in enzyme activities are observed 
at 1/2 hour and 24 hour of insulin preincubation. Enzyme activities diminished, though 
significantly above control level, at 1  hour followed by a return of activity to basal level at 
2 hours of insulin preincubation. Reduced enzyme activities were observed at 48 hours 
and continued to fall below basal level (70-80 % of control) at 72 hours.
In order to verify whether the disappearance in effect of insulin at 48 and 72 hour
-85 -
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Figure 11 . Dose-response curves of (A) 7 « -hydroxylase [ » ] and 5 a -reductase [ ♦ ] and 
(B) 17-OHSD [ b ], 6  a - [ * ] and 16 a -hydroxylases [ d ] to insulin after 48 
hour of preincubation in hepatocytes obtained from normal male rat.
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3). Absolute data is given in Table 8  .
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Figure 12 * Dose-response curves of (A) 7 a -hydroxylase [ ■ ] and 5 « -reductase [ • ] and 
(B) 17-OHSD [ ■ ], 6  p * [ * ] and 16 -hydroxylases [ a ] to insulin after 72 
hour of preincubation in hepatocytes obtained from normal male rat.
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3 ). Absolute data is given in Table 9 .
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( as shown in Figure 13 ) was due to insulin degradation or to ligand-induced insulin 
receptor down-regulation, insulin ( 1 0 ' 1 0  to 1 0 ' 6  M ) was added at 24 hour intervals from 
0 to 72 hour ( Table 10 ). As shown in table 10A, a 24 hour insulin preincubation gave 
a bell-shaped response, consistent with our previous result ( Table 7 ). 
Accumulated addition of insulin at 24 and 48 hours resulted in no significant increase in 
any of the enzymes ( Table 10B and C; see Figure 14 ).
4.1.2 HEPATOCYTES FROM 3-DAYS  STZ-TREATED DIABETIC RAT
4.1.2.1 Preincubation with insulin for 1/2 and 1 hour
Unlike the hepatocytes from normal rats, after 1/2 hour preincubation, the 
enzyme activities in hepatocytes from 3-days STZ-induced diabetic male rat were not 
responsive to insulin over the range of concentration used ( Table 11 ). Lack of insulin 
responsiveness is evident with all the enzymes irrespective of their sex specificity. 
Although' 17-OHSD activity rose to about 20 % above control, this result 
was not statistically significant ( Figure 15 ). As demonstrated in Table 12, serum 
glucose levels in the 3-days STZ-diabetic rats were grossly elevated ( about 3-fold 
increase ) establishing that the rats were diabetic. Whilst the normal rats gained weight, 
the 3-days diabetic rats experienced about 20 g of weight loss. When compared to 
control data ( Table 12 ), 3-days diabetic rats exhibited a decrease in the male-specific 
enzyme activities ( 6 (3-hydroxylase and 17-OHSD ) while the female-specific enzymes 
activities ( 7 a-hydroxylase and 5 a-reductase) were increased.
Similarly, 1 hour insulin preincubation in hepatocytes obtained from 3-days 
STZ- diabetic rat elicited no change in enzyme activities from control ( Table 13 ). When 
expressed in percentage of control, again no significant change in any of
-91 -
Table 10 . Time course effect of cumulative insulin addition on 7 « 6  P - and
16 a -hydroxylases (OHases), 17-OHSD and 5 a -reductase activities in hepatocytes obtained 
from normal male rat. Insulin was added at 24 hour intervals at (A) 0 h r, (B) 24 hr 
and (C) 48 hr of cells preincubation. Results expressed as mean ± SD ( N = 3 );
* P < 0.05 as compared to the respective control.
( A )
Insulin
concentration
Enzyme activities - ( pmoles / min / million cells)
7 a-OHase 6 p* OHase 16 OC-OHase 17 - OHSD 5 a-reductase
Control 33 ± 6 53 ± 4 63 ± 4: 73 ±6 93 ± 6
1 0 ‘10 M 36 ± 6 64 ± 3 67 ± 5 11 ± 6 106 ± 10
-9
10 M 53 ± 6  * 81 ± 3 91 ± 7  * 95 ± 4 * 135 ± 7 *
10-8 M 52 ± 6 * 85 ± 2  * 92 + 6 * 96 ± 7  * 143 ± 5 *
10 ’? M 43 ± 1 * 40 ± 1 50 ± 7  * 60 ± 5 * 78 ± 6 *
-6
10 M 35 ± 6 46 ± 1
*
53 ± 4 72 + 5 93 ± 6
(B )
Insulin
concentration
Enzyme activities ( pmoles / min / million cells)
7 a - OHase 6 p-OHase 16 Ot -OHase 17 - OHSD 5 a  - reductase
Control 47± 3 63 ± 10 77 ± 8 83 + 3 137 ±6
soo
50 ± 3 53 ± 6 63 ± 8 83 ± 4 142 ± 6
-9
10 M 48 ± 2 57 ± 6 77 ± 7 81 ± 9 129 ± 6
sOOOr-H 50 ± 1 67 ± 7 67 ± 4 85 ± 3 143 ± 7
1 0 M 46 ± 4 57 ± 9 67 ± 5 81 ± 4 132 ± 5
■6
10 M 47 ± 2 69 ± 6 73 ± 6 78 ± 5 147 ± 3
-92-
( C )
Insulin
concentration
Enzyme activities ( pmoles / min / million celb)
7 (X-OHase 6 3 -OHase 16 a-OHase 17 - OHSD 5 (X-reductase
Control 47 ± 6 63 ± 6 89 ± 4 87 ±15 127 ±5
10 '10 M 46 ± 6 67 ± 6 87 ± 3 83 ± 9 130 ± 10
-9
10 M 47 ± 6 73 ± 6* 96 ± 7 87 ± 11 120 ± 10
10-8 M 46 ± 6 60 ± 10 83 ± 6 83 ± 6 119 ± 14
-7
10 M 45 ± 6 60 ± 10 87 + 1 87 ± 7 119 ± 10
-6
10 M 44 ± 6 70 ± 10 93 ± 1 85 ± 6 133 ± 6
-93 -
A)
a©©
*s
180
160
140
1 2 0
1 0 0
80
60
40
20
0
I t I
24
—l~
48
—r-
72
Duration of culture (hours)
B)
gV
*S
160 n
140 -
120 -
100 -
80 -
60 -
40
20 -
7 248C 24
Duration of culture (hours)
-9
14. Time course effect of cumulative insulin (10 M) addition on (A) 7 « -hydroxylase [ n ] 
and 5 a -reductase [ ♦ ] and (B) 17-OHSD [ ■ ], 6  P - [ * ] and 16 « -hydroxylases [ o ] 
activities compared to respective control. The arrow ( f ) denotes the point where insulin 
(10~*M) was added during the preincubating phase.
Results are expressed as percentage of the relevant control and mean + S.D ( N = 3 ). 
Absolute data is given in Table 1 0  . C = control
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Figure 15. Dose-response curves of (A) 7 « -hydroxylase [ ■ ] and 5 “ -reductase [ • ] and 
(B)17-OHSD [ ■ ], 6  P - [ * ] and 16 p -hydroxylases [ a ] to insulin after 1/2 hour 
preincubation in hepatocytes obtained from 3 days STZ-treated diabetic male rat. 
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3 ). Absolute data is given in Table 1 1  .
C = control
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Table 12 . Thg—effect o f  StreptQZQtQcin and insulin treatment on the metabolism of
androsti4--ener.3J7-di.Qne in isolated hepatocvtes from male rat and serum glucose 
concentration and changes in body weight of intact animal.
Parameter Control b 3 days STZ diabetic 21 days STZ diabetic 3 days STZ +Insulin c
( Jn-vivo 1
7 a-OHase 37 ± 6 60 ± 9 a 40 ± 7 49 ± 9 a
6 p-OHase 53 ± 7 38 ± 7 a 34 ± 2 a 81 ±  3 a
16a-OHase 43 ±  6 80 ±  1 0  a 44 ±  3 75 ±  7 a
17-OHSD 113 ±  6 85 ±  2 a 123 ± 2 a 116 ± 5
5 a-reductase 117 ± 3 130 ± 9 a 8 6  ± 9 a 112 ± 5
Serum glucose 
(mM)
5.9 ± 0.7 19.7 ± 2.5 a 16.3 ±  3.3 a 7.3 ±  1.2
Initial wt. (g) 225 ±  8 230 ± 10 2 2 0  ±  8 225 ±  9
Change in 
weight (g)
5 ± 2 -20 ±  3 a -25 ± 4 a -2 ± 5
a Significantly different from the relevant control; p < 0.05
b Hepatocytes were preincubated with insulin in serum-free medium as described in the 
Methods Section and all enzyme activities expressed as p moles product/min/106  cells 
and as mean ± S.D. of 4 animals. 
c Animals were given 12 U of insulin as described in the Methods Section. 
Abbreviations : OHase = hydroxylase ; OHSD = oxosteroid oxidoreductase
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Figure 16 »Dose-response curves of (A) 7 * -hydroxylase [ a ] and 5 «* -reductase [ ♦ ] and 
(B)17-OHSD [ »■ ], 6  p -  [ * ] and 16 * -hydroxylases [ a ] to insulin after 1 hour 
preincubation in hepatocytes obtained from 3 days STZ-treated diabetic male rat. 
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3). Absolute data is given in Table 13 .
C = control
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the enzyme activities was seen ( Figure 16 ).
4.1.3 HEPATOCYTES FROM 21-DAYS STZ-TRHATED DIABETIC RAT
4.1.3.1 Preincubation with insulin for 1/2. 1 and 2 hours
At 1/2 hour, hepatocytes from 21-days STZ-diabetic rats were resistant 
to the effect of insulin ( Table 14 ) showing no significant change for all the enzyme 
activities measured throughout the range of insulin concentration used ( Figure 17 ). 
Serum glucose level rose 2.5 times and the animals underwent a weight loss ( Table 12). 
Changes in the basal level of enzyme activity varied in the chronic diabetic rats. No 
significant changes were seen on 7a- and 16a-hydroxylases activity but lowering of 
activities of 6 p-hydroxylase and 5a-reductase were observed.
At 1 hour, low insulin concentrations ( Kb1 0  to 10' 8  M ) increased the enzyme 
activities in a dose - dependent manner ( Table 15 ) but at higher concentrations ( 10' 7  
and 10* 6  M ) there was less effect. Figure 18 illustrates the dose-response effects on 
the female-specific enzymes ( top panel) and male-specific enzymes ( bottom panel) of 
insulin after 1 hour preincubation. It is interesting to note that hepatocytes from chronic- 
diabetic rat ( 2 1 -days) exhibited higher activities for the female-specific enzymes 
(Figure 18A) than the male-specific enzymes (Figure 18B ).
Hepatocytes subjected to 2 hours of insulin preincubation displayed a small 
but significant dose-dependent increase in enzymes activities with maximum 
activity achieved at 10' 8  M insulin concentration ( Table 16 and Figure 19).
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Figure 17 .Dose-response curves of (A) 7 « -hydroxylase [ 0  ] and 5 « -reductase [ • ] and 
(B) 17-OHSD [ 0  J, 6  3  - [ « ] and 16 « -hydroxylases [ 0  ] to insulin after 1/2 hour 
preincubation in hepatocytes obtained from 21 days STZ-treated diabetic male rat. 
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3 ). Absolute data is given in Table 14 .
C = control
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Figure 18, Dose-response curves of (A) 7 « -hydroxylase [ a ] and 5 « -reductase [ ♦ ] and 
(B) 17-OHSD [ a ], 6  p -  [ A ] and 16 « -hydroxylases [ n ] to insulin after 1 hour 
preincubation in hepatocytes obtained from 21 days STZ-treated diabetic male rat. 
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3 ). Absolute data is given in Table 15 .
C = control
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Figure 19. Dose-response curves of (A) 7 « -hydroxylase [ « ] and 5 « -reductase [ • ] and 
(B) 17-OHSD [ “ ], 6 p - [ a J and 16 « -hydroxylases [ o J to insulin after 2 hour 
preincubation in hepatocytes obtained from 21 days STZ-treated diabetic male rat. 
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3). Absolute data is given in Table 16 .
C = control
-106-
4.1.4 HEPATOCYTES FROM INSULIN TREATED 3-DAYS DIABETIC RAT
Different doses of insulin ( 2 , 12 and 16 units ) were administered into the 
acutely STZ-treated diabetic rats ( 3-days ) to investigate their efficacy to stimulate 
in-vitro insulin effect with respect to steroid enzymes activity ( see Methods Section 2 . 2  
for detail). In these experiments, hepatocytes were preincubated with insulin for 1/2 hour 
and then assayed for androst-4-ene-3,17-dione metabolism.
In diabetic rats treated with 2 units insulin, in-vitro insulin addition elicited a 
significant dose-related increase in all of the enzyme activities ( Table 17A ). At 10 6  M 
insulin, enzyme activities were restored to about 50 to 7 5  % of that in normal 
hepatocytes. The enzyme activities increased significantly at concentration as low as 
10 1 0  M insulin and the maximum effect ( about 140 to 160 % of control) was seen 
at lO 8  M concentration for all of the enzymes ( Figure 20).
Similar results were obtained with diabetic rats treated with 12 units insulin. 
Again, partial restoration of the normal rat enzyme activities were noticed ( Table 17B ). 
Generally, statistically significant increases in enzyme activities were seen at 10- 1 0  M 
insulin and above. As shown in Figure 20, all of the enzymes displayed a dose- 
dependent increase in activity reaching maximal responses at 10* 8  M ( except 6(3- 
hydroxylase whose maximal response occurred at 10' 7  M insulin concentration - 
Figure 20C ). Thus the restoration of activity was about the same as that seen with 
diabetic rats treated with 2 units of insulin. With regard to the serum glucose level and 
change in body weight, they were not statistically significant from the control 
( Table 12 ). The 7 a - , 6(3- and 16a-hydroxylase activities were significantly greater 
than controls.
Hepatocytes from diabetic rats treated with 16 units insulin however were 
unresponsive to in-vitro insulin addition throughout the concentration range used
-107-
Table 17. Dose-response effects of 7 « 6 p - and 16 <* - hydroxylases, 17-oxosteroid
oxidoreductase (OHSD) and 5 « -reductase activiiics to insulin after 1/2 hour preincubation in 
hepatocytes obtained from (A) 2 units (B) 12 units (C) 16 units of insulin - treated 3 -days 
STZ diabetic male rat. Results expressed as mean ± SD ( N = 3 ); * P <  0.05
as compared to the respective control..
( A )
Insulin
concentration
Enzyme activities ( pmoles / min /  million cells)
7 a-01Iase 6 (3-OHase 16 (X-OHase 17 - OHSD 5 oc-recluctase
Control 31± 2 79 ± 4 79 ± 3 106±2 54 ±2
10 '10 M 38 ± 2  * 88 ± 7 94 ± 3  * 118 ± 2 * 63 ± 2 *
-9
10 M
*
40 ± 2 100 ± 5  * 102 ± 2 148 ± 4 72 ± 3  *
10 M
*
47 ± 3 117 ± 3 *
*
116 ± 3
*
164 ± 4 87 ± 4  *
-7
10 M 50 ± 3  *
*
114 ± 3 121 ± 3  * 161 ± 6  * 90 ± 3  *
-6
10 M 51 ± 3  * 110 ± 2 *
*
112 ± 3 151 ± 4  * 71 ± 3  *
(B )
Insulin
concentration
Enzyme activities ( pmoles / min /  million cells)
7 0tr OHase 6 (3'OHase 16 a-OHase 17 - OHSD 5 a-reductase
Control 49± 9 81 ± 3 75 ± 7 116 ±5 112 ±5
10 "10 M 47 ± 5 94 ± 5  *
*
63 ± 4 123 ± 6 159 ± 4  *
-9
10 M 47 ± 5 93 ± 10  * 79 ± 15 148 ± 10 * 172 ± 5  *
10 •* M
%
72 ± 1 108 ± 5  *
*
95 ± 9 168 ± 4  * 184 ± 4  *
1 0 M
*
67 ± 4 129 ± 4  * 91 ± 12  * 161 ± 8 189 ± 3  *
-6
10 M *72 ± 6 118 ± 3 * 102 ± 6 * 169 ± 2  * 185 ± 4 *
-108-
( C )
Insulin
concentration
Enzyme activities ( pmoles / min /  million cells)
7 CC -OHase 6 (3-OHase 16 OC-OHase 17 - OHSD 5 ct-reductase
Control 59± 4 105 ± 5 109 ± 7 145 ± 4 114 ±4
10 '10 M 59 ± 3 106 ± 1 106 ± 1 147 ± 4 112 ± 2
-9
10 M 56 ± 3 107 ± 2 108 ± 6 145 ± 8 117 ± 4
200O *52 ± 2 105 ± 6 100 ± 6 140 ± 6 117 ± 1
10 ’7 M
*
51 ± 2 100 ± 6 97 ± 7 139 ± 6 116 ± 2
-6
10 M 58 ± 4 105 ± 3 101 ± 3 143 ± 5 110 ± 6
-109-
Figure 20. Dose-response curves of (A) 7 « -hydroxylase (B) 5 « -reductase (C) 6 p -hydroxylase
(D)16 a -hydroxylase and (E) 17-OFISD activities to insulin after 1/2 hour preincubation 
in hepatocytes obtained from 3 days STZ-induced diabetic male rat treated with 2 units [ a J 
12 units [ ♦ ] and 16 units [ n ] of Neulente insulin.
Results are expressed as percentage of the relevant control and mean + S.D ( N = 3 ). 
Absolute data is given in Table 17 .
C = control
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( Table 17). All enzyme activities were not significantly different from control 
( Figure 20).
4.2 EFFECT OF INSULIN ON CYTOCHROME P-450 CONCENTRATION IN 
ISOLATED MALE RAT HEPATOCYTES
As cytochrome P-450 is one of the major component of the steroid-metabolising 
enzyme system, we decided to investigate the relationship between cytochrome P-450 
content and insulin with respect to steroid metabolism. The cytochrome P-450 content 
was measured after 1/2, 1 , 2 and 24 hours of insulin in-vitro addition in normal 
male rat hepatocytes. As illustrated in Table 18, insulin at 10~ 9  and 10 6  M gave no 
significant changes in the hepatic level of cytochrome P-450 in the acutely ( 1/2, 1 and 2 
hours) or chronically ( 24 hours ) treated hepatocytes. Small amount of cytochrome P-420 
was noted in culture but were ignored.
4.3 EFFECT OF INSULIN ON CYCLIC AMP CONCENTRATION IN
ISOLATED MALE RAT HEPATOCYTES
The effect of insulin on cyclic AMP concentration in hepatocytes from normal 
male rat was investigated. Primary cultures of hepatocytes were preincubated with 
insulin ( 1 0 1 0  to 1 0 6  M ) for 1/2 , 1 and 2 hours and then cyclic AMP content was 
determined as described in Methods Section 2.8.
Table 19 shows that no significant changes in the cyclic AMP concentration was 
seen in hepatocytes previously exposed to insulin for 1 / 2 , 1  and 2  hours. 
There was a slight reduction in cyclic AMP concentration ( to about 83 % of control) by 
10 6  M insulin at 1 hour preincubation but this effect was not statistically significant 
( Figure 2 1  ).
Table 18 . Time course assay of cytochrome P-450 content after 1/2, 1, 2 and 
24 hour preincubation with insulin ( 10~6M and 10'9 M) in hepatocytes 
obtained from normal male rat. Cytochrome P-450 content was determined as 
described in Methods Section. The results are expressed as pmoles million 
cells'1.
The data are the mean and standard deviations from a single experiment 
( representative of six similar experiments ). § denotes no significant difference 
against control.
Preincubation Period
1/2 hr. 1 hr. 2 hr. 24hr.
1) Control 58 ± 4 51 ± 3 53 ± 4 20 ± 3
2) Insulin (10 ~9 M) 57 ± 8 § 49 ± 4  § 49 ± 2 § 22 ± 5 §
3) Insulin (10 ^ M) 56 ± 4  § 52 ± 2  § 51 ± 3 § 24 ± 6 § .
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Table 19. Effect of insulin on cyclic AMP content in hepatocytes from normal male 
rat. Hepatocytes were incubated with insulin for 1/2, 1 and 2 hours at 
the concentrations indicated and cyclic AMP content was determined 
as described in Methods Section 2.8. The data are the mean
and standard deviations from a single experiment ( representative of
three similar experiments). None are significantly different from their 
respective controls.
Insulin 
Concentration 
( M )
cyclic AMP content ( nmol / million cells)
1/2 hour 1 hour 2 hour
Control 11.25 ± 1.35 9.00 ± 0.27 9.00 ± 0.72
so1o 10.80 ± 0.22 9.99 ± 1.19 8.28 ± 0.66
10 -9 M 12.49 ± 0.87 9.36 ± 1.40 8.64 ± 0.52
10 ‘8 M 10.80 ± 0.64 8.64 ± 0.34 9.09 ± 0.27
10'7 M , 10.58 ± 0.53 7.92 ± 0.39 8.37 ± 0.41
10 6 M 9.90 ± 0.39 7.47 ± 0.37 8.64 ± 0.60
cA
M
P 
le
ve
ls 
(% 
of 
co
nt
ro
l)
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Figure 21, Effect of insulin on cyclic AMP content in hepatocytes obtained from 
normal male rat. Hepatocytes were incubated with insulin for 
1/2 [ o ] ,  1 [ ♦ ] and 2 [ * ] hours and cyclic AMP content was 
determined as described in Methods Section 2.8. The results are 
mean values + S.D ( N = 3). None are significantly different from 
their respective controls ( C ).
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4.4 EFFECT QF INSULIN QN PIIOSPHATIDTC ACID AND
PHOSPHATIDYLINOSITOL FORMATION IN ISOLATED MALE RAT 
HEPATOCYTES
4.4.1 Hepatocytes from normal male rat
The effect of insulin on 3 2  Pj incorporation into phospholipid in normal male rat 
hepatocytes was investigated. Figure 22 shows that insulin elicited no significant changes 
in the formation of phosphatidic acid and phosphatidylinositol. There was no significant 
difference in the 32P labelling of phosphatidic acid and phosphatidylinositol between 
control- and insulin-treated cells. As illustrated in Figure 22,the ratio of formed 
phosphatidic acid to phosphatidylinositol was about 3 to 1 ( 6000 c.p.m : 2000 
c.p.m ).
4.4.2 Hepatocytes from 3-davs STZ-treated male rat
Insulin-treated cells gave no significant increase in the 32P labelling of 
phosphatidic acid and phosphatidylinositol when compared to control cells ( Figure 23 ). 
However, the amount of 32P labelling in the control from these diabetic animals was 
dramatically lower than in hepatocytes from normal rats. The amount of labelled [3 2 P]- 
phosphatidic acid formed in normal rat hepatocytes was 46-fold higher than in the 
hepatocytes from the diabetic rats ( 6000 c.p.m versus 130 c.p.m respectively ) and 
about 17-fold higher for [3 2 P]-phosphatidylinositol in the normal rats compared to 
diabetic rats (2000 c.p.m versus 120 c.p.m respectively ). The ratio of formed 
phosphatidic acid to phosphatidylinositol was about 1:1 (Figure 23).
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Figure 22, Concentration-response curves for insulin-induced (A) [ 32-P] phosphatidic acid 
and (B) [ 32-P] phosphatidylinositol formation in hepatocytes obtained from 
normal male rat.
The formation of both labelled-lipids was monitored as described in the Methods 
section. The results are mean values + S.D for 2 experiments performed in 
triplicate. All points were not significantly different from control.
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Figure 23 . ConcentratJon-response curves for insulin-induced (A) [ 3 2  -P] phosphatidic acid 
and (B) [ -P] phosphatidylinositol formation in hepatocytes obtained from
3-days STZ-treated diabetic male rat.
The formation of both labelled-lipids was monitored as described in the Methods 
section. The results are mean values + S.D for 2 experiments performed in 
triplicate. All points were not significantly different from control.
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4.5 PREINCUBATIQN OF MALE RAT HEPATOCYTES WITH
IN§UU-N— IN THE— PRESENCE OF THE PROTEIN KINASE
In h ib it o r  K-252a
4.5.1 Preincubation with insulin for 1/2 hour in the presence of K-252a 120 nM)
Since it is well recognized that the second messengers of hormone action are
proposed to be mediated through activation of protein kinases and phosphorylation of 
proteins plays a key role in regulating cellular functions, we decided to investigate the 
role of protein kinases in insulin action with respect to steroid metabolism. In this study, 
K-252a, a non-selective inhibitor of the protein kinases was used. K-252a was found 
to inhibit cyclic nucleotide-dependent protein kinases and protein kinase C to various 
extents with Kj values at 20 nM ( Kase et.al. 1987).
Table 20 shows that K-252a alone had no effect on androst-4-ene-3,17-one 
metabolism. None of the enzyme activities showed any significant changes when 
compared to control. In the presence of K-252a ( 20 nM ), increasing doses of 
insulin ( 1 0 1 0  - 1 0  6  M ) did not produce any statistically significant changes in 
the enzyme activities ( Figure 24). This should be compared to Table 4 and Figure 7 .
4.5.2 Preincubation with insulin for 24 hours in the presence of K-252a (20 nM)
Table 21 shows that K-252a alone had no effect on androst-4-ene-3,17-dione 
when compared to control. Similar to preincubation with insulin for 1/2 hour, the 
addition of K-252a ( 20 nM ) to the culture medium after 24 hour insulin preincubation 
resulted in no significant changes in all the enzyme activities ( Figure 25 ). The basal 
activity for all of the enzymes was reduced when compared to the activity in 1 / 2  hour 
preincubation with insulin in the presence of K-252a ( see section 4.5.1 ).
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Figure 24 . Dose-response curves of (A) 7 « -hydroxylase [ v ] and 5 « -reductase [ • ] and
(B) 17-OHSD [ ° ], 6  b - [ a ] and 16 « -hydroxylases [ ° ] activities to insulin 
after 1/2 hour preincubation in the presence of 20 nM of K-252a in 
hepatocytes obtained from normal male rat as described in the Methods section. 
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3 ). Absolute data is given in Table 20 .
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Figure 25 . Dose-response curves of (A) 7 « -hydroxylase [ ■ ] and 5 « -reductase [ • ] and 
(B) 17-OHSD [ n ], 6  P - [ a ] and 16 « -hydroxylases [ □ ] activities to insulin 
after 24 hour preincubation in the presence of 20 nM of K-252a in 
hepatocytes obtained from normal male rat as described in the Methods section. 
Results are expressed as percentage of the relevant control and mean ± S.D 
( N = 3 ). Absolute data is given in Table 21.
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5.0 G U ICAGQN
5.1 ACTION— QF— GLUCAGON ON THE MF.TABOLTSM OF
ANDROST- 4-ENE-3.17-DIONE
5.1.1 HEPATOCYTES FROM NORMAL RAT
5.1.1.1 Preincubation with glucagon for 1/2. 1. 2. 5 and 10 minutes
After 1/2 minute preincubation with glucagon, no changes in the activity of 
any of the enzymes were observed ( Table 22 ). Lack of effect could be seen at 
physiological and supraphysiological glucagon concentrations ( Figure 26).
Similar observations were made when the cells were preincubated with 
glucagon for 1 minute ( Table 23 ). When comparing to control, no alteration in the 
enzyme activities was evident. Though all of the five enzyme activities measured were 
shown to increased above their respective controls at 10' 8  M glucagon concentration, 
they were found to be not statistically significant ( Figure 27 ).
At 2 , 5 and 10 minutes after glucagon addition, no effect on any of the 
enzyme activities was seen when compared to their respective controls ( Tables 24, 25 
and 26; Figures 28, 29 and 30 ). It is noteworthy to point out that the basal activity of 
5 oc-reductase ( female-specific enzyme ) was seen to increase with glucagon 
preincubation time ( from 1 / 2  minute to 1 0  minutes ).
5.1.1.2 Preincubation with glucagon for 1/2, 1 and 2 hours
After exposing the hepatocytes to glucagon for 1/2 hour, significant changes in
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Figure 26 . Dose-response curves of (A) 7 « -hydroxylase [ ° ] and 5 * -reductase [ ♦ ] and
(B) 17-OHSD [ “ ], 6  P - [ * ] and 16 « -hydroxylases [ ° ] to glucagon after 1/2 
minute preincubation in hepatocytes obtained from normal male rat.
Results are expressed as percentage of the relevant control and mean + S.D
(N = 3 ). Absolute data is given in Table 22 .
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Figure 27 . Dose-response curves of (A) 7 « -hydroxylase [ n ] and 5 « -reductase [ ♦ ] and 
(B) 17-OHSD [ h ] , 6 p - [ *  ] and 16 « -hydroxylases [ ° ] to glucagon after 1 
minute preincubation in hepatocytes obtained from normal male rat.
Results are expressed as percentage of the relevant control and mean + S.D
(N = 3 ). Absolute data is given in Table 23 .
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Figure 28 . Dose-response curves of (A) 7 « -hydroxylase [ a . ] and 5 « -reductase [ ♦ ] and 
(B) 17-OHSD [ o ], 6  P - [ * ] and 16 « -hydroxylases [ o J to glucagon after 2 
minutes preincubation in hepatocytes obtained from normal male rat.
Results are expressed as percentage of the relevant control and mean + S.D
(N  = 3 ). Absolute data is given in Table 24 .
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Figure 29 . Dose-response curves of (A) 7 « -hydroxylase [ a ] and 5 a -reductase [ ♦ ] and 
(B) 17-OHSD [ p ], 6  jb - [ a ] and 16 « -hydroxylases [ a ] to glucagon after 5 
minutes preincubation in hepatocytes obtained from normal male rat.
Results are expressed as percentage of the relevant control and mean + S.D 
(N = 3 ). Absolute data is given in Table 25 .
C = control
-132-
a>
3
o3
X Ja>u
S
oocs
+ 1
VOo
r H
VO
+ 1
fHo
r*H
cs
+ 1
»nOs
xrt—i
+ 1
OsOs
OVcs
+ 1
ino
rH 10
0
 ± 
26
io
2 s
ft
QC/3
32 + 1
m
+i
C S
+ 1
"S’
+ 1
r-'
+ 1
m
+ 1
c
. 2
1
OI ooT as o>n VO■vj-
OSrf VOT T
a
a>
9
'o
E
3
35
O
in
+ 1
c n
+ 1
C S
+ 1 + 1
c n
+ 1 + 1
D .
8
a
vo
r H
« oin ( S>n >nm Om r Hm rHin
* 3
■4—»Ucn
<D
c a s0 3
32
T f r-H
cs C S c n c n
c
N + 1 + 1 + 1
+ 1 ■H + 1
c
W
w
c d
vo
r -
c n
VO
m m
" i t
c n c n c n
0 )
*
-
S 3
32
O
r H
+ 1
r H
-H
r H
+ 1
rH
+ 1 + 1 + 1
h
cs or H r Hr H csrH rHr H rHrH
t "
G
lu
ca
go
n
co
nc
en
tr
at
io
n
Co
nt
ro
l so
■o
r H
S
o\
o
r H
s
o
rH
s
o
r H
s
o
rH
Ta
ble
 
26 
. 
Do
se
-re
sp
on
se
 
eff
ec
ts 
of 
7 
a 
6 
p 
-,1
6 
a 
-h
yd
ro
xy
las
es
 (
OH
as
es
 )
, 
17
-o
xo
ste
ro
id
 
ox
id
or
ed
uc
tas
e 
(O
H
SD
) 
and
 
5 
a 
-re
du
cta
se
 
ac
tiv
iti
es
 t
o 
glu
ca
go
n 
aft
er 
10 
mi
nu
tes
 
pr
ein
cu
ba
tio
n 
in 
he
pa
to
cy
tes
 
ob
tai
ne
d 
fro
m 
no
rm
al
 
ma
le 
rat
. R
es
ult
s 
ex
pr
es
se
d 
as 
me
an
 
± 
S.D
 
( N 
= 
3 
); 
* 
P 
< 
0.0
5 
as 
co
mp
are
d 
to 
re
sp
ec
tiv
e 
co
nt
ro
ls.
-133-
A)
§
'©
120 -i
100 -
80 -
60 -
40 -
2 0  -
C 1 0 9 8
log [Glucagon] M
B)
o
120 n
100 -
80 -
60 -
40 -
2 0  -
7 68C 1 0 9
log [Glucagon] M
Figure 30 . Dose-response curves of (A) 7 a -hydroxylase [ I and 5 « -reductase [ • ] and 
(B) 17-OHSD [ n ], 6 p - [ * ] and 16 « -hydroxylases [ o ] to glucagon after 10 
minutes preincubation in hepatocytes obtained from normal male rat.
Results are expressed as percentage of the relevant control and mean + S.D 
(N = 3 ). Absolute data is given in Table 26 .
C = control
-134-
enzyme activities could be observed which were dose-dependent ( Table 27 ). At 
physiological concentrations ( 10' 1 0  to lO 8  M ), glucagon caused a dose-dependent 
decrease in all the enzyme activities showing no selective effect on the male- and female- 
specific enzymes in the cultured hepatocytes system ( Figure 31). The maximum effect 
of glucagon was seen at 1 0 ’ 9  M or 1 O' 8  M. Attenuation of glucagon's effect could be 
seen at concentrations of 10" 7  M and above with activity returning near to control levels.
After X hour preincubation glucagon gave exactly an inverse response as 
seen at 1/2 hour preincubation ( Table 28 ). Glucagon, at lower concentrations ( 10' 1 0  
to 10~ 8  M ) caused a dose-dependent increase in all the five enzyme activities with 
maximum response seen at 10~ 8  M ( Figure 32 ). At 10‘ 7  M the activity of all the 
enzymes diminished though still significantly higher than their respective controls. At
10" 6  M, 7a- and 16u-hydroxylase activity returned to control levels while the other 
enzymes had their activity reduced significantly below control. Significant increases in 
activity of the female-specific enzymes ( Figure 32A ) were first observed at 10- 8  M 
concentration and the male-specific enzymes ( except 17-OHSD ) at 10 1 0  M 
( Figure 32B ).
At 2 hour preincubation with glucagon, selective increases in enzyme activities 
were observed. The activity of the femalerspecific enzymes were not significantly altered 
( Table 29 ) but the male-specific enzymes had their activity significantly increased at 
concentrations as low as 10 9  M. The maximum response was seen at 10* 8  M( Figure 33 ) 
after which further increase in glucagon concentration resulted in a reduction in their 
activity despite the fact that all were still significantly greater than control at 10 6  M.
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Figure 31 . Dose-response curves of (A) 7 * -hydroxylase [ a ] and 5 « -reductase [ ♦ ] and
(B) 17-OIISD [ a ], 6 P - [ a ] and 16 « -hydroxylases [ ° ] to glucagon after 1/2 
hour preincubation in hepatocytes obtained from normal male rat.
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3 ). Absolute data is given in Table 27 .
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Figure 32 . Dose-response curves of (A) 7 a -hydroxylase [ a ] and 5 -reductase [ ♦ ] and 
(B) 17-OHSD [ •> ], 6  P - [ * ] and 16 a -hydroxylases [ □ ] to glucagon after 1 
hour preincubation in hepatocytes obtained from normal male rat.
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3 ). Absolute data is given in Table 28 .
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Figure 33 . Dose-response curves of (A) 7 « -hydroxylase [ 0 ] and 5 « -reductase [ • ] and 
(B) 17-OFISD [ o ], 6 p - [ * ] and 16 * -hydroxylases [ ° ] to glucagon after 2 
hour preincubation in hepatocytes obtained from normal male rat.
Results are expressed as percentage of the relevant control and mean ± S.D 
( N = 3 ). Absolute data is given in Table 2 9  .
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5.1.1.3 Preincubatipn with glucagon for 24. 48 and 79. hnun
A similar dose-response effect for glucagon to that observed at 1/2 hour could 
be seen after 24 hour glucagon preincubation ( Table 30). At lower concentrations 
( 10-1^  to 10" 8  M ) glucagon elicited a dose-dependent decrease in activity for all the 
enzymes measured reaching to about 60 to 70 % below control. The maximum effect was 
again seen at 10‘ 8  M concentration. At higher concentrations the effect of glucagon was 
markedly reduced with most activities returning to control at 10*6 M ( Figure 34 ).
After 48 hour preincubation, the enzymes exhibited a triphasic response 
towards glucagon ( Figure 35 ). Significant decreases in enzyme activity seen at 10’ 1 0  M 
was followed by restoration of activity to control level at 10' 9  M ( Table 31 ). Maximum 
increase of enzyme activities occurred at 10' 8  M with a subsequent fall in all enzymes 
activities at higher concentrations.
At 72 hour of glucagon preincubation, the alteration in enzyme activities was 
observed to be sex-dependent. No significant changes in activity could be seen with the 
female-specific enzymes i.e. 7a-hydroxylase and 5a-reductase ( Table 32 ). Increases 
in activity seen with 6 p-hydroxylase and 17-OHSD were found to be dose-dependent 
with maximum response not reached even at 10' 6  M ( Figure 36).
i
5.1.2 HEPATOCYTES FROM 3-DAYS STZ-TREATED DIABETIC RAT
5.1.2.1 Preincubation with glucagon for 1/2 hour
In contrast to hepatocytes from normal rats which exhibited U-shaped dose- 
response curves, preincubation with glucagon for 1 / 2  hour resulted in a dose-dependent 
decrease in all the enzyme activities except the 17-OHSD ( Table 33 ) with the
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Figure 34 . Dose-response curves of (A) 7 « -hydroxylase [ «* ] and 5 « -reductase [ ♦ ] and 
(B) 17-OHSD [ n ], 6  p  - [ * ] and 16 « -hydroxylases [ o ] to glucagon after 24 
hour preincubation in hepatocytes obtained from normal male rat.
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3 ). Absolute data is given m Table 30 .
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Figure 35 . Dose-response curves of (A) 7 <* -hydroxylase [ a ] and 5 « -reductase [ ♦ ] and 
(B) 17-OHSD [ o ], 6 |8 - [ * ] and 16 « -hydroxylases [ ° ] to glucagon after 48 
hour preincubation in hepatocytes obtained from normal male rat.
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3 ). Absolute data is given in Table 31.
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Figure 3 6  . Dose-response curves of (A) 7 « -hydroxylase [ q ] and 5 « -reductase [ • ] and 
(B) 17-OHSD [ « ], 6 /» - [ * ] and 16 « -hydroxylases [ q ] to glucagon after 72 
hour preincubation in nepatocytes obtained from normal male rat.
Results are expressed as percentage of the relevant control and mean + S.D 
( N =  3  ). Absolute data is given in Table 32 .
C = control
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Figure 37 . Dose-response curves of (A) 7 « -hydroxylase [ a ] and 5 a -reductase [ • ] and
(B) 17-OHSD [ * ], 6 p - [ a ] and 16 « -hydroxylases [ a J activities to glucagon 
after 1/2 hour preincubation in hepatocytes obtained from 3 days STZ-treated 
diabetic male rat.
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3 ). Absolute data is given in Table 33 .
C = control
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maximum effect being seen at 10  ^ M ( about 70 to 80 % of control) ( Figure 37 ). 
Glucagon had no effect on 17-OHSD activity. Female-specific 5a-reductase basal level 
was higher than the male-specific enzymes ( 6|3- and 16ot-hydroxylases ) and the 
response to glucagon of the 5a-reductase activity had not reach its maximum even at 
10'6 M.
Experiments involving preincubation with glucagon for more than 1/2 hour were 
not conducted.
5.1.3 P R E IN C U B A T IO N  OF MALE RAT HEPATOCYTES WITH 
GLUCAGON IN THE PRESENCE OF THE PROTEIN KINASE 
INIIIBITQR__K-252a
5.1.3.1 Preincubation with glucagon for 1/2 hour in the presence of K-252a 
(20 nM )
No significant changes in enzyme activities were observed after hepatocytes were 
preincubated for 1/2 hour with glucagon in the presence of the non-selective protein 
kinase inhibitor, K-252a ( Table 34 ). The U-shaped dose-response curves
induced by glucagon ( refer to Section 5.1.1.2 ) were abolished in the presence of 
20 nM K-252a ( Figure 38 ). As shown in Table 34, K-252a alone produced no 
significant changes in androst-4-ene-3,17-dione metabolism.
5.1.3.2 Preincubation with glucagon for 24 hours—in the Rfesencg Qf K-252a
In the presence of K-252a (20 nM), glucagon, at lower concentrations 
(10  10 to 10'8 M ) elicited a dose-dependent increase in all the enzyme activities with
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Figure 38 . Dose-response curves of (A) 7 « -hydroxylase [ ® ] and 5 a -reductase [ • ] and
(B) 17-OHSD [ a ], 6 P - [ * ] and 16 <* -hydroxylases [ a ] activities to glucagon 
after 1/2 hour preincubation in the presence of 20 nM of K-252a in 
hepatocytes obtained from normal male rat as described in the Methods section. 
Results aite expressed as percentage of the relevant control and mean + S.D 
( N = 3 ). Absolute data is given in Table 34 .
C = control (20 nM K-252a dissolved in the vehicle).
maximum effect of glucagon seen at 10*8 M ( Table 35 ); at higher concentrations the 
effect of glucagon was markedly reduced despite still being significantly greater than 
their respective controls ( Figure 39 ). At lO 8 M, glucagon increased 7a- 
hydroxylase and 5a-reductase activity to 333 % and 315% of control respectively 
( Figure 39A ), while 6(3- and 16a-hydroxylases and 17-OHSD activities rose to 
410 %, 500 % and 231 % of control respectively ( Figure 39B ).
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Figure 39 . Dose-response curves of (A) 7 a -hydroxylase [ ® ] and 5 « -reductase [ • ] and
(B) 17-OHSD [a ], 6 P - [ * J and 16 a -hydroxylases [ ° ] activities to glucagon 
after 24 hour preincuoation in the presence of 20 nM of K-252a in 
hepatocytes obtained from normal male rat as described in the Methods section. 
Results are expressed as percentage of the relevant control and mean +_ S.D 
( N = 3 ). Absolute data is given in Table 35 .
C = control (20 nM K-252a dissolved in the vehicle).
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6.0 INSULIN AND GLUCAGON
6.1 EFFECT. OF COMBINATIONS OF INSULIN a n d  o t .t ic a o o n  o n
ANPROST-4-ENE-3.17-DIQNE METABOT.TSM
6.1.1 HEPATOCYTES FROM NORMAL RAT
6.1.1.1 Preincubation with insulin and glucagon for 1/2 hour
In this experiment only two concentrations ( 10-9 and 10 6 M ) for insulin 
and glucagon were chosen and dose-response experiments were conducted based on 
these two concentrations. Various combinations of insulin and glucagon were added 
directly to the cultured hepatocytes and the cells assayed as described in Methods 
Section 2.6.
As shown in Table 36 and Figure 40, insulin caused a significant dose- 
dependent increase in all of the enzyme activities. Glucagon significantly decreased all of 
the enzyme activities at 10‘9 M. At 10'6 M glucagon, however, all enzyme activities were 
at the control level. 10'9 M glucagon significantly decreased the effect of 10‘9 M insulin 
on 16a-hydroxylase and 17-OHSD whereas the 7a- and 6P-hydroxylases and 5a- 
reductase activities were not affected. At supraphysiological concentration ( 10'6 M ), 
glucagon's effect on 10'9 M insulin resulted in selective changes in enzyme activities,
only seen with cytochrome P-450-independent enzymes. The effect of 10 9 M insulin on 
17-OHSD activity was significantly blocked while the potentiation of insulin effect on
5a-reductase activity could be seen in the presence of 10  ^M glucagon.
It is evident that 10’9 M glucagon potentiated the effect of 10*6 M insulin on 6p-
-157-
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Figure 40. Dose-response effects of (A) 7 a -hydroxylase [ © ], (B) 5 a -reductase [ j.
(C) 6 a - [ B ] and (D)16 a -hydroxylases [ 0 ] and (E) 17-OHSD [ m ] activities 
to insulin (1) or glucagon (G) or to various combinations of both hormones 
after 1/2 hour of preincubation in hepatocytes obtained from normal male rat. 
Results are expressed as percentage of the relevant control and mean + S.D 
(N = 3V Analysis of data : * P < 0.05 when compared to the respective hormone 
control; t P < 0.05 with respect to 10“* M insulin; 5 P < 0.05 with respect to 
10‘6 M insulin.
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hydroxylase and 5a-reductase activity while an antagonistic effect was observed with 
l6a-hydroxylase. 10-9 M glucagon appears to block the action of lfr6 M insulin on 7a- 
hydroxylase and 17-OHSD activity. Similar effects could be seen with Kb6 M insulin in 
the presence of 10*6 M glucagon. Potentiation of insulin ( Kb6 M ) effect by 
glucagon could be observed with 6(3—hydroxylase and 5a-reductase while antagonism 
of glucagon on insulin effect could be seen with 16a-hydroxylase and 17-OHSD. HP6 M 
glucagon appears to block the effect of 106 M insulin on 7a-hydroxylase activity.
6.1.2 HEPATOCYTES FROM 3-DAYS STZ-TREATED RAT
6.1.2.1 Preincubation with insulin and glucagon for 1/2 hour
As expected insulin at 109 and 10-6 M concentrations had little effect on the 
enzyme activities in hepatocytes from STZ-treated diabetic rats (Table 37 and Figure 41). 
Comparing the control levels, all of the enzyme activities in the diabetic rat 
hepatocytes were markedly lower ( refer to Table 36 and 37 ) than in the 
hepatocytes from normal rat. Both 10"9 M and 10'6 M glucagon produced no 
significant changes on 10'9 M insulin effect on the female specific 7a-hydroxylase and 
5a-reductase activities. On the other hand, 10-9 M glucagon significantly increased the 
effect of lO-9 M insulin on 16a-hydroxylase activity, whereas 10*6 M glucagon 
significantly increased the effect of 10-9 M insulin on 6P-hydroxylase and 17-OHSD. 
However at lfr6 M insulin, both physiological and supraphysiological concentrations did 
not significantly affect the effect of the former on all the enzyme activities.
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Figure 41 . Dose-response effects of (A) 7 « -hydroxylase [ i  ], (B) 5 « -reductase [O],
(C) 6 3 - [ g  J and (D) 16 « -hydroxylases [ 0 ] ana (E) 17-OHSD f ® ] activities 
to insulin (I) or glucagon (G) or to various combinations of both hormones 
after 1/2 hour of preincubation in hepatocytes obtained from 3 days STZ-treated 
diabetic male rat
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3 ). Analysis of data : * P < 0.05 when compared to the respective 
hormone control; t P < 0.05 with respect to 10"9 M insulin; § P < 0.05 with 
respect to 10“6 M insulin.
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7.0 IT-Na -trinitrQDb£llYlhistidine.l2-homoargininel Pliiragon fTH-Cf UC ACON1
7.1 E FFE C J QE— TH-GLUCAGON ON THE METAROT JSIVJ Op
ANPRQST-4-ENEr 3,17-PIONE IN HEP AT Of! YTF.S ISOT.atfxi
FROM NORMAL MALE RATS
The effect of [ I-Na - trinitrophenylhistidine, 12-homoarginine ] glucagon, 
( TH-glucagon), on androst-4-ene-3,17-dione metabolism was only tested on hepatocytes 
from normal rat.
7.1.1 Preincubation with TH-glucagon for 1/2. 1 and 2 hours
Preincubation of hepatocytes with TH-glucagon for 1/2 hour resulted in a 
dose-dependent increase in 7 a - , 6(3- and 16a-hydroxylases , 17-OHSD and 5a- 
reductase activities ( Table 38 ) with maximum effect observed at 10~8 M concentration. 
At higher concentrations the effect of TH-glucagon was markedly reduced despite being 
significantly greater than their respective controls even at 10~6 M concentration 
( Figure 42).
At 1 hour preincubation, TH-glucagon gave little change in any of the enzyme 
activities studied ( Table 39 ). Only at 10'8 M concentration did TH-glucagon 
significantly increased the cytochrome P-450 dependent enzymes, 7 a - , 6(3- and 16a- 
hydroxylases but had no effect on the non-cytochrome P-450 dependent enzymes, 17- 
OHSD and 5a-reduct4se though the significance in the differences seen is not known 
( Figure 43 ).
The effect of TH-glucagon on the enzyme activities after 2 hour preincubation
varies according to the enzyme studied. 7 a-hydroxylase and 17-OHSD activities were
-165-
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Figure 42 . Dose-response curves of (A) 7 a -hydroxylase [ ■ ] and 5 « -reductase [ • ] and 
(B) 17-OHSD [ ■ ], 6 p - [ * ] and 16 « -hydroxylases [ o ] to TH-glucagon after
1/2 hour preincubation in hepatocytes obtained from normal male rat.
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3 ). Absolute data is given in Table 38 .
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Figure 43 . Dose-response curves of (A) 7 « -hydroxylase [ ■ ] and 5 « -reductase [ * J and 
(B) 17-OHSD [ b |, 6 3 - [ a ] and 16 « -hydroxylases [ a ] to TH-glucagon after
1 hour preincubation in hepatocytes obtained from normal male rat.
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3 ). Absolute data is given in Table 39 .
C = control
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not altered. At low concentration ( 10'10 - 10'9 M ) TH-glucagon increased 60- and 
16a-hydroxylases and 5tt-reductase activity but at 10~^  M the enzyme activities were 
reduced significantly below control ( Table 40 and Figure 44).
7.1.2 Preincubation with TH-glucagon for 24 hours
After 24 hour of preincubation, TH-glucagon caused a marked, dose- 
dependent decrease in all of the enzyme activities ( Table 41 ). Maximum response 
could be observed at 10'9 M with the activity of the 7a-hydroxylase and 5a- 
reductase reduced to about 40 % and 60 % of respective control and the 60- and 
16a-hydroxylase and 17-OHSD activities reduced to about 40 % , 25 % and 55 % of 
control respectively ( Figure 45 ). Significant reduction in enzyme activity could be 
seen at concentrations as low as 10*10 M.
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Figure 44 . Dose-response curves of (A) 7 « -hydroxylase [ ■ ] and 5 a -reductase [ ♦ ] and 
(B) 17-OHSD [ ■ J, 6 3 - [ • ]  and 16« -hydroxylases [ ° J to TH-glucagon after 
2 hour preincubation in hepatocytes obtained from normal male rat.
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3 ). Absolute data is given in Table 40 .
C = control
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Figure 45 . Dose-response curves of (A) 7 « -hydroxylase [ ■ J and 5 « -reductase [ • ] and 
(B) 17-OHSD [ b ], 6 P - [  ^ ] and 16 « -hydroxylases [ *> ] to TH-glucagon after 
24 hour preincubation in hepatocytes obtained from norma! male rat 
Results are expressed as percentage of the relevant control and mean + S..D 
( N = 3 ). Absolute data is given in Table 41.
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8.0 ORAL HYPQGLYCAEMIC AGENTS
8 1  XHE-EFFECTS OF p h e n f o r m in  a n d  t o l b u t a m id e  o n  t h f ,
METABOLISM OF ANDROST-4-ENE-3.17-OTONF,
8.1.1 HEPATOCYTES FROM NORMAL RAT
8.1.1.1 Preincubation with phenformin or tolbutamide alone
The hepatocytes were treated with the oral hypoglycaemic agents as described in 
the Methods Section 2.5.6. Phenformin and tolbutamide dose/response curves were 
examined using concentrations of the drugs from 10~6 to lfr3 M.
Phenformin significantly increased steroid metabolism at concentrations as 
low as 10'6 M ( Table 42; Figure 46) and maximum response observed was at 
5 x 10'5 M ( 182 % of control for 7a-hydroxylase; 194 % of control for 5a-reductase; 
214 % of control for 6p-hydroxylase; 140 % of control for 16a-hydroxylase; 186 % of 
control for 17-OHSD ). No selective effect of phenformin on the enzymes tested is 
evident.
Similarly, tolbutam ide induced a dose-dependent effect on all of the enzyme 
activities. Again, a significant increase in activity could be seen at concentrations as low 
as 10'6 M but maximum response was achieved at a slightly higher concentration 
( 10’4 M ). However, at the highest concentration used i.e. KT3 M, enzymes activity 
decreased below the maximum seen despite being significantly above the control level 
( Figure 47 ). Maximum responses achieved were lower than attained by phenformin ; 
A t l ( H M tolbutamide increased 7a-and 6p-hydroxylases activity 52% above control,
75 % above control for 16tt-hydroxylase, 102 % and 63 % above control for 17-
-175-
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Figure 46 . Dose-response curves of (A) 7 « -hydroxylase [ e J and 5 « -reductase [ • ] and
(B) 17-OHSD [‘ ■ ], 6 P - [ * J and 16 « -hydroxylases [ □ ] activities to phenformin 
after 24 hour preincubation in hepatocytes obtained from normal male rat.
Results are expressed as percentage of the relevant control and mean + S.D
( N = 3 ). Absolute data is given in Table 42 .
C = control
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Figure 47 . Dose-response curves of (A) 7 « -hydroxylase [ ° ] and 5 « -reductase [ • I and
(B) 17-OHSD[ ■ ],6 P -[ * J and 16 « -hydroxylases [ ° ] activities to tolbutamide
after 24 hour preincubation in hepatocytes obtained from normal male rat.
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3 ). Absolute data is given in Table 43 .
C = control
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OHSD and 5a-reductase respectively ( Table 43 and Figure 47 )
8.1.1.2 DQSg-rgSPQnse curve for insulin in the presence of phenformin or tolbutamide 
( 10-3 M 1
In this experiment the hepatocytes were first preincubated with phenformin or 
tolbutamide ( 10'3 M ) in serum-free medium for 24 hours. Subsequently, insulin ( from 
10-10 to 10'6 M ) was added and then left in the incubator for an additional 30 minutes 
after which the steroid assay was carried out.
Insulin at 10*9 M alone significantly increased all the enzyme activities 
( between 120 % to 170 % of control). Phenformin ( 10~3 M ) alone increased aU the 
enzyme activities to the same extent as insulin ( Table 44 ). When compared to 1 mM 
phenformin alone as control, the effect of increasing insulin concentrations in the 
presence of 10-3 M phenformin was enzyme dependent. No further increase in activity 
was observed for 7a- and 16a-hydroxylases except at 1 jiM insulin concentration for 
the latter. Potentiation of phenformin effect by insulin could be observed with 6p- 
hydroxylase, 17-OHSD and 5a-reductase and was maximum at 0.1 nM insulin 
( Figure 48 ).
Similarly, tolbutamide ( 10'3 M ) alone significantly increased all the enzyme 
activities (between 120 % and 160 % of control) (Table 45). Insulin in the presence of 
10 3 M tolbutamide increased the 5a-reductase activity to the same extent as tolbutamide 
alone ( Figure 49 ). In the presence of 1 mM tolbutamide, increasing the concerntratnon of 
insulin resulted in a further increase in 7a-, 6(3- and 16a-hydroxylases and 17-OHSD 
activities.
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Figure 48 . Dose-response effects of (A)7 « -hydroxylase [ B ], (B) 5 a -reductase [ ♦ ] 
(C)6 p -[  * ] and (D) 16 « -hydroxylases [ □ ] and (E) 17-OHSD [ a ] 
activities to insulin (I) 1/2 hour preincubation after 24 hour exposure to 
1 mM phenformin (P) in hepatocytes obtained from normal male rat.
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3 ). Absolute data is given in Table 44 .
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Figure 49 . Dose-response effects of (A) 7 « -hydroxylase [ ■ ], (B) 5 « -reductase [ ♦ ], 
6 .P " t A  ^ and 0°) 16 « -hydroxylases [ ° ] and (E) 17-OHSD [ * ] 
activities to insulin (I) 1/2 hour preincubation after 24 hour exposure to 
1 mM tolbutamide (T) in hepatocytes obtained from normal male rat.
Results are expressed as percentage of the relevant control and mean ± S.D 
( N = 3 ). Absolute data is given m Table 45 .
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8.1.1.3 Dose-response curves for phenformin or tolbutamide in the presence of
10 9 M insulin
Both insulin ( 10"9 M ) and phenformin ( 10'3 M ) caused significant increases 
in all the enzyme activities ( Table 46 ). In normal rat hepatocytes, phenformin gave a 
dose-related increase in all the enzyme activities ( Figure 46 ). This effect of 
phenformin could also be seen in the presence of lO 9 M insulin ( Figure 50 ).When 
compared to 1 nM insulin alone as control, phenformin significantly potentiated the effect 
of insulin ( 1 nM ) on all the enzyme activities measured. This potentiating effect of 
phenformin could be observed at concentration as low as 1 pM for all the enzymes 
except 16a-hydroxylase ( at 10 pM ) ( Table 46).
Similarly, tolbutamide ( 10'3 M ) and insulin ( 10~9 M ) cause significant increases 
in all the enzyme activities ( Table 47 ). Tolbutamide in the presence of 10-9 M insulin 
increased 7a- and 6(3-hydroxylase activities to the same extent as 10-9 M insulin ( except 
at 1 pM tolbutamide). However, tolbutamide in the presence of 10*9 M insulin caused a 
dose-dependent increase in the activity of the cytochrome P-450 independent enzymes, 
17-OHSD and 5a-reductase (Figure 51). Only at higher tolbutamide concentrations 
( > 0.1 mM ) was potentiation of insulin's effect observed with the 16a-hydroxylase.
8.1.2 HEPATOCYTES FROM 3-DAYS STZ-TREATED DIABETIC RAT
8.1.2.1 Preincubation with phenformin or tolbutamide alone
t
No selective effect of phenformin on the enzymes tested is evident ( Table 48 ). 
In the diabetic rat hepatocytes, phenformin still exhibited a dose-dependent effect on all
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Figure 50 . Dose-response effects of (A) 7 « -hydroxylase [ □ ], (B) 5 « -reductase [ ♦ ], 
(C) 6 0  - [ * ] and (D) 16 « -hydroxylases [ □ J and (E) 17-OHSD [ a ] 
activities to phenformin (P) after 24 hour preincubation followed by another 1/2
hour exposure to 1 nM insulin (I) in hepatocytes obtained from normal male rat. 
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3 ). Absolute data is given in Table 46 .
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Figure 51 . Dose-response effects of (A) 7 « -hydroxylase [ ■ ], (B) 5 « -reductase [ • ], 
(C) 6 3 - [ * ] and (D) 16 « -hydroxylases [ □ ] and (E) 17-OHSD [ n ] 
activities to tolbutamide (T) after 24 hour preincubation followed by another 1 /2 
hour exposure to 1 nM insulin (I) in hepatocytes obtained from normal male rat. 
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3 ). Absolute data is given in Table 47 . “
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Figure 52 . Dose-response curves of (A) 7 a -hydroxylase [ “ ] and 5 « -reductase [ • ] and
(B)17-OHSD*[ o ],6 3 -[ * ] and 16 « -hydroxylases [ ° J activities to phenformin 
after 24 hour preincubation in hepatocytes obtained from 3-days STZ-treated 
diabetic male rat.
Results are expressed as percentage of the relevant control and mean + S.D
( N = 3 ). Absolute data is given in Table 48 .
C = control
of the enzyme activities. However, the maximum response was much depressed when 
compared to that in the normal rat hepatocytes ( Table 42 and 48 ). Phenformin 
significantly increased androst-4-ene-3,17-dione metabolism at concentrations as low 
as 10-5 M and maximum response was observed at 5 x 105 M ( Figure 52 ). The basal 
level of all the enzyme activities ( except 7cc-hydroxylase) were also markedly reduced 
in the diabetic rat hepatocytes.
With the exception of the 16a-hydroxylase and 17-OHSD, all of the enzymes 
responded to tolbutamide dose-dependently ( Table 49). Significant increases in activity 
could be seen at concentrations as low as 10'6 M for 6p-hydroxylase and 5a-reductase 
and 10'5 M for 7a-hydroxylase. Higher concentrations were needed for significant 
increases in 16a-hydroxylase and 17-OHSD activity ( 10"4 M or 5 x 10"4 M 
respectively). The maximum effect could be seen at 5 x 10'5 M tolbutamide (Figure 53).
8.1.2.2 Dose-response curve for insulin in the presence of phenformin or tolbutamide 
( 10-3 M )
As shown in Table 50, phenformin ( 10'3 M ) alone significantly increased all 
of the enzyme activities and to the same extent as insulin ( 10"9 M ) . In the 
presence of 10-3 M phenformin , increasing concentrations of insulin did not increase 
the 16a-hydroxylase, 17-OHSD or 5a-reductase activities any further except at 
10-8 M insulin for both 16a-hydroxylase and 17-OHSD ( Figure 54). When compared to 
1 mM phenformin alone as control, physiological insulin concentrations ( 10 10 and 
10*9 M ) potentiated the effect of 10-3 M phenformin on 7a- and 6P-hydroxylase. No 
potentiation or additive effect was observed at higher insulin concentration.
A similar observation was noted when 10'3 M tolbutamide was used with
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Figure 53 . Dose-response curves of (A) 7 a -hydroxylase [ B ] and 5 a -reductase [ ♦ ] and
(B) 17-OHSC) [ b ], 6 P - [ * ] and 16 a -hydroxylases [ a ] activities to tolbutamide
after 24 hour preincubation in hepatocytes obtained from 3-days STZ-treated 
diabetic male rat.
Results are expressed as percentage of the relevant control and mean + S.D
( N = 3 ). Aosolute data is given in Table 49 .
C = control
-198-
*e
du
ct
as
e
c o
+1
CN
+1 +1 +1
VO
+1
CN
+1
CO
+1
VO
-H
m
^ r
»n VO
Ov
VO
t"-
OO
r - r~ r -
CN
r~
c
.2 17 
- 
O
H
SD CN
+1
t-H
m 66
 
± 
2
+1
s
T
+1
O
r -
•n
+1
r -
*
CN
+1
t '-
i-H
+1
3 67
 
± 
2
.G
©
S
a .
.8Z3 1
6 
oc
 
-O
H
as
e
+1
O
TT 50
 
± 
4
46
 
+ 
2 cn
+1
52
 
± 
3
*
N"
+1
VO
CO
+1
o
48
 
± 
2
©C3
1
w
cu
3
X
O
CO
+1
CO
+1
CO
+1
*
CN
+1
*
CN
+1 +1
*
+1
CN
+1
c a
V©
VO r~~
vn
CO
m VO VO
CN
VO
CN
VO
VO
<n
<v
c s
X
o ± 
2 VO
+1
<N
+1
*
CN
+1
*
CN
+1
CO
+1
CN
+1
CN
+1
S Ov
CN
OO
CO
VO
CO 5 OON- OvCO
1-H
N"
o
D
ru
g
co
nc
en
tr
at
io
n
Co
nt
ro
l
1 n
M 
I 
alo
ne
§
1 
mM
 
P 
alo
ne
0.1
 
nM 
I 
+ 
P
1 
nM 
I 
+ 
P
1
10 
nM 
1+ 
P
100
 
nM 
I + 
P
1 
uM 
I + 
P
Ta
ble
 
50 
. D
os
e-
re
sp
on
se
 
eff
ec
ts 
of 
7 
a 
6 
p 
16 
a 
-h
yd
ro
xy
las
es
 (
O
H
as
es
), 
17
-o
xo
ste
ro
id
 
ox
id
or
ed
uc
tas
e 
(O
H
SD
)
and
 
5 
a 
-re
du
cta
se
 
ac
tiv
iti
es
 t
o 
ins
uli
n 
(I) 
1/2 
ho
ur 
pr
ein
cu
ba
tio
n 
aft
er 
24 
ho
ur 
ex
po
su
re 
to 
1 m
M 
ph
en
fo
rm
in
 
(P
) 
in 
he
pa
to
cy
tes
 o
bta
ine
d 
fro
m 
3-
da
ys
 S
TZ
-tr
ea
ted
 
dia
be
tic
 m
ale
 r
at.
 R
es
ult
s 
ex
pr
es
se
d 
as 
me
an
 
±S
.D
 
( N 
= 
3 
);
* P 
< 
0.0
5 
wi
th 
re
sp
ec
t 
to 
§ 
.
-199-
Figure 54 . Dose-response effects of (A) 7 « -hydroxylase [ ■ ], (B) 5 « -reductase [ ♦ ],
(C) 6 P - [  * ] and (D) 16 « -hydroxylases [ □ ] and (E) 17-OHSD [ » ’]
activities to insulin (I) 1/2 hour preincubation after 24 hour exposure to
1 mM phenformin (P) in hepatocytes obtained from 3-days STZ-treated diabetic 
male rat.
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3 ). Absolute data is given in Table 50 .
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increasing insulin concentrations ( Table 51 ). With the exception of 16a-hydroxylase at 
10'8 and 10-7 M insulin addition, no further increases in activity were seen with insulin in 
the presence of tolbutamide than would be seen with insulin ( 10'9 M ) or 
tolbutamide ( 10*3 M ) alone ( Figure 55 ).
8.1.2.3 Dose-response curves for phenformin or tolbutamide in the presence of 10~9 M 
insulin
Insulin ( 10'9 M ) or phenformin ( 10'3 M ) alone significantly increased all of 
the enzyme activities above control ( Table 52 ). With the exception of 7a- 
hydroxylase,the effect of 10*9 M insulin was significantly enhanced by increasing the 
concentrations of phenformin ( at concentrations as low as lO 6 M ) when compared to 
the effect of 10"9 M insulin alone. Phenformin is known to elicit lower responses in 
hepatocytes from diabetic rat than in normal rat ( see Section 8.1.2.1 ). In the 
presence of a physiological insulin concentration ( 10*9 M ), the effect of phenformin 
on the enzyme activities was partially or fully restored. Thus, a combination of 
phenformin and insulin was able to restore some or all of the activity exhibited by 
phenformin in normal rat hepatocytes ( compare between Figures 46, 52 and 56).
A similar observation was noted with tolbutamide in the presence of insulin 
( 10-9 M ). Tolbutamide ( KT3 M ) and insulin ( KT9 M ) both increased the enzyme 
activities to about the same extent ( Table 53 ). No further increase in 7a- and 16a- 
hydroxylase or 5a-reductase activities were visible when increasing concentrations of 
tolbutamide were added to the medium in the presence of 10'9 M insulin ( Figure 57 ). 
Increasing the concentration of tolbutamide ( as low as 1 pM for 6(3-hydroxylase and 
0.1 mM for 17-OHSD ) potentiated the effect of insulin when compared to 1 nM insulin 
alone.
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Figure 55 . Dose-response effects of (A) 7 a -hydroxylase [ a ], (B) 5 a -reductase [ ♦ ], 
(C) 6 0 - [ a ] and (D) 16 « -hydroxylases [ o J and (E) 17-OHSD [ ■ ] 
activities to insulin (I) 1/2 hour preincubation after 24 hour exposure to
1 mM tolbutamide (T) in hepatocytes obtained from 3-days STZ-treated diabetic 
male rat.
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3 ). Absolute data is given in Table 51 .
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Figure 56 . Dose-response effects of (A) 7 « -hydroxylase [ 8 ], (B) 5 « -reductase [ • ],
(C) 6 P - [ * ] and (D) 16 « -hydroxylases [ n ] and (E) 17-OHSD [ d ]
activities to phenformin (P) after 24 hour preincubation followed by another 1/2
hour exposure to 1 nM insulin (I) in hepatocytes obtained from 3-days STZ- 
treated diabetic male rat.
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3 ). Absolute data is given in Table 52 .
C = control (1 nM Insulin alone)
A)
I
o
*
160 - ]
140 -
120 -
P ( 1 mM ) alone100 -
80 -
60 -
40 -
20 -
1 uM 10 uM 50 uM 0.1 mM0.5 mM 1 mMC
Phenformin concentration +1 nM Insulin
B)
I 
I
*S
$
140 -I
120 -
100 -
80 -
60 -
40 -
20 -
1 uM 10 uM 50 uM 0.1 mM0.5 mM 1 mM
Phenformin concentration +1 nM Insulin
-207-
C)
*3
ha
©
1 6 0  -i
140
120 -
P (1  mM ) alone100 -
80 -
60 -
40 -
20  -
1 uM 10 uM 50 uM 0.1 mM0.5 mM 1 mM
Phenformin concentration +1 nM Insulin
D)
o
160 -i
140 -
120 -
P (1  m M ) alone
100 -
60 -
40 -
20 -
C 1 uM 10 uM 50 uM 0.1 mM0.5 mM 1 mM
Phenformin concentration +1 nM Insulin
E)
160 -i
140 -
120 -
P ( 1 mM ) alone
100
80
60
40
20  -
Phenformin concentration +1 nM Insulin
-208-
n
3
ON • n NO x r c n CO f " OO i n
I
-H +1 +1 + ) +1 + i +1 +1 +1
VO
x r
o
r -
ON
NO
ON
p -
x f
r -
CN pH
o o
ON
P ~ r -
2 1
8
c - O
H
SD NO
+1
o o
+1
■NT
+1
CN
+1 +1
r~~
+1
*
i n
+1
*
i n
+1
#
c n
+ 1
r -
1
2
8
1
6
4
1
6
8
1
7
5
1
8
2
3
1
9
3 c no o
1
8
4
c
s
- < c n Tj- i n CN. ■xT
o .
'6
a
o
0
NO
+ i
o
<N 31
 
±
32
 
±
31
 
± +1
c n 29
 
±
33
 
±
33
 
±
31
 
±
>
w
O
03
* * * # *
3
a :
o + 1 ± 
3 o
-H +1
i n
HH
CN
+1
\Q
+1
CN
+11
(O '
+III
W OQ
NO
ON
CNl
mC*1 r -xr c nx r Oi n OOc n x rin* O nx p C lx f
O
H
as
e
fOl
+1 ± 
5
+1
CN
+11
i n
+11 ± 
2 x r
+1
X f
+ 1
ir—1<1
+1
a ■inCNl o•'T o'N'J" CN ox f c o
c n
x r
c n
H r
OO
■co
D
ru
g
l
Co
nt
ro
l
fiOo
ij>
C
iQ1
*3 «
M 
T 
alo
ne
+
H
+
H
+
H
+
L-iIP*
+
H
IK—Hi 
+
1 DLrii
I ! or “ <i O 1■in o mo Table 
53 
* D
os
e-
re
sp
on
se
 
eff
ec
ts 
of 
7 
«%
 
6 
p 
16 
a 
-h
yd
ro
xy
las
es
 (
OH
as
es
 )
, 
17
-o
xo
ste
ro
id
 
ox
id
or
ed
uc
ta
se
 
(O
HS
D 
) 
and
 
5 
« 
-re
du
cta
se
 
ac
tiv
iti
es
 t
o 
to
lbu
tam
id
e 
(T)
 a
fte
r 
24 
ho
ur 
pr
ein
cu
ba
tio
n 
fo
llo
we
d 
by 
an
ot
he
r 
1/2
 
ho
ur
 e
xp
os
ur
e 
to 
1 n
M 
ins
uli
n 
(I) 
in 
he
pa
to
cy
tes
 
ob
tai
ne
d 
fro
m 
3-
da
ys
 
ST
Z-
tre
ate
d 
dia
be
tic
 m
ale
 
rat
 
Re
su
lts
 
ex
pr
es
se
d 
as
me
an
 
± 
S,D
 
(N 
« 
3 
); 
* 
P 
< 
0,0
5 
wi
th 
re
sp
ec
t 
to 
§ 
.
- 209 -
Figure 57 . Dose-response effects of (A) 7 « -hydroxylase [ ■ ], (B) 5 « -reductase [ • ],
(C) 6 P - [ * ] and (D) 16 a -hydroxylases [ n J and (E) 17-OHSD [ ■ j ’ 
activities to tolbutamide (T) after 24 hour preincubation followed by another 1/2 
hour exposure to 1 nM insulin (I) in hepatocytes obtained from 3-days STZ- 
treated diabetic male rat.
Results are expressed as percentage of the relevant control and mean + S.D 
( N = 3). Absolute data is given in Table 53 .
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90 DEVELOPMENT AND CHARACTERIZATION OF A HORMONE- 
FREE HEPATOCYTE CULTURE s y s t e m
The biotransformation of a wide variety of endogenous and exogenous compounds 
such as drugs, hormones, chemical carcinogens and mutagens in the body is affected by 
many factors ranging from environmental pollutants to the pathological state of the body 
( Gibson and Skett, 1986 ). One major mechanism by which the body regulates the 
bio transformation of exogenous compounds is by hormonal control. Sex-dependent 
hepatic metabolism of steroids and xenobiotics in rats is now well recognized. Studies 
on the metabolism of 5a-androstane-3a,17(3-diol ( Berg and Gustafsson, 1973 ) 
androst-4-ene-3,17-dione, 4-pregnene-3,20-dione and 7a-hydroxy-4-cholesten-3-one 
( Skett, 1986; Einarsson et.al., 1973 ) all show the existence of sex-related differences. 
Sexual dimorphism is also shown in the field of drug metabolism. Such sex differences 
in hepatic metabolism of drugs have been shown for lidocaine and imipramine ( Skett 
et.al., 1980 ), aminopyrine, antipyrine and hexobarbitone ( Quinn et.al., 1958 ). These 
sex-specific differences in hepatic metabolism have been shown to be related to the 
steroid environment in the body during development. It was initially thought that, at least 
in the rat, that sex differences in xenobiotic metabolism was maintained by androgens. 
Later studies indicated that neonatal exposure to androgens is responsible for the 
appearance of sex differences in xenobiotic and steroid metabolism at puberty in the rat 
( for a review, see Skett and Gustafsson, 1979 ). Hypophysectomy of male and female 
animals abolished the sex differences in steroid metabolism ( Gustafsson and Stenberg, 
1974) and treatment of the hypophysectomized animals with androgens does not restore 
the condition to normal (Gustafsson and Stenberg, 1976).The emergence of the 
hypothalamo-pituitary axis hypothesis, forwarded by Gustafsson and co-workers 
( Gustafsson et.al., 1983 ), in the regulation of sex differences in hepatic steroid and
- 21 2 -
xenobiotic metabolism, has provided a different approach to this area of research. 
Denef ( 1974 ) suggested that the sex difference in the rat resided in a secretion from the 
pituitary gland and this pituitary factor, termed ' feminizing factor ', was later identified 
to be the growth hormone ( Skett et.al., 1978 ). The sex differences in xenobiotic 
metabolism are thought to be due to the differences in the secretory patterns of growth 
hormone in the adult female and male rat ( Skett, 1987 ). This is substantiated by the fact 
that treatment of rats with growth hormone by intermittent injection to mimic the male 
pattern and by minipump to mimic the female pattern does, indeed, account for the sex 
differences in drug and steroid metabolism in the rat liver.
The effect of diabetes mellitus on hepatic drug and steroid metabolism is well 
recognized and has been shown to be sex-dependent ( Dixon et.al., 1961; Skett, 1986 ). 
It was originally thought that diabetes in some way interfered with the androgenic 
stimulation of drug metabolism in the male and, thus, exerted its sex-dependent effect. 
Indeed, it was found that diabetes interferes with the production of testosterone in the 
male rat ( Murray et.al., 1981) and testosterone can reverse the effect of diabetes on drug 
metabolism ( Skett et.al., 1984 ). However, it was confirmed by the latter group that 
there is a complete lack of correlation between androgens and drug metabolism in STZ- 
treated animals. Skett and Gustafsson ( 1979) have shown that androgens do not exert a 
direct effect on the liver but have an indirect action via the hypothalamo-pituitary axis. It 
is also known that the diabetic state can greatly influence growth hormone secretory 
patterns in the rat ( Tannenbaum, 1981 ) and STZ-diabetes induces different 
neuroendocrine and morphological alterations in the hypothalamo-pituitary axis of male 
and female rats ( Bestetti et.al., 1985 ). Diabetes, thus, could affect drug metabolism by 
its action on testosterone secretion. Another possible mechanism is by a direct effect of 
insulin on the liver since insulin is the principal hormone affected in the diabetic 
condition. Therefore, a suitable method or system is needed that would enable us to study
-213-
the direct action of insulin in the rat liver.
The hormonal control of xenobiotic metabolism represents a complex and intricate 
system whereby interaction of hormones are always involved. Due to this complex 
interactive system , it is not possible to evaluate or assess the effect of one particular 
hormone in an intact animal without changing the secretion of other hormones, thus 
making it impossible to ascribe a certain functional effect to that particular hormone. This 
project aims at dissecting that intricate hormonal system by testing the effect of two 
pancreatic hormones, glucagon and insulin, in an in-vitro animal model system cultured 
in a well defined hormone- and serum-free medium.
Mixed-function monooxygenase enzymes function not only in the metabolism of 
drugs, but also in the metabolic conversion of a wide variety of endogenous substrates, 
such as steroid hormones, fatty acids, cholesterol, and vitamin D ( Conney and 
Kuntzman, 1971 ). The breakdown of steroids as well as drugs by the liver and other 
tissues are, to a great extent, dependent on the mixed-function oxidase system.
Previous studies using rat liver microsomes, have indicated that diabetes 
mellitus can affect steroid metabolism in the rat and this effect can be reversed by insulin 
administration to the diabetic animals ( Skett, 1986 ). As steroid metabolism is closely 
related to drug metabolism in the rat liver by the enzymes involved and by an apparent 
common control mechanism ( Skett et al., 1984), it was of interest to study the effect of 
insulin on androst-4-ene-3,17-dione metabolism in primary cultures of rat hepatocytes. 
The culture medium employed enabled us to examine the effect of insulin alone without 
the interference of other hormones. The biological effects of insulin vary in their time of 
onset from very rapicj responses of enzymes ( seconds to minutes ) to quite slow 
modulations of cell proliferation that may take many hours to be expressed. Therefore in 
our protocol , we have conducted the experiments ranging from 1/2 hour to 72 hours. 
Only male rats were used in all the experiments because previous study had shown that
-214-
the effect of diabetes mellitus on steroid metabolism is sex-dependent i.e. only seen in the 
male and unaffected by the same treatment in the female ( Skett, 1986).
Early studies on drug metabolism and the effect of diabetes have mainly involved 
the use of microsomal preparations of the animal tissues ( Dixon et.al., 1961; Dixon 
et.al., 1963, Kato and Gillette, 1965b ). Although microsomes are easy to prepare and 
can be stored for weeks under optimal conditions with minimal loss of enzyme activities, 
they suffer from a non-physiological nature with a loss of the tissue interaction as well as 
cell integrity. Alternative studies of drug metabolism were carried out in both hepatic 
and nonhepatic tissues in culture. Alfred and Gelboin ( 1967 ) first demonstrated that 
benzpyrene hydroxylase activity was induced by polycyclic hydrocarbons in hamster 
embryonic cells grown in-vitro. However, because of the relatively limited drug- 
metabolizing capacity of these easily cultured mesenchymal tissues, other methods were 
sought. Later, isolated liver perfusion was used in drug metabolism studies where drugs 
were administered in-situ. Although a good correlation was found to exist between the 
drug metabolism in-vivo ( Bickel and Minder, 1970 ) and in the perfused liver, the 
length of time that the isolated liver will continue to perform its normal metabolic 
functions is a question of obvious concern ( Kesters and Lambotte, 1973 ). Moreover, 
only one or two preparations may be run at one time, the setting up of the isolated 
perfused liver requires a high degree of skill and they can only be kept viable for a few 
hours. This makes this method unsuitable for long-term experiments on the effects of 
hormones on steroid metabolism Thus, newer systems were explored. In-vitro 
preparations of whole cells were used as alternatives and these include tissue slices, 
isolated hepatocytes an^ cells in culture. At present the most promising of these systems 
in the mammal is the hepatocyte in culture.
The development of techniques for the isolation and cultivation of hepatocytes 
from adult rats provided a useful intermediate model system for studies on-hepatic
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function and differentiation. Although tissue integrity is destroyed and, thus, the 
potentially important cell-cell contacts, the cellular structure is maintained ( for 
comparison of different liver preparations used in assessing drug metabolism, refer to 
Table 54). Many studies have demonstrated the short-term maintenance and induction of 
microsomal cytochromes and / or monooxygenase activities by various xenobiotics 
and cofactors ( Michalopoulos et.al., 1976a) in primary cultures of hepatocytes prepared 
from normal or regenerated adult rat liver ( Sirica and Pitot, 1980 ). Monolayer cultures 
of rat hepatocytes have also been shown to be responsive to hormones like insulin and 
glucagon and to demonstrate several major metabolic functions characteristic of liver 
in-vivo ( Bissell et.al., 1973 ).
The rapid loss of cytochrome P-450 in culture is a major problem, however, and 
attempts to maintain the concentration of this protein at initial or in-vivo levels has till 
now remained elusive. Many methods have been tried to prevent the loss of cytochromes 
including modifications of the culture medium, such as the addition of hormones ( Dich 
et.al., 1988 ), nicotinamide or other pyridines ( Paine et.al., 1979 ), or omission of 
certain amino acids ( Paine et.al., 1982) or selenium and other trace elements 
( Engelmann et.al., 1985 ). None of these, however, have succeeded in more than partly 
preventing the decline. Earlier attempts to extend the lifespan of primary cultures of 
hepatocytes included coculturing of hepatocytes with a rat liver epithelial cell line ( Begue 
et.al., 1984 ) and culturing on an extracellular matrix ( Michalopoulos et.al., 1976b; 
Rojkind et.al., 1980 ). Numerous modifications of the culture medium have been 
formulated to attempt to retain the in-vivo levels of cytochrome P-450 and in most 
cultivation techniques fQr hepatocytes from adult rats, media with high concentrations of 
rat or calf serum or hormones are used ( Bissell et.al., 1973, Stenberg et.al., 1978, 
Varandani et.al., 1985 ). Despite its drawback in lacking surface contact and rapid loss 
of cytochrome P-450 in-vitro, we have decided to use hepatocytes in our studies because
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Table 54 . Comparison of liver preparations in assessing drug metabolism
Method Degree of difficulty In-vivo relevance Reproducibility
Perfused liver High Good Poor
Liver slices Moderate Fan- Fair
Liver cubes Moderate Fair Fan-
Liver cells Moderate Fair Fair
Subcellular fraction Low Fair-poor Good
[ Taken from Gibson and Skett (1986), Introduction to Drug Metabolism, Chapman
and Hall, pp 217]
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they can be obtained in high yields allowing us to conduct more experiments and long 
term hormonal studies.
The initial purpose of the present investigation has been to develop a simple 
technique for the cultivation of rat hepatocytes under maximally controlled conditions and 
thus to make it possible to study hormonal influences on hepatic steroid metabolism. 
Androst-4-ene-3,17-dione was chosen as a substrate because it has a sex-dependent 
pathway of metabolism which is well characterized ( Stenberg, 1976) and also because it 
has commonly been used in our laboratory. Its metabolites are well defined and are easily 
separated. Multiple enzymes have been identified to be involved in its metabolism and 
they have been shown to consist of cytochrome P-450-dependent and cytochrome P-450- 
independent enzymes. The enzymes involved in its metabolism have been shown to be 
sexually-specific i.e. male- and female-specific. Moreover, insulin has been demonstrated 
to affect its metabolism in-vivo ( Skett, 1986) and its labelled and unlabelled forms are 
easily available. All these criteria indicate that androst-4-ene-3,17-dione is an excellent 
substrate to be used in the study of hormonal regulation of steroid metabolism in isolated 
hepatocytes from the rat liver.
Initially, we developed a system whereby primary cultures of hepatocytes were 
maintained in Ham's F-10 culture medium supplemented with 2.5 % foetal calf serum 
and 15 % horse serum. The purpose of culturing the cells in a medium with serum 
supplements was to test the sensitivity of the system i.e. whether the steroid metabolizing 
enzyme activities are seen in the cell culture system or not. After 3 days in culture, all of 
the enzymes in the male rats showed a decrease in activity to less than half the values 
measured in the freshly, prepared cells ( Table 1 -top panel). Our data are consistent with 
previously reported work where Stenberg et.al. ( 1978 ) had reported a reduction of 
16a-hydroxylase and 5cc-reductase activities to less than 50 % of initial values on day 3 
when the liver cells were cultured in a medium containing 1 % rat serum. In the female
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rat, selective alterations in enzyme activities were seen ( Table 2 -top panel). The activity 
of the female-specific enzymes, 7a-hydroxylase and 5<x-reductase were selectively 
reduced while the activities of the male-specific enzymes, 6p-hydroxylase and 17-OHSD 
were significantly increased. 16oc-hydroxylase activity was not altered. The difference 
seen could possibly be attributed to the marked alteration in hormonal environment of the 
cells in culture compared to in-vivo. In particular, growth hormone has been postulated 
to be a feminizing factor and in the intact animal it maintains the female-type metabolism 
in the liver ( Gustafsson et.al., 1983; Skett, 1987 ). The decrease in the female-specific 
and increase in the male-specific enzyme activities in the female rat is in agreement with 
this hypothesis since the influence of growth hormone was removed in-vitro. The 
maintenance of the 16a-hydroxylase activity is, however, inconsistent with this theory 
and alternative control mechanisms may have to be sought
After six days in culture, the female-specific enzyme activities ( 7a-hydroxylase 
and 5a-reductase ) in the male rat were restored to 90 % and 80 % of control 
respectively. Of the male-specific enzymes, only 17-OHSD activity returned to control 
level while the 6(3- and 16a-hydroxylase activities only improved slightly. In the female 
rat, all of the enzyme activities except 5a-reductase, exceeded the activities of the freshly 
prepared cells. It is interesting to note that a recent study has reported an analogous 
observation on the cytochrome P-450 content in male and female rat hepatocytes ( Vind 
et.al., 1988 ); in hepatocytes from female rat, the cytochrome P-450 content decreased by 
65 % at day 3 of culture but addition of 1 }iM dexamethasone or 1 mM phenobarbital 
gave rise to an induction of cytochrome P-450 ( 285 % ) which was maintained for 3 
weeks. In hepatocytes from male rat, however, the cytochrome P-450 content decreased 
by 45 % at day 3 of culture and the decrease continued irrespective of the presence of 
dexamethasone and/or phenobarbital. Could the observed alteration in the steroid enzyme 
activities seen in our study be related to the changes in the cytochrome P-450 isoenzymes 
concentration ? This remains to be investigated.
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Since the foetal calf and horse serum used contained indefinite quantities of 
various hormones, growth factors and peptides, it was impossible to attribute the 
maintenance of the steroid metabolizing enzyme activities to any of the serum 
constituents. We therefore replaced the serum with 2 % Ultroser G, a multihormone 
serum substitute. The culture medium used was, therefore, well-defined ( for 
composition of Ultroser G - see Table 55 ) and promoted cell attachment. At day 3, the 
fall in the enzyme activities was more pronounced in the male rat ( Table 1 - bottom 
panel) than in the female rat ( Table 2 -bottom panel). As seen with cells cultured in 
Ham's F-10 supplemented with horse and foetal calf serum, the reduction in enzyme 
activities was greater with the female-specific than the male-specific enzymes. The 
explanation behind this effect is probably the same as discussed above. At day 6, the 
enzyme activities in the female rat hepatocytes had returned to or exceeded the control 
level. On the other hand, in the male rat hepatocytes, improvement of the enzyme 
activities was very slight irrespective of the enzyme studied. The reason for the 
differential effect between the male and female hepatocytes is unclear but could be due to 
a poorer adaptation of the steroid metabolizing enzymes of the male rat to in-vitro 
environment or the lack ( or the lack of effect) o f ' masculinizing factor/s ' in the culture 
medium. As is seen from the composition of the serum substitute, we are still not 
working with a hormone-free medium. Indeed it would be impossible to investigate the 
effect of physiological concentrations of insulin in this system as the final concentration 
of insulin in the medium is in the order of 1 }iM. Thus, although Ultroser G maintains 
enzyme activities as well as serum, it is of little use for our investigations.
In a further sqt of experiment, designed to develop a totally hormone-free 
hepatocyte culture system, we have modified the cultivation of the rat hepatocytes by 
initially plating the cells in Ham's F-10 supplemented with 2 % Ultroser G for 24 hour 
( Table 3 -top panel). The cells were then washed and cultured for a further 24,48 and
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Table 55 . CQinpQSitiQn—of the synthetic multi-hormone culture medium.
Ultroser G ( LKB ) f content / vial 1
Calcium Bovine serum albumin
Selenium Traces of sulphates, inositol, thyroxine
Transferrin and calmodulin.
Insulin ( ~ ljiM ) (3-2 macroglobulin not used in
Oestradiol manufacture but may be present.
Testosterone Glucose none added but may be
Progesterone some endogenous.
Triiodothyronine Glutamine 1.6 pM
Dexamethasone
( Information obtained from LKB, Sweden )
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72 hours in Hams F-10 containing only 0.1 % bovine serum albumin. In these 
experiments, we used only hepatocytes from male rats as we intended to examine the 
role of insulin in regulating hepatic steroid metabolism and insulin's effect is only seen in 
the male rat in-vivo ( Skett, 1986).
No difference between the male-specific and female-specific enzyme activities 
was observed. All the enzyme activities fell after 1 day in culture. Apparently, the 
cytochrome P-450 enzymes were more prone to changes in activity than the non­
cytochrome P-450 when cultured in this culture medium. At day 2, partial restoration of 
the cytochrome P-450 enzyme activities were observed while the activity of the non­
cytochrome P-450 enzymes exceeded the control values. This level of enzyme activity 
was maintained for at least 3 days in culture. Hepatic steroid metabolism could, thus, be 
maintained in cultures of male rat hepatocytes in the complete absence of hormones or 
serum and, indeed, was maintained better than if hormones were present.
We have further extended the work by modifying the above method by replacing 
Ultroser G with 0.1 % bovine serum albumin ( Table 3 - bottom panel ). We have 
discovered that the enzyme activities were better maintained in this medium than in the 
other cell culture systems and that steroid metabolizing enzyme activities were returned to 
control level after 2 days in culture. The mechanism by which albumin maintained the 
enzyme activities is not well understood though it has been reported that human serum 
albumin caused protoporphyrin, that is generated in the cultured liver cells, to be 
transferred to the culture medium ( Granick et.al., 1975 ) and, thus, relieves the feed­
back inhibition on haem biosynthesis and/or decreases the activation of haem oxygenase 
by the porphyrin. We, therefore, have a hepatocyte culture method to evaluate the effects 
of insulin and glucagon on hepatic steroid metabolism in serum- and hormone-free,
chemically defined medium.
We have further characterized the metabolism of androst-4-ene-3,17-dione by
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finding the optimum number of hepatocytes ( Figure 5 ) and period of incubation 
( Figure 6 ) to be used in the assay. Since the relationship between the number of cells 
used and increasing period of incubation and the amount of metabolite formed are linear,
we have chosen 30 minutes of incubation time and 3 x 106 cells per incubation in the 
steroid assay throughout the study. We recognize the limitation of the cell culture system 
used but such a system is essential in order to evaluate, without interference, the effect of 
a single hormone on androst—ene-3,17-dione metabolism.
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91 — EEFECT— QE— INSULIN ON ANDROST-4-ENE-3.17-DIONE
METABOLISM IN NORMAL MALE RAT HEPATOCYTES
The role of insulin in rat hepatic drug and steroid metabolism is known indirecdy 
from the effect of diabetes mellitus on both the above liver parameters since insulin is the 
principal hormone altered in the diabetic state. This was first demonstrated by Dixon 
et.al., ( 1961 ) where they found that the metabolism of hexobarbitone, chlorpromazine 
and codeine was impaired in the alloxan-treated diabetic animals. Later, the alloxan- 
induced diabetes was replaced by the STZ-diabetes model system to investigate the role 
of insulin in the regulation of drug and steroid metabolism since the former was criticized 
for its overt toxicity ( Hoftiezer and Carpenter, 1973 ). Early studies indicated that the 
effect of STZ-induced diabetes on drug and steroid metabolism is sex-dependent in the rat 
( Kato, 1974; Warren et.al., 1983 ). Investigation from our laboratory later indicated that 
the effects of STZ-induced diabetes are time-dependent i.e. the effects of acute diabetes 
on drug metabolism are not seen in animals left diabetic for 20 days ( Skett and Joels, 
1985 ). All of these effects of STZ are reversed by insulin treatment. Diabetes mellitus is 
associated with a decrease in serum androgen levels though there was no direct 
correlation between the latter and the effect of diabetes on drug metabolism ( Skett et.al., 
1984 ). A suggestion has been put forward that insulin and androgens affect drug 
metabolism in the rat liver indirectly by stimulating the pituitary gland to release growth 
hormone ( Skett, 1987 ). However, up to date, no study has been conducted to 
investigate the possible direct effect of insulin on the rat liver pertaining to steroid 
metabolism. The success in the development of a hormone- and serum-free cell culture 
system which is responsive to insulin will enable us to assess the effect of insulin alone
without the interference of other hormones.
After 1/2 hour exposure to insulin, there was a significant increase in all of the
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enzyme activities at physiological concentrations ( 10'10 - 10'9 M ) of the hormone 
( Figure 7 ). This is in contrast to the selective effects of insulin reported by Skett 
( 1986 ) in the intact rat. In this latter study, STZ-induced diabetes caused a reduction in 
16oc- and 6P-hydroxylase activities and 17-oxosteroid oxidoreductase, all of which are 
male-specific i.e. found higher in male than female rats but 7ot-hydroxylase activity, 
which is higher in the female, is increased by diabetes. Insulin was able to reverse all of 
these effects. However, the experiment was carried out using liver microsomes, a system 
different from that used in this study . The variation observed could possibly be 
explained by the complex continuous interactive hormonal system in-vivo. The 
maintenance of different hormones at their respective physiological concentrations 
in-vivo is a consequence of mutual hormonal modulation and interaction. For example, 
in the diabetic state, not only the serum insulin and glucose levels are affected but also the 
serum glucagon, growth hormone and testosterone levels are among those altered and 
thus, this may explain the sex-dependent effect of insulin on drug and steroid metabolism 
observed in rats but not in isolated liver cells. At supraphysiological concentrations 
7 6( 10" and 10’ M ), insulin further increased the enzyme activities without reaching a 
maximal response, an effect also seen with insulin's effect on lipogenesis in primary 
cultures of hepatocytes ( Amatruda and Chang, 1983b).
In order to discuss the possible mechanism of action of insulin in increasing the 
activity of the steroid-metabolizing enzymes, it is necessary first to look at the nature of 
the enzymes themselves. Many of the enzymes are monooxygenases ( the hydroxylating 
enzymes ) and cytochrome P-450 is the terminal oxidase component of the 
monooxygenase system responsible for many xenobiotic oxidation reactions including 
those of steroids. In view of this, it is extremely important for us to understand how it is 
regulated. Cytochrome P-450 isolated from phenobarbital treated rats has been shown to 
be phosphorylated by the catalytic subunit of cyclic AMP-dependent protein kinase in its
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isolated form as well as in microsome- and liposome-bound states ( Pyerin et.al., 1983 ; 
Pyerin et.al., 1984 , Pyerin et.al. , 1986 ). This phosphorylation has been demonstrated 
to result in the conversion of cytochrome P-450, by the incorporation of a phosphoryl 
group into the cytochrome P-450 molecule at serine residue 128, to enzymatically inactive 
cytochrome P-420 followed by the loss of heme ( Taniguchi et.al. , 1985 ) with 
consequent decrease in the monooxygenase activity ( Pyerin et.al., 1984). A recent study 
has demonstrated that cytochromes P-450 are phosphorylated in an isoenzyme-specific 
manner ( Pyerin et.al., 1987 ) where some isoenzymes were phosphorylated either by 
cyclic AMP-dependent protein kinase ( protein kinase A ) or calcium/phospholipid- 
dependent protein kinase ( protein kinase C ) or both and some by none of these two 
kinases. Thus, in our study, the effect of any drugs or hormones in the regulation of 
protein kinase activity would be crucial in the outcome of the amount of metabolites 
produced; at least for the cytochrome P-450 driven reactions.
The molecular basis for insulin action on cellular metabolism involves the 
modulation of the phosphorylation state of many key regulated enzymes ( Krebs and 
Beavo, 1979 ; Cohen, 1982 ). Insulin action involves a cascade of events and has been 
shown to modulate various components of the effector systems distal to receptor binding. 
Below is a hypothetical description of the post-receptor effects of insulin and how it may 
bring about the observed increase in the enzyme activities studied. Stimulation of the 
intrinsic receptor tyrosine kinase results in the activation of a putative G-protein known as 
Gins ( Houslay, 1985) resulting in the activation of low Km , membrane-bound 
cyclic AMP phosphodiesterase ( Heyworth et.al., 1983a ) and inhibition of adenylate 
cyclase ( Heyworth an<J Houslay, 1983 ) culminating in the decrease of intracellular 
cyclic AMP concentration below basal level. Recent experiments by Irvine and 
Houslay ( 1988 ) suggested that insulin attenuates the functioning of ADP-nbosylated 
stimulatory guanine nucleotide regulatory protein Gs by acting as a substrate for the
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insulin receptor, resulting in the attenuation of cholera-toxin stimulated adenylate cyclase. 
It is well established that under appropriate conditions, insulin can cause a diminution in 
the concentration of cyclic AMP in fat and liver cells. Convincing decreases in cyclic 
AMP concentrations can be observed when these cell are incubated with 
insulin in the presence of other hormones ( e.g. glucagon ) which increase cyclic AMP 
( Kiss, 1978 ). However, under basal conditions i.e. in the absence of other hormones, 
little or no effect of insulin on cyclic AMP levels in liver and fat cells is found. As 
indicated in our study, no significant changes in intracellular cyclic AMP concentration 
was seen after 1/2, 1 and 2 hours exposure to insulin ( Figure 21 ). Insulin has been 
shown to inhibit hepatic cyclic AMP-dependent protein kinase in the absence of any 
changes in cyclic nucleotide concentrations ( Miller and Lamer, 1973 ; Mor et.al., 1981 ; 
Gabbay and Lardy, 1984 ). Similar inhibition of protein kinase activity has been 
observed in diaphragm ( Walkenbach et.al., 1978 ), and skeletal muscle ( Walaas et.al., 
1973 ). However, the mechanism of this response has remained obscure. The effect of 
insulin to activate liver glycogen synthase without increasing cyclic AMP concentration 
shown by Walkenbach et.al. (1980) and Mor et.al. (1981) is analogous to the effect of 
insulin on androst-4-ene-3,17-dione metabolism seen in this study. Insulin here has been 
suggested to decrease the protein kinase activity by decreasing the sensitivity of the 
enzyme to its positive modulator cyclic AMP. Mor et.al. ( 1981 ) have reported that 
insulin caused a small shift in the affinity of protein kinase A for cyclic AMP in isolated 
hepatocytes. Gabbay and Lardy ( 1987 ) reported that insulin decreased the affinity of 
protein kinase A for cyclic AMP, raising the Ka without influencing the Vmax , and 
therefore decreasing thp capacity of the protein kinase to be dissociated. The holoenzyme 
of the cyclic AMP-dependent protein kinase is dissociated by cyclic AMP according to the
following equation :
r 2C2 + 4 cAMP ---------► R2cAMP4 + 2C
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Based on Gabbay and Lardy s data, it appears that insulin shifts the equilibrium of this 
reaction to the left by decreasing the affinity of the regulatory subunit for cyclic AMP. 
Rannels and Corbin ( 1980 ) and Corbin et.al. ( 1981 ) have discovered that the 
regulatory subunit of the cyclic AMP-dependent protein kinase contains two intrachain 
cyclic AMP binding domains, termed site 1 and 2 and both binding sites appear to be 
involved in protein kinase activation ( Robinson-Steiner and Corbin, 1983 ; Ogreid et.al., 
1983 ). Gabbay and Lardy ( 1987 ) in their experiments suggested that insulin may act to 
decrease the affinity of protein kinases for cyclic AMP through a possible regulation of 
intrachain site 2 binding. Walkenbach et.al. ( 1978 ) proposed that an insulin- generated 
protein kinase inhibitor (X) may be directly associated with the type 1 holoenzyme (RC) 
as a result of insulin treatment, forming an altered protein kinase species ( X-RC), which 
has a reduced ability to bind cyclic AMP.
Insulin Hormone
1
X cAMP
X-RC v—  RC v ^  R-cAMP + C
It was recently demonstrated that the interaction of insulin with its receptors is 
followed by the hydrolysis of a novel glycophospholipid, resulting in the release of 1- 
alky 1-2-acyl glycerol and phospho-oligosaccharide ( Saltiel and Cuatrecasas, 1986; Saltiel 
et.al., 1986 ; Mato et.al., 1987a ). The phospho-oligosaccharide, termed inositol 
phosphate-glyean ( IPG ) by Saltiel was generated by phosphodiesteratic hydrolysis with 
a phosphatidylinositol-'specific phospholipase C from Staphylococcus aureus ( Kelly 
et.al., 1986 ; Kelly et.al., 1987a ) and was found to contain inositol, glucosamine, 
galactose and phosphate ( Mato et.al., 1987b ). This inositol phosphate- glycan was 
shown to mimic the effect of insulin to stimulate the high-affinity cyclic AMP
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phosphodiesterase ( Kiechle and Jarett, 1981 ; Saltiel et.al., 1986 ) and pyruvate 
dehydrogenase ( Saltiel, 1987 ), and to inhibit adenylate cyclase ( Saltiel, 1987 ; Malchoff 
et.al., 1987 ) and cyclic AMP-dependent protein kinase ( Malchoff et.al., 1987 ; Villalba 
et.al., 1988 ). However, it had no effect on the calcium/phospholipid-dependent protein 
kinase ( Villalba et.al., 1988 ). The ability of this inositol phosphate-glycan to modulate 
this long list of insulin-sensitive enzymes suggests that it functions as a second 
messenger for insulin action. In human serum, increased mediator concentrations 
( molecular weight ~  1000-2000 ) have been observed with increased insulin 
concentrations during glucose tolerance tests ( Sinha and Caro, 1985 ). This 
glycophospholipid could be derived from the glycosyl-phosphatidyl inositol structure 
which is thought to anchor proteins to the plasma membrane ( Low, 1987 ). The insulin­
like effects of this inositol phosphate-glycan were shown to be attributed to 
dephosphorylation of insulin-sensitive enzymes. As demonstrated by Villalba et.al.
( 1988 ), the phosphorylation of both phospholipid methyltransferase and histone IIA by 
the catalytic subunit of cyclic AMP-dependent protein kinase was almost completely 
inhibited by the addition of the inositol phosphate-glycan. In relation to the effect of 
insulin on steroid metabolism, the overall inhibition of the cyclic AMP-dependent protein 
kinase and the adenylate cyclase activity and stimulation of the cyclic AMP-dependent 
phosphodiesterase by this inositol phosphate-glycan would theoretically decrease the 
phosphorylation of cytochrome P-450 to its inactive cytochrome P-420 form, therefore, 
would explain the increased amount of substrate ( i.e. androst-4-ene-3,17-dione) being 
metabolized. The mechanism by which the inositol phosphate-glycan inhibits the cyclic 
AMP protein kinase activity still remains unresolved. It had no effect on cyclic AMP 
binding by the cyclic AMP-dependent protein kinase and does not compete with ATP for 
the same binding site in the catalytic subunit of the cyclic AMP-dependent protein kinase 
( Malchoff et.al., 1987 ; Villalba et.al., 1988 ) and has been suggested by the latter group
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to act by binding to a different site of the catalytic subunit of the cyclic AMP-dependent 
protein kinase.
Another possible explanation for the observed increase in enzyme activity is the 
ability of insulin to regulate the protein phosphatase(s). An ATP/Mg - dependent 
multifunctional protein phosphatase has been identified in mammalian nervous and non- 
nervous tissues ( Yang et.al., 1980 ; Yang and Fong, 1985 ). This enzyme can be 
activated in the presence of ATP/Mg and an activating factor termed FA, a cyclic AMP -
and Ca2+ - independent protein kinase ( Vandenheede et.al., 1980 ; Hemmings et.al., 
1981 ). This protein phosphatase activating factor, FA, has been isolated from the brain, 
liver, heart, smooth and skeletal muscles ( Yang et.al., 1987 ). A recent report indicated 
that insulin can activate and cause the translocation of protein kinase FA in human 
platelets ( Yang et.al., 1988 ). The FA exists mostly in an inactive form in the particulate 
fractions of the human platelet. The exposure of the platelets to physiological
9 8concentrations of insulin (10 -10 M ) resulted in an increase in cytosolic FA 
activity ( molecular weight ~45 kDa ) as assayed as an activator of ATP.Mg-dependent 
protein phosphatase, to about 300 % of control values in the absence of insulin and in a 
corresponding decrease in FA activity in the membrane. A 46-kDa membrane 
phosphoprotein of the fat cells was recently shown to be phosphorylated by insulin 
exclusively on tyrosine residues. Insulin stimulates the tyrosine phosphorylation 3- to 4- 
fold within 150 seconds in the intact cell in a dose-dependent way at insulin 
concentrations between 0.5 nM and lOOnM. This protein is not immunoprecipitated by 
antibodies against different regions of the insulin receptor and its HPLC tryptic peptide 
map is different from the tryptic map of the insulin receptor, suggesting that it is not 
derived from the receptor (3-subunit ( Hanng et.al., 1987 ). It still remain to be elucidated 
whether phosphoprotein discovered by Hanng and colleagues ( 1987 ) is similar to the 
protein kinase FA isolated by Yang et.al. ( 1987 ). Interestingly, the increase in all the
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enzyme activities active on androst-4-ene-3,17-dione following 1/2 hour exposure to 
insulin varies from 200 to 300 % of control. In addition to ATP/Mg-dependent protein 
phosphatase as its substrate, FA is capable of acting on many substrate proteins including 
glycogen synthase ( Vandenheede et.al., 1980 ; Hemmings et.al., 1981 ), the regulatory 
subunit of cyclic AMP-dependent protein kinase ( Hemmings et.al., 1982 ), the nerve 
growth factor receptor proteins ( Taniuchi et.al., 1986 ) and myelin basic protein ( Yang, 
1986 ). FA has been shown to promote dephosphorylation of myelin basic protein in 
the central nervous system ( Yang and Fong, 1985 ; Yang, 1986 ) however, its possible 
physiological function in regulating the monooxygenase enzyme system remains to be 
elucidated.
It is apparent that insulin's effect on androst-4-ene-3,17-dione metabolism involves 
a phosphorylation reaction since the protein kinase inhibitor, K-252a, completely 
inhibited the effect of insulin on androst-4-ene-3,17-dione metabolism ( Figure 24 and 
25 ). Paradoxically, if protein kinase A and C activity are inhibited, it might be expected 
that insulin would further increase the enzyme activities as both of these kinases are 
known to decrease steroid metabolism in isolated hepatocytes ( Berry and Skett, 1988; 
Allan and Skett, 1988 ) and to phosphorylate cytochrome P-450 ( Pyerin et.al., 1987 ). 
K-252a has been shown to competitively inhibit the protein kinases with respect to ATP 
and this inhibition is reversed by ATP indicating that K-252a directly interacts with the 
catalytic site of the kinase competing with ATP ( Kase et.al., 1987 ). If the protein kinase 
A activity is inhibited, it is anticipated that the equilibrium will be shifted from 
cytochrome P-420 to P-450 leading to increase in enzyme activities. As explained above, 
the insulin mediator, inositol phosphate-glycan acts at a different site from the protein 
kinase inhibitor, K-252a. A recent study ( Hagiwara et.al., 1988 ) has reported that 
bioflavonoids ( eg. quercitin and myncetin ) which have a similar mode of action to 
K-252a, by competing with ATP at the catalytic fragment of the protein kinases, also
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inhibited insulin receptor tyrosine kinase. The tyrosine kinase activity could be 
responsible for the initial effects of insulin where the self-phosphorylation of the 
receptor is essential for the transmission of the signal ( Espinal, 1987 ), therefore it 
is assumed that inhibition of the insulin receptor tyrosine kinase could also alter the 
activity of the protein kinases on phosphorylation. It is interesting to note that Hagiwara 
and co-workers ( 1988 ) demonstrated that the Kj values of myricetin for insulin receptor 
tyrosine kinase, cyclic AMP-dependent protein kinase and protein kinase C were 2.6 |iM, 
27.5 |lM and 12.1 jiM respectively. Until now the effect of K-252a on insulin receptor 
tyrosine kinase has not been reported. However, at this stage there is insufficient 
evidence to do more than to speculate that K-252a inhibition of insulin effect with respect 
to androst-4-ene-3,17-dione metabolism is due to its inhibition of the tyrosine kinase 
analogous to the effect of the bioflavonoids.
Protein kinase C ( PKc ) has been demonstrated to be an important transmembrane 
signalling system in a number of cell responses to various effectors ( Nishizuka, 1986 ). 
Recently hepatic steroid metabolism was shown to be inhibited by activation of protein 
kinase C suggesting that it may be one of the mechanisms by which the regulatory 
hormones affect steroid metabolism in the liver ( Allan and Skett, 1988 ). Insulin 
enhances de novo synthesis of phosphoinositides in fat cells ( Pennington and Martin,
1985 ) and provokes, through rapid activation of phospholipase C ( Farese et.al.,
1986 ), increases of diacylglycerol, which is the physiological activator of PKC. 
However, the role of PKC in insulin action has been questioned, in particular by the 
recent finding ( Glynn et.al., 1986 ) that the hormone proved unable to provoke, as does 
4P-phorbol-12p-myrist^te-13a-acetate ( PMA ), a translocation of PKc from soluble to 
particulate fractions. The results from several laboratories indicated that the rate of 
diacylglycerol and phosphatidic acid turnover in response to insulin is tissue specific. In 
myocytes ( Farese et.al., 1985b ) and adipocytes ( Pennington and Martin,. 1985 ),
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insulin has been reported to increase de novo synthesis of phosphoinositides, 
diacylglycerol and phosphatidic acid. In rat liver, insulin has no effect on the turnover of 
the major phospholipids, including the polyphosphoinositides, in several subcellular 
compartments including plasma membranes, microsomes, lysosomes, mitochondria and 
nuclei ( Sakai and Wells, 1986 ). The result we have obtained are in accord with those
above where no significant increase in incorporation of 32P into phosphatidic acid and 
phosphatidylinositol between control and insulin-treated liver cells were observed 
( Figures 22 and 23 ). The tyrosine kinase of certain viral oncogenes has been suggested 
to phosphorylate phosphatidylinositol and phosphatidylinositol-4-P to the corresponding 
polyphosphoinositides ( Sugimoto et.al., 1984; Macara et.al., 1984 ). Taylor et.al. 
( 1985 ) have investigated the role of insulin in phosphoinositide metabolism using rat 
liver plasma membranes and isolated hepatocytes. Their findings suggested that the 
tyrosine kinase activity of liver insulin receptors is not important in phosphoinositide 
formation.
If the investigation of insulin's effect on hepatic steroid metabolism is extended, 
an attenuation of insulin's effect is observed after 1 hour of insulin pre-incubation. At
-8concentrations higher than 10 M, the enzyme activities returned to basal level 
( Figure 8 ). A return of all enzyme activities within the range of insulin concentration
used ( 10'10 - 10'9 M ) to basal level occurred after 2 hours of insulin incubation 
( Figure 9 ). As previously reported, acute exposure ( between 0 - 2 hours ) of intact 
cells to insulin has no effect on receptor concentration ( Gavin et. al., 1974 ). The 
decrease in insulin's effect could possibly be due to the desensitization of the second 
messenger system/s as occurs after a transient rise in the activity of the second messenger 
system with the effect of insulin on the activation and translocation of protein kinase FA 
( an activator of the ATP. Mg-dependent multifunctional protein phosphatase ) as 
reported by Yang et.al.(1988). However, no direct relationship between translocation of
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protein kinase FA and steroid metabolism has been studied. The modulation of the cyclic 
AMP level involving the adenylate cyclase or the phosphodiesterase can be ruled out 
since no significant changes in cyclic AMP content was observed after 1 and 2 hours of 
insulin preincubation. Another possible explanation for the attenuated insulin response 
is related to the degradation of insulin in-vitro. Varandaniand Nafz, ( 1976 ), have 
reported that about 30 to 50 % of insulin is degraded after 15 minutes of incubation in 
isolated liver cells. The dissociation of insulin from receptor sites on liver membranes is 
biphasic and can be resolved into rapid and slow components ( McCaleb and Donner, 
1981; Corin and Donner, 1982 ). The fraction of the rapidly dissociating hormone 
decreases as the incubation time between liver cells or membranes is lengthened and this 
is accompanied by a proportionate increase in the amount of slow dissociating insulin 
( Donner and Corin, 1980 ). The dissociation of insulin from its receptors could also 
possibly explain the gradual decrease in insulin effect from 1/2 to 2 hours of incubation.
A further increase in enzyme activities is seen after 24 hour insulin incubation. 
However, a notable difference between the effect of insulin at 1/2 hour and 24 hour is 
that the former showed a dose-related increase in enzyme activities which had not
reached a maximum at 10'6 M insulin ( compare Figure 7 and 10 ). However, at 24 
hours, the enzyme activities fell significantly below control level as the insulin
concentrations were increased above 10 8 M. Thus it is apparent that the effect of insulin 
observed at 1/2 and 24 hours could be mediated by two different mechanisms, and 
differentiated by time. Chronic exposure of cells to high concentrations of insulin
( 10'8 and 10'6 M ) in-vitro has been reported to produce a decrease in insulin receptor 
concentrations i.e. insulin-induced receptor down-regulation ( Gavin et. al.,1974 ). A 
recent study by McClain and Olefsky ( 1988 ) indicated that the rate and extent in 
internalization of insulin receptors in a human hepatoma cell line is dependent on the
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insulin concentration. Their study showed that cells exposed to lower concentrations of 
insulin internalise fewer receptors and slower than cells exposed to a high insulin 
concentration. They concluded that internalization of insulin receptors can be mediated by 
two independent pathways depending upon the concentration of insulin used. It is not 
known whether the effect of insulin observed at 24 hour is linked to these two pathways. 
It is known that high concentrations of insulin do cause a greater degree of receptor 
down-regulation in adipocytes when exposed for a prolong period to insulin ( Marshall 
et.al., 1984 ). However recycling rates of the insulin receptor were two fold higher in 
cells treated with high insulin concentration than in lower concentration ( McClain and 
Olefsky, 1988 ). Its relevance to insulin effect on androst-4-ene-3,17~dk>»e metabolism 
after 24 hour of exposure is again unclear.
Specific binding sites for insulin have been described in different intracelluiar
organelles from liver ( Goldfine, 1981 ). Recently intracellular insulin has been
demonstrated to stimulate RNA and protein synthesis in oocytes from Xenopus laevis
( Miller, 1988 ). However with regards to protein synthesis, the level of cytochrome
P-450 was found not to be significantly altered after 24 hour of incubation with
*
insulin, an effect similarly observed at 1/2 hour ( Table 18 ). Another similar effect 
seen at 1/2 and 24 hours was the effect of the non-specific protein kinase inhibitor, 
K-252a, on the metabolism of androst-4-ene-3,17-dione by insulin ( refer to Figure 24 
and 25 ). Resembling the effect seen at 1/2 hour, preincubation of the liver cells with 
K-252a for 24 hours abolished the effect of insulin to increase the enzyme activities 
implying that the insulin effect observed at 24 hours is mediated by protein 
phosphorylation.
The effect of' insulin observed at 48 and 72 hours was further investigated 
to identify whether the attenuation or disappearance of insulin effect seen is due to the 
degradation of insulin or to down-regulation of insulin receptors. To determine this, 
insulin was added at 24 hour intervals from 0 to 72 hours ( Figure 14 ). If the fall in
* A lthough  the total cytochrome P-450 content did not change, it is possible that 
alteration in the level of specific isoenzymes could occur.
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activity ( at 48 and 72 hours ) is due to breakdown of insulin molecules, we should 
expect a maintenance of increased enzyme activities at 24 hours as well as at 48 and 72 
hours. However the cumulative addition of insulin at 48 and 72 hours did not sustained 
the increased enzyme activity seen at 24 hours indicating that the fall in activity at 48 and 
72 hours could probably be attributed to the down-regulating effect of insulin on its 
receptors which is consistent with the documented chronic effect of insulin on its receptor 
in intact cells ( Gavin et.al., 1974).
In summary, the effect of insulin on steroid metabolism over the period studied 
was characterized by the presence of two increases in enzyme activities i.e. at 1/2 and 24 
hours. These effects of insulin are observed within the physiological range of insulin 
concentrations. The dose-response curves indicated that the acute effect ( at 1/2 hour) of 
insulin on steroid metabolism could be mediated by a mechanism distinct from the 
chronic effect (24 hours ) of insulin. The data gathered in this study suggest that insulin 
acts as a general stimulator of the enzymes in the liver metabolizing androst-4-ene-3,17- 
dione. We have presented data indicating the direct effect of insulin on steroid metabolism 
in the rat liver supporting our contention that insulin is a major factor in the regulation of 
xenobiotic metabolism in the rat liver. However, it is important to consider other 
possible interactions with other hormonal systems, since insulin also interferes with the 
secretion of other hormones and vice-versa.
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92  THE EFFECT OF INSULIN ON ANDROST-4-ENE-3.17-DIONE 
METABOLISM IN HEPATOCYTES ISOLATED FROM STREPTOZOTOCIN- 
DIABETIC MALE RATS
Streptozotocin was used as a diabetogen instead of alloxan because of its more 
selective (3-cell toxic action ( Anson and Feudale, 1967; Hoftiezer and Carpenter, 1973 ) 
and because its effect on the liver has been shown to be due to its diabetogenic action 
since treatment with insulin could reverse the effects seen ( Reinke et.al., 1978; Reinke 
et.al., 1979; Favreau and Schenkman, 1987 ). On the other hand, alloxan has been 
criticized for its overt toxicity ( Hoftiezer and Carpenter, 1973 ) and thus may not be a 
good model of diabetes. Other workers have used different doses of streptozotocin to 
induced diabetes; at a dose of 60 mg/kg, STZ has been shown to induce hyperglycaemia 
and hyperlipidaemia in adult rats ( Skett, 1986) but we have chosen the dose of 
100 mg/kg to ensure that the animals were ketotic since ketoacidosis is more commonly 
manifested in type 1 or insulin dependent diabetes mellitus than in type 2 or non-insulin 
dependent diabetes mellitus and since STZ-treated animals have been used as a 
model for type 1 diabetes ( Junod et.al., 1969; Like and Rossini, 1976 ).
We have only used male rats in our study of the effect of the diabetic state on the 
response to insulin of steroid metabolism in hepatocytes because previous studies have 
indicated that the effect of diabetes on steroid and drug metabolism is sex-dependent i.e. 
only seen in the male rat ( Skett, 1986; Skett and Joels, 1985 ). The activity of the 
enzymes studied were markedly reduced in the male but were unaffected in the female. 
The effect of STZ-induced diabetes on phase 1 drug metabolism has been found to be 
time-dependent ( Skett and Joels, 1985 ). The effect of diabetes was conspicuous after 3 
days of STZ-treatment but these effects were not observed in rats left diabetic for 20 
days. With regard to this, it is of interest to investigate whether steroid metabolism is
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similarly affected by STZ-induced diabetes since they share a common hepatic 
metabolism control mechanism.
As shown in Table 12, the animals lost weight and were hyperglycaemic, 
establishing that they were in fact diabetic. In this study it was shown that STZ-induced 
diabetes mellitus causes a change in the metabolism of androst-4-ene-3,17-dione. The 
changes in the enzyme activities were dependent on the enzyme being studied, with the 
basal activity of the male-specific enzymes ( 6P-hydroxylase and 17-OHSD ) being 
decreased while the female-specific enzyme activities ( 7a-hydroxylase and 5 a- 
reductase ) were increased. This data is in general agreement with the results obtained 
from studies using hepatic microsomes ( Reinke et.al., 1978; Skett, 1986) except that the 
16a-hydroxylase and 5a-reductase activities were unexpectedly increased, whereas, 
Skett ( 1986 ) showed that 16a-hydroxylase and 5a-reductase activities were 
respectively decreased and unaffected in hepatic microsomes from acutely STZ-treated 
diabetic male rats. The variability of the observed effects may reflect the physiological 
status of the preparation used and the use of hepatocytes probably represent a more 
physiological situation. Abnormal testosterone metabolism by liver slices from alloxan- 
diabetic rats has been demonstrated and the formation of androst-4-ene-3,17-dione, 
dehydroepiandrostenedione and androsterone from testosterone was decreased in the 
diabetic animals ( Demchenko and Tron'ko, 1975 ). Subbiah and Yunker ( 1984 ) have 
reported an increased 7a-hydroxylase activity in STZ-treated rats. The present report 
supports these previous observations and indicates altered steroid metabolism in diabetes.
Hepatocytes isolated from chronically diabetic rats ( 21 days post-STZ treatment), 
on the other hand, gave somewhat different results. There were no changes seen in the 
basal 7a- and 16a-hydroxylase activities ( refer to Table 12 ). The basal activity of 6p- 
hydroxylase and 5a-reductase were decreased but the 17-OHSD activity was increased. 
Thus, it is clear that the effect of diabetes mellitus on phase 1 steroid metabolism .in the rat
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is time-dependent and is not the same in the acute and chronic phase. Also, the overall 
effect of chronic diabetes is much less than that seen in the acute phase, a result 
strikingly similar to that observed in microsomal drug metabolism ( Dixon et.al., 1963; 
Skett and Joels, 1985 ). The hepatocyte system as used in this study is, thus, a good 
model for the effect of acute and chronic diabetes in-vivo.
The response of the cells to insulin is also markedly affected if the cells are derived 
from diabetic animals. Cells derived from an acutely diabetic ( 3 day ) male rat did not 
respond to insulin at any time point or at any concentration ( Figures 15 and 16 ), 
whereas the effect of insulin on the cells derived from the chronically diabetic (21 day) 
animals depended on the period of pre-incubation with insulin ( Figures 17, 18 and 19 ). 
At 1/2 hour, hepatocytes from normal rats responded in a dose-dependent fashion to 
insulin for all the enzyme activities measured with a significant increase in activity
as low as 10'10 M insulin which had not reached a maximum at 10’6 M ( Figure 7 ). 
However, primary cultures of hepatocytes from 3- and 21-days STZ-diabetic rats were 
not responsive to in-vitro  insulin addition throughout the range of insulin 
concentrations used.
The effect of insulin after 1 hour of exposure in hepatocytes from chronically 
diabetic rats resembles its effect in normal rat hepatocytes although the effect is not as 
marked ( Figure 18 ). The bell-shape curves of enzyme activity after 1 hour exposure to 
insulin in normal rat hepatocytes were similarly exhibited in the chronic diabetic 
hepatocytes indicating that the phenomenon of insulin resistance in rats may be caused by 
a defect in the signal transduction system early in insulin action. The insulin resistance, 
similarly observed at l.hour in acute diabetes, is different from the chronic phase in that 
the liver cells were still unresponsive to insulin in the former, and hence could possibly 
explain the differential effect of acute and chronic diabetes seen in this study and others 
( Skett and Joels, 1985; Dixon et.al., 1963 ). However, the ability of insulin to cause a
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small but significant increase in all the enzyme activity after the liver cells from chronic 
diabetic rats were exposed to insulin for 2 hours is unexpected and different from 
that in the normal rat ( compare Figure 9 and 19 ). It seems, therefore, that in the 
chronically diabetic rat, the response to insulin is delayed and attenuated.
The incidence of insulin resistance is not restricted to liver alone. It has been 
shown to occur in adipocytes ( Haring et.al., 1986 ), erythrocytes ( Grigorescu et.al., 
1984), lymphocytes ( Kakehi et.al., 1988 ), denervated slow and fast muscles 
( Turinsky, 1987 ), duodenum and gastric-fundus ( Altan et.al., 1987 ). In the human, 
insulin resistance occurs in many patients with diabetes mellitus, obesity, acromegaly, 
Cushing's syndrome ( Berson and Yalow, 1970 ) and acanthosis nigricans ( Kahn et.al., 
1976). In other work, it has been shown that adrenaline, acting primarily through a 
p-adrenergic receptor, markedly impairs tissue sensitivity to an increase in plasma insulin 
levels ( Deibert and DeFronzo, 1980 ). Thus, the phenomenon of insulin resistance is not 
restricted to one species only. However, whether the pathogenesis of insulin resistance in 
experimental animals and human is similar or not is still unsolved and is currently a 
subject of a great deal of research. Recently ( Hussin and Skett (1988) have suggested 
that the 3 days STZ-diabetic rat may be a model for type 2 or non-insulin-dependent 
diabetes mellitus since insulin resistance has been shown to be a characteristic feature of 
type 2 diabetes mellitus ( Kolterman et.al., 1983 ).
Insulin resistance may be said to exist whenever normal concentrations of insulin 
produce a less than normal biologic response ( Kahn, 1978 ). In this study liver cells 
from acute- and chronically-treated STZ-diabetic rats were shown to be fully or 
partially resistant to pie effect of insulin in-vitro. Resistance to the acute effects of 
insulin on lipogenesis has also been reported in primary cultures of hepatocytes from 
diabetic and fasted rats ( Amatruda and Chang, 1983b) and this occurred in the presence 
of normal to increased insulin binding ( Cech et.al., 1980 ) suggesting a postreceptor
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defect in insulin's action. Following its synthesis and transport to target tissues, insulin 
exerts its biological effects by binding initially to its specific cell receptors. The overall 
target tissue insulin resistance can be subdivided into receptor and postreceptor defects. 
However, the currently available evidence indicates that resistance is largely related to 
postreceptor defects in insulin action. Since insulin action involves a cascade of events, it 
is apparent that abnormalities at any step distal to binding can cause or contribute to target 
tissue defects in insulin action. Insulin resistance can also be classified according to a 
decrease in sensitivity i.e. a rightward shift of the dose-response curve ( receptor defect) 
or a decrease in responsiveness i.e. a decrease in the maximal response ( postreceptor 
defect ) or both. It is apparent that the insulin resistance with regards to steroid 
metabolism seen here could probably be attributed to both receptor and postreceptor 
defects since the liver cells were completely unresponsive to insulin addition up to
10~6 M concentration.
STZ-induced diabetes in experimental animals has been reported to be associated 
with numerous alterations of many insulin-modified intracellular biochemical steps at 
receptor and postreceptor levels. Recently, it was reported that the biosynthesis, the 
terminal glycosylation and the intracellular transport of the 190-kDa receptor precursor to 
the cell surface proceeded normally in a patient with extreme insulin resistance, but 
proteolytic maturation to oc and (3 subunits does not occur ( Kakehi et.al., 1988 ). They 
postulated that the defect results either from mutation(s) within the insulin-receptor gene 
or from a defect in the receptor processing gene. In another study, the lymphocytes from 
a patient with leprechaunism ( inherited condition of severe insulin resistance) have been 
shown to have lower numbers of insulin receptors when compared to the normal 
population. The patient also exhibited a marked reduction in the level of lymphocyte 
insulin-receptor mRNA ( Ojamaa et.al., 1988 ). Since the synthesis of the insulin 
receptor precursor proceeded at a normal rate in these patients, the authors suggested that
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the defect in the posttranslational processing of the receptor or in its translocation to the 
plasma membrane could have accounted for the insulin resistance observed in these 
patients. Diabetes also has been demonstrated to induce structural and functional 
changes in insulin receptors ( Burant et.al., 1986 ). The electrophoretic mobility of a 
subpopulation of [3-subunits derived from diabetics was slightly decreased when 
compared to control. It appeared that excess sialidation may account, in part, for the 
altered mobility of the diabetic derived [3-subunits since neuraminidase decreased or 
abolished the differences in electrophoretic mobility between controls and diabetics.
The insulin receptor is a tyrosine-specific protein kinase. Upon binding of 
insulin, the kinase is activated resulting in autophosphorylation of the receptor. Insulin- 
stimulated tyrosine-kinase activity has been demonstrated to decrease in erythrocyte and 
cultured fibroblast insulin receptors in patients with syndromes of severe insulin 
resistance ( Grigorescu et.al., 1984; Grigorescu et.al., 1987 ), Cloudman S91 melanoma 
cell line ( Haring et.al., 1984b ), rat skeletal muscle ( Burant et.al., 1986 ), skeletal 
muscle biopsies from obese and type 2 diabetic male patients ( Amer et.al., 1987b ), 
skeletal muscle of insulin-resistant obese mice ( Le Marchand-Brustel et.al., 1985 ) and 
adipocytes of non-insulin-dependent diabetic patients ( Freidenberg et.al., 1987 ). This 
long list of tissues affected in man and experimental animals indicates that defective 
tyrosine kinase activity may play a vital role in the pathogenesis of insulin resistance. 
Since the kinase activity has been shown to be an early step in the insulin transmembrane 
signalling, it is logical to see reduced insulin responses in patients and animals with 
insulin resistance.
Insulin resistance has also been associated with altered modulation of insulin 
action by protein kinase C ( Van de Werve et.al., 1987 ). In lean rat hearts, phorbol 
myristate acetate provokes a translocation of the protein kinase C from a soluble to a 
particulate fraction. In obese rat hearts which are insulin resistant, the basal distribution
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of protein kinase C is altered i.e. more activity found in the soluble and less in the 
particulate fraction. Moreover, phorbol esters have been demonstrated to modulate insulin 
receptor phosphorylation and insulin action ( Takayama et.al., 1984 ) by increasing the 
tyrosine kinase Km for ATP ( Haring et.al., 1986 ). In this study we have discovered
that insulin does not significantly affect the 32P labelling of phosphatidic acid and
phosphatidylinositol when compared to control ( Figure 22 ). However the amount of 32P 
labelling of the phospholipids were tremendously reduced in the diabetic rat ( Figure 23 ) 
indicating a possible role of phospholipid in the appearance of diabetes. The importance 
of changes in phospholipid metabolism during the action of insulin is presently unknown 
but a recent report has indicated that phospholipid environment alters the hormone- 
sensitivity of the purified insulin receptor kinase ( Lewis and Czech, 1987 ).
Insulin resistance in rats has also been associated with the failure of insulin to 
stimulate the release of a chemical modulator of pyruvate dehydrogenase ( Amatruda and 
Chang, 1983a ). Extracts of the mediator fractions were prepared from liver particulate 
fractions incubated in the absence or presence of insulin ( 2 nM ). The liver particulate 
fraction from STZ-diabetic rats were resistant to the ability of insulin to generate the 
activator of pyruvate dehydrogenase activity. The situation could be rectified by treating 
the diabetic rats with insulin for 2 days. Recently, the chemical mediator was isolated and 
identified as the polar head group of an insulin-sensitive glycophospholipid ( Gottschalk 
and Jarett, 1988 ). This polar head group, which was released by treating the 
glycophospholipid with a phosphatidylinositol-specific phospholipase C, stimulated 
pyruvate dehydrogenase in both subcellular and whole cell assays.
Experimental STZ-diabetes is associated with both a decrease in low Km cyclic 
AMR phosphodiesterase and calmodulin as well as an apparent subcellular redistribution 
of these components ( Smoake and Solomon, 1980, Solomon et.al., 1986b ). STZ 
diabetes is also associated with a reduction in Vmax of the low Km cyclic AMP
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phosphodiesterase in both liver and fat tissues ( Solomon et.al., 1986b ).
It has been reported that somatomedins ( insulin-like growth factors, IGF's ) are 
produced in the liver , based on observations using liver perfusions ( Schalch et.al., 
1979; Miller et.al., 1981 ) and monolayer cultures of rat hepatocytes ( Kogawa et.al., 
1983 ). STZ-induced diabetes mellitus has been associated with both a decrease in 
hepatic production and serum levels of IGF and its carrier protein in the rat and these 
can be restored towards normal by insulin replacement therapy ( Miller et.al., 1981). The 
IGF 1 receptor resembles the insulin receptor in every aspect ( Kasuga et.al., 1981a), the 
two peptides ( insulin and IGF-1) have several biological activities in common and they 
crossreact with each others' receptors ( Zapf et.al., 1978 ).
STZ-induced diabetes has also been associated with altered responsiveness of 
hormone-sensitive adenylate cyclase in liver ( Soman and Felig, 1978 ), decreased 
guanylate cyclase activity ( Vesely et.al., 1977 ), modification of a distinct species of 
guanine nucleotide regulatory protein [ G ^  ] ( Houslay, 1985 ) and, recently, the loss of 
expression of inhibitory guanine nucleotide regulatory protein, Gj ( Gawler et.al., 
1987 ).
It still remain to be elucidated whether any one or a combination of these STZ- 
induced changes are associated with the insulin resistance seen in this study.
Insulin treatment of STZ-diabetic rats is known to reverse the effect of other 
measured parameters to control level. In the literature , a wide range of doses of insulin 
were used to treat diabetic animals. In this study we have used different doses of insulin 
( 2, 12 and 16 units ) purposely to study the efficacy of each dose in reversing the 
depressive effect of diabetes on androst-4-ene-3,17-dione metabolism. We found that 
both 2 and 12 units of insulin equally, partially restored the ability of the 3-days STZ- 
induced diabetic hepatocytes to respond to in-vitro insulin ( Figure 20 ). The maximal
effec t o f  in-vitro insulin is seen at 10 8 M concentration in the treated diabetic rats,
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whereas in untreated control rat, insulin response on the enzyme activities had not
reached its maximum even at 10 6 M. In-vivo insulin treatment restores about 60 to
85 % of the enzymes responsiveness of the normal rat at 10 8 M. Insulin treatment could 
restore the sensitivity of the cultured cells toward in-vitro insulin as can be seen by the
effect of insulin at 10 M in the diabetic rat. Treatment with 16 units of insulin resulted 
in effects as seen in untreated diabetic rats ( Figure 15 ). The absence of effect seen is 
probably due to the down-regulation of insulin receptors caused by the high dose of 
insulin administered (16 units/day for 3 days ). However, we have no direct evidence to 
support this notion but others ( Kahn et.al., 1972; Archer et.al., 1973 ) have found that 
the concentration of insulin receptors per cell fluctuates in response to altered conditions 
in-vivo. The partial restoration of other measured biological effects after in-vivo insulin 
treatment has also been reported by others ( Favreau and Schenkman, 1987; Gawler 
et.al., 1987 ). In-vivo insulin treatment has been reported to restore liver microsomal 
drug metabolism and the ability of insulin to stimulate the release of a chemical modulator 
of pyruvate dehydrogenase to normal ( Dixon et.al., 1963; Amatruda and Chang, 
1983a ). The restoration of responsiveness seen after in-vivo treatment with insulin but 
not in-vitro treatment suggests the presence of a factor/factors in-vivo which is/are 
absent in-vitro, which is/are important in reversing the hepatic insulin resistance in 
diabetes. Hepatocytes generally require insulin, corticosteroids and thyroxine to maintain 
differentiated functions in cell culture ( Varandani et.al., 1982 ). It is interesting to note 
that recent work ( Van der Hoeven and Galivan, 1987 ) has reported the effect of 
hormonal control of microsomal NADPH-cytochrome P-450 reductase in primary 
cultures of isolated hepatocytes. They reported that insulin and dexamethasone alone 
improved the retention of reductase activity and protein. Only when hepatocytes were 
cultured in insulin, triiodothyronine and dexamethasone could NADPH-cytochrome 
P-450 reductase activity and protein be maintained at the original level.
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In summary, hepatocytes from diabetic rats ( acutely and chronically treated) are 
not responsive to insulin in-vitro with respect to androst-4-ene-3,17-dione metabolism 
and the responsiveness is partially restored by in-vivo treatment with insulin. The need 
for insulin treatment in order to restore insulin responsiveness in the diabetic rat 
hepatocytes signifies the major role of insulin in the regulation of steroid metabolism in 
the rat liver.
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93 THE EFFECT. QF GLUCAGON AND TH-GLUCAGON ON ANDROST-
4.-ENE-3.17-PTONE METABOLISM IN NORMAL MALE RAT
HEPATOCYTES
The liver plays a prominent role in the regulation of glucose and ketone 
homeostasis. The regulation of both of these parameters involves insulin and its counter- 
regulatory hormone, glucagon. Physiological changes in the diabetic rat include an 
increase in the ratio of glucagon to insulin production ( Mackrell and Sokal, 1969 ) and a 
markedly diminished hepatic capacity for metabolizing drugs ( Weiner et.al., 1972 ). 
Since starvation, diabetes, and glucagon have been shown to increase the level of cyclic 
AMP in the liver ( Sutherland and Robison, 1966) and insulin has been demonstrated to 
have the opposite effect ( Sen ft et.al., 1968 ), it is possible that the inhibition of drug 
metabolism produced by starvation and diabetes is mediated by an increase in intracellular 
cyclic AMP. With respect to the adenylate cyclase system, the acute activation could be 
due to changes in the insulin-glucagon ratio ( Unger and Orci, 1975 ) and in the diabetic 
state an increased sensitivity to glucagon could be involved ( Allgayer et.al., 1982 ). In 
fact after treatment of the diabetic rat with insulin this increased sensitivity to glucagon 
stimulation returned to normal values ( Hepp, 1972 ). Up to date very little work has 
been done to investigate the effect of glucagon on xenobiotic metabolism. The many 
counter-regulatory effects of glucagon on the effects of insulin and the role of cyclic 
AMP-dependent phosphorylation in the control of xenobiotic metabolism in the liver 
( Banhegyi et.al., 1988 ) prompted us to investigate the effect of glucagon on steroid
metabolism.
A time-course experiment indicated that there is a lag phase in glucagon effect on 
androst-4-ene-3,17-dione metabolism ( Figure 26 - 30). The effects of glucagon began 
to be manifested at 1/2 hour of preincubation ( Figure 31 ). Glucagon decreases the
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activity of the enzymes active on androst-4-ene-3,17-dione at physiological 
-10 -8concentrations (10 - 10 M ). Higher concentrations are less effective. The
maximum effect of glucagon was always seen at 10 8 M for all enzymes. This effect of 
glucagon was exactly reproduced when the primary cultures of hepatocytes were 
preincubated with glucagon for 24 hours ( Figure 34). Recently, Wakelam et.al. ( 1986) 
have suggested that the effects of glucagon in the liver are mediated by its interaction with 
two distinct receptors, GR-1 ( a receptor coupled to the stimulation of inositol 
phospholipid breakdown ) and GR-2 ( a receptor coupled to the stimulation of adenylate 
cyclase activity ). The biphasic effect of glucagon on androst-4-ene-3,17-dione 
metabolism observed is similar to that seen for the glucagon-stimulated production of 
inositol phosphates, with inhibition occurring at higher glucagon concentrations. The 
inhibitory second phase of the glucagon-stimulated inositol phosphates production occurs 
at higher glucagon concentrations when adenylate cyclase activity is maximally stimulated 
( Wakelam et.al., 1986 ). The use of TH-glucagon, a glucagon analogue which 
stimulates the production of inositol phosphates in a dose-dependent manner but does not 
activate adenylate cyclase or cause any increase in cyclic AMP in hepatocytes, helped to 
place the puzzle into a better perspective. Recently, we have presented evidence showing 
the dose-dependent effect of TH-glucagon on androst-4-ene-3,17-dione metabolism, an 
analogous observation with the effect of TH-glucagon on inositol phosphate turnover 
( Hussin et.al., 1988 ) suggesting that the effect of glucagon on steroid metabolism is 
mediated via the GR-1 receptor linked to phosphatidylinositol-4,5-bisphosphate turnover. 
TH-glucagon is a potent antagonist of glucagon activation of the hepatic adenylate cyclase 
assay system ( Johnson et.al., 1982 ) and is 7 % as active as glucagon in binding to 
glucagon receptors in the rat liver ( Epand, et.al., 1976 ). We have earned out dose- 
response studies with TH-glucagon at different periods of preincubation in order to 
investigate the possible molecular mechanism of action of glucagon in mediating its effect
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on steroid metabolism.
From our study, we have gathered that the effect of TH-glucagon on steroid 
metabolism is time-dependent. The acute effect ( 1/2 hour) of TH-glucagon was seen to 
increase all the enzyme activities ( Figure 42 ) while its chronic effect ( 24 hours ) 
was to decrease the activities ( Figure 45 ). In isolated hepatocytes, TH-glucagon is 
an extremely weak partial agonist for cyclic AMP accumulation by having no ability to 
activate adenylate cyclase nor to stimulate protein kinase activity ( Cote and Epand, 
1979 ). However, TH-glucagon is a full agonist for the stimulation of glycogenolysis, 
gluconeogenesis and urea synthesis in rat hepatocytes ( Corvera et.al., 1984 ), thus 
mimicking the effect of the endogenous hormone, glucagon. TH-glucagon causes a 
dose-dependent increase in the production of inositol 1,4,5-trisphosphate ( Wakelam 
et.al., 1986 ) with concomitant release of diacylglycerol which stimulates the 
calcium/phospholipid-dependent protein kinase, protein kinase C. This is consistent with 
our observation of TH-glucagon's effect on androst-4-ene-3,17-dione metabolism at 24 
hour of preincubation. We have also presented evidence that 4(3-phorbol-12p-myristate- 
13a-acetate (PMA) but not A 23187, a calcium ionophore, was able to mimic the effect 
of glucagon and TH-glucagon on the enzyme activity suggesting that glucagon activated
-8protein kinase C via generation of diacylglycerol. The dose-response curves to 10 M 
TH-glucagon at 24 hour is similar to that of glucagon at 1/2 and 24 hour implying that 
glucagon effects at both 1/2 and 24 hours are mediated by protein kinase C. The ability of 
protein kinase C to mediate the effect of glucagon on xenobiotic metabolism is not 
surprising since the phosphorylation of a number of cytochrome P-450 isoenzymes by 
protein kinase C has been demonstrated elsewhere ( Pyerin et.al., 1987; Allan and Skett, 
1988 ). Thus the inhibitory effect of glucagon on androst-4-ene-3,17-dione metabolism 
can be seen at 1/2 hour and 24 hour, a similar time-scale to the stimulatory effect of 
insulin ( refer to Figure 31 and 34) as discussed in the earlier section. The physiological
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relevance of the observed opposing effects of insulin and glucagon occurring at the same 
time in the cultured hepatocytes is not known and remains to be elucidated.
The paradoxical effect of TH-glucagon at 1/2 hour preincubation was not 
expected. This is surprising because of the ability of TH-glucagon to mimic the effect of 
glucagon on various liver parameters such as gluconeogenesis and 
glycogenolysis ( Cote and Epand, 1979 ). However, TH-glucagon has been seen to 
reduce the blood sugar levels in streptozotocin-diabetic rats suggesting that it may be 
blocking the metabolic effects of glucagon in these hyperglycaemic animals ( Johnson 
et.al., 1982 ). The maximal effect of TH-glucagon was observed after 5 minutes of drug 
administration and maintained for at least 105 minutes. Thus the effect of TH-glucagon 
does not always mimic the effect of glucagon. Following this, it is not surprising to see 
an increase in all the enzyme activities by TH-glucagon at 1/2 hour and to extend 
even up to 1 hour of preincubation ( Figure 43 ). However the exact mechanism by 
which TH-glucagon increased the enzyme activities at the short time periods remains 
unclear.
As expected, the incubation of the cells with glucagon and the non-specific 
protein kinase inhibitor, K-252a, resulted in the returning of the enzyme activities to 
control, confirming our hypothesis that glucagon's effect on androst-4-ene-3,17-dione 
metabolism is mediated by phosphorylation. Preincubation with glucagon for 1/2 hour in 
the presence of K-252a resulted in the complete abolition of the glucagon dose-response 
curves ( Figure 38 ). Longer period of preincubation with K-252a i.e. 24 hours, 
resulted in the inversion of the dose-response curves ( Figure 39 ). This was not 
expected and the explanation for this is not known and remain to be elucidated.
The effect of glucagon on steroid metabolism at 1 and 48 hour and at 2 and 72 
hour were similar. Therefore their results will be discussed together. At 1 and 48 
hour ( Figure 32 and 35 respectively ) of preincubation, the effect of glucagon on the
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enzyme activities was the reverse of that seen at 1/2 and 24 hour. Maximum stimulation
of enzyme activities could be seen at 10 8 M glucagon. Glucagon has been shown to 
stimulate a low Km membrane bound phosphodiesterase in the adipose tissue ( Solomon, 
1975 ) and liver ( Loten et.al., 1978 ). By devising a technique, Heyworth and 
colleagues ( 1983b) managed to resolve the subcellular membrane fractions and identify 
cyclic AMP phosphodiesterase activity in both membrane and cytosol fractions in 
hepatocytes. They have discovered that glucagon is able to activate a fraction which they 
had called 'dense vesicle' phosphodiesterase, with criteria similar to the membrane bound 
low Km phosphodiesterase described by Loten et.al. ( 1978 ). Both Loten and co­
workers ( 1978 ) and Solomon ( 1975 ) have reported the ability of glucagon to
activate the phosphodiesterase at physiological concentrations ( 10’10 - 10’8 M ) with an 
absence of effect at higher concentrations. Interestingly, this effect of glucagon was 
found to be similar to the effect of glucagon on androst-4-ene-3,17-dione metabolism 
suggesting that the effect of glucagon on steroid metabolism at 1 hour could possibly be 
mediated via the activation of the low Km phosphodiesterase.
At 2 and 72 hours of preincubation, glucagon showed a sex-differentiation in its 
effects on enzyme activities ( Figure 33 and 36 respectively). None of the female-specific 
enzyme activities were significantly altered by glucagon. On the other hand, the male- 
specific enzyme activity were significantly increased. The mechanism behind this 
differential effect of glucagon at 2 and 72 hours is not known and neither is its 
physiological relevance. It is worth mentioning that in man, significant increments in 
growth hormone levels were found within 2-3 hours of subcutaneous administration of 
glucagon ( Mitchell et.al., 1969 ). There is a possibility that some of the effect of 
glucagon on xenobiotic metabolism could be mediated indirectly via the pituitary gland.
In summary, glucagon has a time- and concentration-dependent effect on androst- 
4-ene-3,17-dione metabolism by acting directly on the liver. Glucagon decreases the
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steroid metabolism at 1/2 and 24 hour of preincubation. This effect of glucagon has been 
shown to be mediated by a phosphorylation reaction since its effect was abolished by a 
protein kinase inhibitor, K-252a. The phosphorylation reaction is thought to be brought 
about by the activation, by diacylglycerol, of protein kinase C subsequendy leading to a 
decrease in the enzyme activities. This is supported by the observed effect of TH- 
glucagon at 24 hour of preincubation on androst-4-ene-3,17-dione metabolism and the 
fact that PMA mimicked the effect of glucagon in decreasing the enzyme activities. It 
should be noted though that at other periods of preincubation with glucagon, increased 
enzyme activities were also observed. The data gathered suggest that glucagon does have 
a role in the regulation of steroid metabolism in the rat liver. As for the TH-glucagon, its 
effect on androst-4-ene-3,17-dione metabolism is time-dependent. The enzyme activities 
were increased at 1/2 and decreased at 24 hour respectively.
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9-4 THE, EFFECT OF GLUCAGON ON ANDROST-4-ENE-3.17-DIONE
METABOLISM IN HEPATOCYTES ISOLATED FROM STREPTOZOTOCIN-
DIABETIC MALE RATS
Glucagon influences many metabolic parameters in the liver and among the 
important ones is the regulation of ketone and glucose homeostasis. In type 2 diabetes, 
glucose metabolism by the liver is altered partly due to the high serum glucagon level 
( Best et.al., 1982). Since hyperglucagonaemia is usually present in uncontrolled type 2 
diabetes, this hormonal excess has been implicated in the overall pathophysiology of the 
disease ( Unger and Orci, 1981 ). With regards to drug metabolism, glucagon has been 
shown to increase the metabolism of various drugs in the mouse ( Rouer et.al., 1985 ). 
Since glucagon has been shown to have an influence on steroid metabolism ( previous 
section ) and has been implicated in the overall picture of the diabetic condition, it is 
pertinent for us to extend our investigation to the effect of glucagon in the diabetic rat 
hepatocytes.
In the diabetic ( 3 days STZ-treated) rats, the second phase of glucagon action 
normally seen at 1/2 hour in normal rat hepatocytes was not evident ( Figure 37 ). In fact,
the first depressive phase of glucagon, which reached a maximum at 10 M, was 
maintained at higher glucagon concentrations ( about 70 to 80 % of control). These data 
indicate that the repressive effect of the adenylate cyclase system on inositol phosphate 
production had not occur, possibly due to a defect in the adenylate cyclase system. The 
ability of glucagon to stimulate liver membrane adenylate cyclase is, indeed, decreased 
in diabetic rats ( Portha et.al., 1983 ). Dighe et.al. ( 1984) reported a 50 % reduction in 
glucagon stimulation of adenylate cyclase accompanied by a 67 % reduction of the 
glucagon receptor levels. This result is similarly seen in man, Arner et.al. ( 1987a) 
reported a r e d u c t i o n  of adenylate cyclase activity of 35-50% in membranes from type
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2 diabetic patients. The activity of the low Km phosphodiesterase was also decreased in 
plasma membranes from diabetic rats accounting for the increased tissue levels of cyclic 
AMP ( Pilkis et.al., 1974 ). The reduced adenylate cyclase activity could probably be 
due to a decrease in the amount of adenylate cyclase in the liver plasma membranes 
( Portha et.al., 1983) or a modification of the guanine nucleotide regulatory protein 
( Gawler et.al., 1987 ). This could probably account for the maintenance of the first, 
inhibitory phase of glucagon's effect on androst-4-ene-3,17-dione metabolism in the 
diabetic rat hepatocytes seen in this study.
In summary, glucagon causes a dose-dependent decrease in androst-4-ene-3,17-
dione metabolism in diabetic rat hepatocytes with maximum effect seen at 10 M 
concentration distinct from the V-shaped dose-response curves exhibited in normal rat 
hepatocytes. These differences could probably be attributed to a defect in the adenylate 
cyclase system in the diabetic hepatocytes.
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9-5 THE EFFECT QF COMBINATIONS OF INSULIN AND GLUCAGON 
ON ANDROST-4-ENE-3.17-DIONE METABOLISM IN HEPATOCYTES 
FROM NORMAL AND STZ-DIABETIC MALE RATS
Numerous studies performed in animals and in man have shown the existence 
of peripheral plasma insulin and glucagon oscillations. The frequency of these 
oscillations is remarkably stable but their amplitude is increased after a meal and 
decreased by food deprivation. ( Lefebvre et.al., 1987 ). The oscillatory pattern of 
plasma hormone levels may be physiologically important to reduce down-regulation of 
receptors and, consequently, to enhance hormone action. The interaction of these 
hormones and the feedback mechanism will determine the concentration of a particular 
hormone at one given time and hence influence the outcome of its physiological effects. 
For this reason we have decided to test the effect of insulin plus glucagon by adding them 
together in various combinations. In the result analysis we have decided to look at the
9 6influence of physiological (1 0  M ) and supraphysiological (1 0  M ) glucagon
concentrations on insulin effect on androst-4-ene-3,17-dione metabolism due to the
markedly different effects of the two concentrations of glucagon when given alone.
9 9In the normal rat, glucagon at 10" M selectively decreased the effect of 10 M
insulin on 16a-hydroxylase and 17-OHSD while having little effect on the other enzyme
activities studied ( Figure 40 ). A selective decrease in the activity of the male-specific
enzymes is evident indicating, for the first time, the possible importance of hormonal
interaction in expressing sexual differences in steroid metabolism. In the normal rat,
many reports have indicated the ability of insulin to lower the cyclic AMP concentration
when it is added in the presence of glucagon ( Loten et.al., 1978; Hey worth et.al.,
1983b) and the magnitude of this effect was dependent on insulin concentration
( Heyworth et.al., 1983a ). Insulin and glucagon together, each in a maximally effective
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concentration have a greater effect on the low Km phosphodiesterase than does either
hormone alone ( Loten et.al., 1978; Heyworth et.al., 1983b ). Presumably at 10'9 M, the 
activation of protein kinase C by glucagon ( and, thus, a decrease in enzyme activity ) is 
dominant over the effect of insulin to increase the enzyme activities. Moreover, protein 
kinase C, which is activated by phorbol esters, has been shown to phosphorylate the 
serine residue of the insulin receptor, resulting in about 65 % reduction of the tyrosine 
kinase activity ( Bollag et.al., 1986 ). However, it is not known why only the 16a- 
hydroxylase and 17-OHSD activity were selectively inhibited.
Again in the normal rat, glucagon at 10’9 M, selectively inhibited the effect of
10"6 M insulin on the 16a-hydroxylase while potentiating the effect of insulin on the 6£-
hydroxylase and 5a-reductase activity. At both 10"9 and 10-6 M insulin, the physiological 
glucagon concentration was able to reduce the activity of 16a-hydroxylase below the
control indicating the susceptibility of this enzyme to glucagon. At 10"6 M insulin, 6fi- 
hydroxylase and 5a-reductase activity were preferentially increased while the effect of 
insulin was significandy suppressed by glucagon.
In the normal rat, a supraphysiological glucagon concentration ( 10'6 M ) could
g
selectively antagonize and potentiate the effect of 10 M insulin on 17-OHSD and 5a- 
reductase activity respectively. It is interesting to note that only the non-cytochrome 
P-450-dependent enzymes are involved. This possibly indicates that the two non­
cytochrome P-450-dependent enzymes are more susceptible to alteration by these two 
hormones at the concentrations used. These effects were only observed in vitro and 
whether they have any significant relevance in-vivo is not known.
In normal rat, 10'6 M glucagon potentiated the effect of insulin ( 10'6 M ) on 6p- 
hydroxylase and 5a-reductase while antagonizing the effect of insulin on 16a- 
hydroxylase and 17-OHSD. The activity of 7a-hydroxylase was suppressed by insulin
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( 10’6 M ) in the presence of 10'6 M glucagon.
In the acutely diabetic rat, physiological concentration of glucagon ( 10’9 M ) 
selectively increased the activity of 16a-hydroxylase only in the presence of insulin 
-9(1 0  M ) whereas insulin alone has little effect ( refer to Figure 41 ). Thus there is a 
differential effect seen in normal and diabetic rat. The insulin receptor tyrosine kinase 
activity has been found to decrease in the diabetic rat ( see section 9.2 ) but the glucagon- 
stimulatable protein kinase C activity is unaffected. It is expected that the insulin and
glucagon combination ( both at 10’9 M ) would result in a decrease in the enzyme activity. 
In the diabetic rat it is not known why the 16a-hydroxylase activity was increased.
In the diabetic rat, all the enzyme activities were not significantly altered by other
9 6glucagon and insulin combination (10  and 10 M respectively ) and no explanation 
could be given presuming that the protein kinase C could still be activated by glucagon in 
the diabetic rat.
Glucagon at 10’6 M, selectively increased the effect of 10’9 M insulin on the 6(3- 
hydroxylase and 17-OHSD activities but had little effect on the remaining three
enzymes.With glucagon ( 10"6 M ) and insulin ( 10‘6 M ) combination, none of the 
enzyme activities were significantly altered in the presence of this hormonal combination. 
This is consistent with our hypothesis that the adenylate cyclase system was defective in 
the diabetic state. This together with the defective second messenger systems associated 
with insulin would result in the absence Of effect seen in the diabetic hepatocytes by the 
insulin and glucagon combination.
In summary, differential effects on the enzyme activities are evident when different 
concentrations of insulin and glucagon are added together. The effects are variable 
depending on the combinations of insulin and glucagon added. Therefore it can be 
speculated that different plasma levels of insulin and glucagon could partly contribute to
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the role of hormonal regulation in sex-differentiation seen in the rat liver.
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9.6 XHE EFFECT OF PHENFORMIN ON ANDROST-4-ENE-
3il7-PIQNE METABOLISM IN NORMAL AND STZ-DIABETIC
MALE RAT HEPATOCYTES
Sulphonylureas as well as biguanides are widely used as hypoglycaemic agents 
in the treatment of diabetes mellitus. Both group of drugs are used for the treatment of 
type 2 or insulin-independent diabetic patients. Since both drugs are most effective in 
those patients with the ability to secrete insulin, it has been postulated that both may act to 
potentiate the effects of insulin at the cellular level ( Shen and Bressler, 1977 ). The 
clinical use of these drugs is well reported on, but little is known about their mechanism 
of action at the cellular level up to date despite numerous reports from many laboratories. 
Our objective was to study the effect of these drugs, using phenformin and tolbutamide 
as representatives of biguanide and sulphonylurea respectively, and their possible 
interaction with insulin on steroid metabolism in rat liver.
In normal rat hepatocytes, phenformin has been demonstrated to cause a dose- 
dependent increase in all the enzyme activities with maximum response observed at
5 x 10’5 M ( Figure 46 ). Many hypotheses have been put forward to explain the 
mechanism of action of phenformin and other biguanides. One possible mechanism is 
their ability to alter the function and physical structure of membranes by changing the 
electrostatic surface potential of the membrane. The perturbation of the membrane 
structure and physical membrane properties may then be transmitted to integral 
membrane proteins and their catalytic function ( Schafer, 1976 ). Studies in-vitro have 
shown a rapid dose-dependent effect of biguanides on insulin binding to target cells 
( Cohen et.al., 1980; Vigneri et.al., 1982 ). They have been shown to increase insulin- 
receptor binding in a variety of cultured cells ( Pezzino et.al., 1982 ) and cells from 
diabetic ( Pagano et.al., 1983 ) and non-diabetic subjects ( Bailey , 1988 ). However,
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many studies have reported pharmacological and biochemical effects of biguanides to 
enhance insulin action without measurable effect on hepatocyte insulin-receptor binding 
( Lord et.al., 1985; Purrello et.al., 1988 ), suggesting that the biguanides can influence 
postreceptor sites of insulin action independently of insulin receptor binding. This idea 
was substantiated by a report (Jacobs et.al., 1986) showing the ability of metformin 
( another biguanide ) to enhance hexose transport in the absence or presence of insulin 
despite seeing no changes in the insulin receptor number or affinity or the insulin-receptor 
tyrosine kinase activity. The effect of biguanide was not blocked by cycloheximide 
indicating that synthesis of new receptors is not required to increase insulin binding 
( Pezzino et.al., 1982 ).
Any influence ( direct or indirect) by phenformin on the phosphorylation state 
of the cytochrome P-450 could affect the amount of metabolites being produced. In 
relation to this, a study has demonstrated that phenformin stimulated a high affinity cyclic 
AMP phosphodiesterase of isolated liver plasma membrane in a dose-dependent way, 
decreasing the intracellular cyclic AMP content of the isolated hepatocytes without being 
effective on plasma membrane-bound adenylate cyclase ( Luly et.al., 1977 ). These 
effects on the high affinity cyclic AMP phosphodiesterase and on the intracellular cyclic 
AMP content could probably account for the observed increase in all the enzyme 
activities by phenformin.
In the diabetic hepatocytes , phenformin still exhibited a dose-dependent increase 
in all the enzymes activities but there was a decrease in the drug responsiveness 
and sensitivity ( Figure 52) suggesting the existence of receptor and postreceptor defects. 
As for the latter, there was a slight shift in the dose-response curve. In diabetic rats, the 
hepatocytes were not responsive to insulin but were still able to respond to phenformin. 
Metformin has been reported to increase insulin-mediated glucose uptake by rat 
adipocytes without affecting the insulin receptor binding and insulin receptor p-subunit
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phosphorylation ( Jacobs et.al., 1986 ). Presuming that phenformin has a similar effect 
as metformin, the former could possibly exerts its effect on androst-4-ene-3,17-dione 
metabolism by acting through mechanisms that may be beyond insulin receptor binding 
that has yet to be determined. Phenformin has been shown to cause an increase in insulin 
binding in diabetic rat liver plasma membrane ( Chaujar et.al., 1984 ). Biguanides have 
been suggested to ameliorate insulin resistance by causing a positive influence on tissue 
sensitivity to insulin by acting at the postreceptor level ( Lord et.al., 1983; Lord et.al., 
1985 ). Recently Gawler et.al. ( 1987 ) demonstrated that metformin was able to restore 
the ability of insulin to inhibit glucagon-stimulated adenylate cyclase activity and 
suggested an effect of metformin distal to insulin binding.
Many studies have demonstrated the potentiating effect of biguanides on insulin 
actions ( Lord et.al., 1985; Jacobs et.al., 1986 ). Recently, metformin has been shown 
to enhance only some of the actions of insulin ( Purrello et.al., 1988 ). Metformin
potentiated insulin-stimulated [ H] glucose incorporation into glycogen and tyrosine-
aminotransferase activity but had no effect on insulin-stimulated [1-14C] aminoisobutyric 
acid uptake. In our study using normal rat hepatocytes, insulin in the presence of
phenformin (10" M ) selectively produced greater effect on the 6p-hydroxylase, 17- 
OHSD and 5a-reductase activities than with insulin or phenformin alone ( Table 44). 
This concentration of phenformin was used since it appears to be very close to the drug
clinical serum level ( Luly et.al., 1977 ). In the presence of phenformin ( 10'3 M ) the
maximum effect of insulin was achieved at 10"9 M concentration while the effect of
insulin has not even reached its maximum at 10"^  M in the absence of phenformin ( refer 
to Figure 46 ). It seems that phenformin may inhibit the ability of insulin to increase the 
activity of 7a- and 16a-hydroxylases. On the other hand, it is apparent that phenformin
(10"3 M) markedly lowered the maximal response of the cells to insulin ( compare to
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dose-response effect of insulin in normal rat hepatocytes-Figure 7 ). Mutual inhibition of 
the stimulatory effect of insulin and phenformin on the high affinity cyclic AMP 
phosphodiesterase activity has also been reported by Luly et.al. ( 1977 ). They have 
reported that insulin in the presence of phenformin produced lower stimulation of the 
high affinity cyclic AMP phosphodiesterase activity than that produced by insulin or 
phenformin alone. The mechanism by which phenformin reduces the response of the 
liver cells to insulin is not known and further work is needed for its elucidation.
In the diabetic rat hepatocytes, phenformin (10 ' M ) shows no potentiation of 
the effect of insulin on any of the enzymes except the 7a- and 6P-hydroxylase activity at
10 9physiological insulin concentrations (10' and 10' M ) ( Table 50 ). The high
phenformin concentration (10  M ) has no potentiating effect on insulin within the 
range of insulin concentrations used.
If the format of the experiment is changed to observe the influence of
physiological insulin ( 10'9 M ) on the effect of a range of concentrations of phenformin
-9on the enzyme activities, it is seen, in normal rat, that insulin (1 0  M ) potentiated 
phenformin effect on all the enzyme activities ( Table 46). Again phenformin plus insulin
9 9produced higher enzyme activities than 10' M insulin or 10 M phenformin alone.
In the diabetic rat, a physiological insulin concentration (10 M ) potentiated 
the effect of phenformin on all the enzyme activities with the exception of the 7a- 
hydroxylase ( Table 52). Insulin only potentiated the effect on 16a-hydroxylase and 5a-
-3reductase activity at high phenformin concentration i.e. 10 M which would account for
the lack of effect of 10'3 M phenformin on increasing insulin concentration mentioned in 
the last paragraph. It is apparent that in the diabetic rat, that a physiological insulin 
concentration is only able to potentiate the effect of submaximal phenformin 
concentrations.
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In summary, phenformin was shown to have a direct effect on the liver in 
elevating androst-4-ene-3,17-dione metabolism. It is able to mimic the effect of insulin in 
normal and diabetic rat hepatocytes with respect to androst-4-ene-3,17-dione metabolism 
though there was a decrease in the liver cells responsiveness and sensitivity in the latter. 
Physiological insulin concentration potentiated the effect of phenformin on almost all of 
the enzyme activities. A direct effect of phenformin on cytochrome P-450 cannot be ruled 
out.
9-7 THE EFFECT OF TOLBUTAMIDE ON ANDROST-4-ENE-3.17-DIONE 
METABOLISM IN NORMAL AND STZ-DIABETTC MALE RAT 
HEPATOCYTES
In normal rat hepatocytes, tolbutamide elicited a dose-dependent increase in 
androst-4-ene-3,17-dione metabolism ( Figure 47 ) similar to that exhibited by 
phenformin. The mechanism by which tolbutamide increased all the steroid enzyme 
activities is unclear at present. There is some evidence that part of the therapeutic effects 
of sulphonylureas on glucose metabolism are due to an extrapancreatic action of the 
drugs. It has been suggested that sulphonylureas , administered in-vivo ( Olefsky and 
Reaven, 1976; Feinglos and Lebovitz, 1978 ) or employed in-vitro ( Prince and 
Olefsky, 1980 ), may enhance insulin action through increasing the hormone binding to 
its receptors. However, exposure of cultured cells to sulphonylureas has yielded variable 
results. Various reports have reported no changes in insulin receptor binding ( Maloff and 
Lockwood, 1981; Vigneri et.al., 1982; Dolais-Kitabgi et.al., 1983 ). The report of an 
enhancement of maximal insulin-stimulated glucose uptake ( Maloff and 
Lockwood, 1981 ) and lipogenesis ( Salhanick et.al., 1983 ) in the absence of any 
effect on insulin receptor binding, suggests a direct effect of sulphonylureas on the post­
binding pathways of insulin action.
Specific binding of sulphonylureas to receptors on the P-cell membrane has been 
shown ( Lebovitz, 1984) and it has been suggested that the sulphonylurea receptor may 
constitute part of an ATP-sensitive K channel ( Sturgess et.al., 1985 ). Tolbutamide has 
been suggested to decrease the K permeability of the P-cell membrane ( Henquin, 
1980 ) by inhibiting ATP-sensitive K+ channels ( Sturgess et.al., 1985 ). The inhibition 
of an ( Na+-K+ )-ATPase by chlorpropamide has been reported in isolated liver plasma 
membrane ( Luly et.al., 1977 ). It is not known whether part or all of tolbutamide effect 
on the steroid metabolism is mediated via an alteration of this enzyme.
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Another possible mechanism through which tolbutamide could affect the steroid 
metabolism is its effect on cyclic AMP metabolism. Sulphonylureas have been shown to 
alter the activity of the adenylate cyclase. However, the changes induced in cyclic AMP 
level may be variable, depending upon the tissue studied and the experimental system 
used ( Blumenthal, 1977; Leichter and Chase, 1978 ). Sulphonylureas have been 
demonstrated to increase adenylate cyclase activity in the heart ( Lasseter et.al., 1972 ) 
but have the opposite effect in the kidney and liver ( Leichter and Galasky, 1981 ) 
while having no effect on plasma membrane-bound adenylate cyclase in the liver 
( Luly et.al., 1977 ).
Another means through which tolbutamide could increase androst-4-ene-3,17- 
dione metabolism is by lowering intracellular cyclic AMP concentration via activation of 
the nucleotide degrading enzyme, phosphodiesterase. In fact, sulphonylureas have been 
shown to affect the activity of low Km cyclic AMP phosphodiesterase but the effects 
reported have been inconsistent. Goldfine et.al.( 1971) have reported an inhibition of the 
cyclic AMP phosphodiesterase activity by tolbutamide in rat liver, lung, kidney and brain 
tissues. Brooker and Fichman ( 1971 ) also reported an inhibition of the cyclic AMP 
phosphodiesterase by chlorpropamide and tolbutamide in rat kidney. However, these two 
studies were conducted using microsomal preparation and no measurement of cyclic 
AMP concentration were made. A more pertinent report to our study, and probably a 
more physiological study, was conducted by Luly et.al. ( 1977 ). They have found a 
chlorpropamide-stimulated low Km cyclic AMP phosphodiesterase of isolated liver 
plasma membrane. The drug also decreased the intracellular cyclic AMP content of 
isolated hepatocytes without affecting the plasma membrane-bound adenylate cyclase 
indicating that chlorpropamide has no effect on the synthesis of cyclic AMP.
Recently, it was reported that tolbutamide inhibited the protein kinase A activity 
in rat liver cytosol by inhibiting the activity of the catalytic units of the protein kinase A in
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a dose-dependent manner ( Okuno et.al., 1988 ). Androst-4-ene-3,17-dione metabolism 
is controlled by specific enzymes, the activities of which seem to be altered by the 
phosphorylation states of the liver cells. Thus, the ability of tolbutamide, presumably 
having a similar mechanism of action, to inhibit the activity of protein kinase A is 
consistent with the observed dose-response increase in androst-4-ene-3,17-dione 
metabolism by tolbutamide.
Tolbutamide has also been reported to increase soluble and particulate guanylate 
cyclase activity in rat liver, lung, heart, spleen, colon, pancreas and kidney cortex 
( Vesely, 1986 ). Cyclic GMP has been suggested to play a role in glucose homeostasis 
( Vesely et.al., 1979 ). It still remain to be seen whether the Ying-Yang hypothesis with 
the observed increased cyclic GMP and reported decreased in cyclic AMP, has any role to 
play in steroid metabolism.
In the diabetic rat, tolbutamide was still able to increase all the enzyme activities 
despite a reduction in responsiveness ( Figure 53 ). Selective decreases in the enzymes' 
sensitivity were also observed. The 16a-hydroxylase and 17-OHSD only responded to
tolbutamide at higher concentrations ( 10-4 and 5 x 1CT4 M respectively ). Solomon etal.
( 1986a ) have reported a decrease in activity of cyclic AMP phosphodiesterase and 
calmodulin in the STZ-treated rat. Treatment with glyburide, a sulphonylurea, fully 
restored both activities to normal indicating both cyclic AMP phosphodiesterase and 
calmodulin as sites of action of glyburide, distal to the insulin receptor. A decrease in the 
cyclic AMP phosphodiesterase activity in the diabetic rat and the ability of tolbutamide to 
partially restore the enzyme's activity in the rat hepatocytes corresponds well with those 
of their reported antidiabetic effects ( Melander, 1987 ).
In the normal rat, tolbutamide selectively inhibits the insulin-stimulated 5a- 
reductase activity ( Table 45 ). With regard to the other enzymes, increasing insulin
con centration s potentiated the effec t o f  10'3 M tolbutam ide w hen com pared to
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-3tolbutamide ( 1 0  M ) alone. Similar to phenformin, tolbutamide reduces the 
responsiveness of the insulin-stimulated steroid enzyme activities and the mechanism 
responsible for this is yet to be determined. In diabetic hepatocytes, increasing insulin
concentrations in the presence of 10’3 M tolbutamide did not increase the enzyme
activities except for the 16a-hydroxylase at 10'8 and 10"7 M insulin , when compared to 
-3tolbutamide 10 M alone ( Table 51 ). When compared to the normal rat, there were
fewer effects in the diabetic rat hepatocytes when insulin and tolbutamide 10’ M were 
added together. This is possibly due to the postreceptor defects that exist in the diabetic 
state.
In the normal rat, increasing tolbutamide concentration selectively potentiated 
the insulin-stimulated activities of the non-cytochrome P-450 enzymes in a dose- 
dependent manner while the cytochrome P-450 enzyme activities were not significantly
different from 10’9 M insulin alone ( Table 47 ). In the diabetic rat, the drug and 
hormone combinations no longer selectively potentiated the non-cytochrome P-450
activities ( Table 53 ). Only higher tolbutamide concentrations ( > 5 x 10’5 M )
potentiated 10’9 M insulin effect on 17-OHSD activity. The effect of insulin ( 10"9 M ) 
on 16a-hydroxylase activity was potentiated by tolbutamide at concentrations as low as
10’6 M concentration. It is apparent that the combination of tolbutamide and insulin 
reduces the maximal response attained by tolbutamide or insulin alone in normal and
diabetic rat hepatocytes.
In summary, tolbutamide has been shown to exert a direct effect on the liver 
in-vitro and mimicked the effect of insulin in stimulating the steroid enzyme activities in 
normal rat. Similar to phenformin, tolbutamide was still able to increase all the enzyme 
activities in diabetic hepatocytes with a shift in the drug responsiveness when compared
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to its effect in normal rat hepatocytes. Although many biochemical actions have been 
reported on the potentiation of insulin action by tolbutamide and other sulphonylureas, 
we have found that, with respect to steroid metabolism, tolbutamide reduced the 
responsiveness of the liver cells towards insulin.
A direct effect of tolbutamide on cytochrome P-450 cannot be ruled out.
-268-
9.8 GENERAL DISCUSSION
All the results can be summarised as follows :
i) In normal rat hepatocytes, addition of insulin in-vitro caused an increase in steroid 
enzyme activities at 1/2 and 24 hour. The dose-response curves indicated that the effect of 
insulin at 1/2 hour could be mediated by a mechanism distinct from the effect of insulin at 
24 hour pre-incubation. Our data suggested that insulin , in-vitro, acts as a general 
stim ulator of the enzymes in the liver metabolizing androst-4-ene-3,17-dione 
substantiating our contention that insulin is a major factor in the regulation of xenobiotic 
metabolism in the rat liver.
ii) Hepatocytes from acutely STZ-treated diabetic rats are not responsive to insulin 
in-vitro with respect to androst-4-ene-3,17-dione metabolism and the responsiveness is 
partly restored by treating the diabetic rats with insulin. However, in the hepatocytes 
from chronically STZ-treated diabetic rats, the response to insulin is delayed and 
attenuated.
iii) In normal rat hepatocytes, the effect of glucagon on androst-4-ene-3,17-dione 
metabolism is time- and concentration-dependent.Glucagon decreases the steroid 
metabolism at 1/2 and 24 hours of pre-incubation and exhibited V-shaped dose-response 
curves. Our data indicated that the effect of glucagon is mediated by a phosphorylation 
reaction and is thought to be brought about by the activation by diacylglycerol of protein 
kinase C leading to a decrease in the enzyme activities.
iv) In the diabetic rats, glucagon causes a dose-dependent decrease in androst-4-ene-
3,17-dione metabolism but no longer exhibit the V-shaped dose-response curves as seen 
in normal rat hepatocytes. It is suggested that these differences could probably be due to a
defect in the adenylate cyclase system.
v) Differential effects on the enzyme activities are observed when different 
concentrations of insulin and glucagon are added together. Selective changes in the
-269-
activity of the male-specific and female-specific enzymes are evident indicating, for the 
first time, the possible importance of hormonal interaction in expressing sexual 
differences in steroid metabolism.
vi) Phenform in is able to mimic the effect of insulin in the normal and diabetic rat 
hepatocytes with respect to androst-4-ene-3,17-dione metabolism though there was a 
decrease in the liver cells responsiveness and sensitivity in the latter. Physiological 
insulin concentration potentiated the effect of phenformin on almost all of the enzyme 
activities.
viii) Tolbutamide is able to mimic the effect of insulin with respect to androst-4-ene-
3,17-dione metabolism in normal rat hepatocytes. In the diabetic rat hepatocytes, there 
was a shift in the drug responsiveness. Unlike with phenformin, our data indicated that 
tolbutamide reduced the responsiveness of the liver cells towards insulin.
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APPENDIX I. abbreviations
The following abbreviations have been used :-
ADP Adenosine-5'-diphosphate
ATP Adenosine-5'-triphosphate
BSA Bovine serum albumin
[ Ca2+ ]j Intracellular concentration of free calcium
c.p.m. Counts per minute
Cyclic AMP Cyclic adenosine-3’,5'-monophosphate
Cylic GMP Cyclic guanosine-3',5'-monophosphate
DMSO Dimethylsulphoxide
EGF Epidermal growth factor
FCS Foetal calf serum
g Gram
g Centrifugal g-force
G Glucagon
Gj Inhibitory guanine nucleotide regulatory protein
Gjns Guanine nucleotide regulatory protein specific
for insulin.
G-protein Guanine nucleotide regulatoiy protein
Gs Stimulatory guanine nucleotide regulatory
protein.
GTP Guanosine-5'-triphosphate
HBSS Hank's balanced salt solution
H.P.L.C High performance liquid chromatography
HS Horse serum
I Insulin
IBMX 3-isobutyl-1 -methylxanthine
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IGF
IPG
Ka
kDa
Ki
Km 
Ks 
Mr
M.W.
NADP
NADPH
NIDDM
OHase
OHSD
P
PI
PLC
PMA
Protein kinase A 
Protein kinase C / PKC 
Protein kinase FA 
RNA 
S.D
SDS-PAGE
Insulin-like growth factor 
Inositol phosphate-glycan 
Association constant 
Kilodalton
Inhibitory constant
Substrate concentration producing half-maximal 
velocity.
Spectral dissociation constant 
Relative mass 
Molecular weight
Nicotinamide adenine dinucleotide phosphate 
(oxidized).
Nicotinamide adenine dinucleotide phosphate 
(reduced).
Non-insulin-dependent diabetes mellitus 
Hydroxylase
Oxosteroid oxidoreductase 
Phenformin 
Phosphatidy linos itol 
Phospholipase C
4p-phorbol-12p-myristate-13a-acetate 
Cyclic AMP-dependent protein kinase 
Calcium phospholipid-dependent protein kinase 
A multifunctional protein phosphatase activator 
Ribonucleic acid 
Standard deviation
Sodium dodecyl sulphate polyaciylamide gel 
electrophoresis.
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STZ
T
TH-glucagon
tl.c.
Tyr
U
Vv max
Streptozotocin
Tolbutamide
[ l-Na -trinitrophenylhistidine, 12-homoarginine ] 
glucagon.
Thin layer chromatography
Tyrosine
Unit
Maximal velocity
K-252a ( 8R*, 9S*, 1 IS* )-(-)-9-hydroxy-9-methoxy- 
carbonyl-8-methyl-2,3,9,10-tetrahydro-8,11- 
epoxy-1H , 8 H, 1 lH -2 ,7 b ,l la -triazad ibenzo
( a>g) cycloocta ( cde ) trindene-l-one
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